



US 20180119174A1

(19) **United States**(12) **Patent Application Publication**  
**Scharenberg et al.**(10) **Pub. No.: US 2018/0119174 A1**(43) **Pub. Date: May 3, 2018**(54) **ENHANCING ENDONUCLEASE BASED  
GENE EDITING IN PRIMARY CELLS****Publication Classification**(71) Applicant: **Seattle Children's Hospita (dba  
Seattle Children's Research Institute,**  
Seattle, WA (US)(72) Inventors: **Andrew Scharenberg**, Seattle, WA  
(US); **David Rawlings**, Seattle, WA  
(US); **Michael C. Jensen**, Bainbridge  
Island, WA (US); **Kamila Sabina**  
**Gwiazda**, Seattle (CA); **Alexandra**  
**Grier**, Seattle, WA (US)(21) Appl. No.: **15/572,761**(22) PCT Filed: **May 12, 2016**(86) PCT No.: **PCT/US2016/032153**

§ 371 (c)(1),

(2) Date: **Nov. 8, 2017****Related U.S. Application Data**(60) Provisional application No. 62/161,104, filed on May  
13, 2015.(51) **Int. Cl.****C12N 15/90** (2006.01)**A61K 38/46** (2006.01)**C12N 15/861** (2006.01)**A61K 48/00** (2006.01)**C12N 7/04** (2006.01)**C12N 15/113** (2006.01)**A61P 35/00** (2006.01)(52) **U.S. Cl.**CPC ..... **C12N 15/907** (2013.01); **A61K 38/465**  
(2013.01); **C12N 15/8616** (2013.01); **A61K**  
**48/005** (2013.01); **C12N 2310/20** (2017.05);  
**C12N 15/113** (2013.01); **A61P 35/00**  
(2018.01); **C12N 2750/14143** (2013.01); **C12N**  
**2800/80** (2013.01); **C12N 7/045** (2013.01)

(57)

**ABSTRACT**

Disclosed herein are nuclease-based systems for genome editing and methods of using the system for genome editing. Also, disclosed are approaches to enhance Cas9-mediated gene editing efficiency in primary human cells with minimal toxicity when using adeno-associated virus vectors (AAV) to express the guide RNAs necessary for CRISPR/Cas9-based genome editing in the presence of helper proteins.




FIG. 1A




FIG. 1B




FIG. 1C









FIG. 1D



*FIG. 1E*



*FIG. 1E (Con'd)*


*FIG. 1E (Con'd)*

FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A






FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4A




FIG. 4B





FIG. 4C



Condition	4 Days (%)	1 Week (%)	2 Weeks (%)
Cas9 +	~15	~18	~22
AAV.sg +	~48	~25	~15
E1b55k WT 0.33	~55	~55	~55
H373A 0.03	~55	~55	~55
H354 0.03	~55	~55	~55
+ E4orf6	~5	~5	~5




FIG. 5B






FIG. 5C






FIG. 6








FIG. 7B




FIG. 8A



FIG. 8B




FIG. 8C






FIG. 8D



FIG. 9




FIG. 9 (Con'd)




FIG. 10A




FIG. 10B




FIG. 10C






FIG. 11



C9: Cas9  
mC: mCherry  
HR: CRISPR repair  
template  
HR MT: mega TAL  
repair template  
Ad5: E4orf6 and  
E1b55k-H354  
G2: ssTCRa G2-GF  
G4: ssTCRa G4-GF










FIG. 12A (Con'd)



**C9:** Cas9  
**mC:** mcherry  
**HR:** CRISPR repair template  
**Ad5:** E4orf6 and E1b55k-H354  
**G2:** ssTCRa G2-GFP  
**G4:** ssTCRa G4-GFP






FIG. 13A




FIG. 13A (Con'd)




FIG. 13B




FIG. 14A








FIG. 15A




FIG. 15B




FIG. 15C




FIG. 16A

AACAAATGTGTCACAAAGTA (SEQ ID NO: 15)

ACAAACTGTGCTAGACATG (SEQ ID NO: 16)

TGTGCTAGACATGAGGTCTA (SEQ ID NO: 17)

TCAAGAGCAACAGTGCTG (SEQ ID NO: 5)

FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E






FIG. 16F




FIG. 16G




FIG. 16H




FIG. 161




FIG. 17

MERRNPSE RGV P A G F S G H A S V E S G C E T Q E S P A T V V F R P P G D N T D G G A A A A G G S Q A A A A G A E  
P M E P E S R P G S G M N V V Q V A E L Y P E L R R I L T I T E D G Q G L K G V K R E R G A C E A T E E A R N L A F S L M T R H  
R P E C I T F Q Q I K D N C A N E L D L L A Q K Y S I E Q L T T Y W L Q P G D D F E E A I R V Y A K V A L R P D C K Y K I S K L V N I R  
N C C Y I S G N G A E V E I D T E D R V A F R C S M I N M W P G V L G M D G V V I M N V R F T G P N F S G T V F L A N T N L I  
L H G V S F Y G F N N T C V E A W T D V R V R G C A F Y C C W K G V C R P K S R A S I K K C L F E R C T L G I L S E G N S R V R  
H N V A S D C G C F M L V K S V A V I K H N M V C G N C E D R A S Q M L T C S D G N C H L L K T I H V A S H S R K A W P V F E  
H N I L T R C S L H L G N R R G V F L P Y Q C N L S H T K I L L E P E S M S K V N L N G V F D M T M K I W K V L R Y D E T R T R C  
R P C E C G G K H I R N Q P V M L D V T E E L R P D H I L V L A C T R A E F G S S D E D T D (SEQ ID NO: 1)

FIG. 18

MERRNPSERGVPAGFSGHASVESGCETQESPATVVRPPGDNTDGGAAAAAGGSQAAAAGAEPEPESRPGPSGMNVVQVAELYPELRRILITITEDGQGLKGVKRERGACEATEEARNLAFSLMTRHRP  
ECITFQQIKDNCANELDLLAQKYSIEQLTTYWLQPGDDFEEAIRVYAKVALRPDCKYKISKLVNIRNCCYISGNGAEVEIDTEDRVAFRCSMINMWPGVLGMDGVVIMNVFRFTGPNFSGTVFLANTNLILHGV  
VSFYGFNNTCVEAWTDVVRVRGBCAFYCCWKGVVCRPKSRASIKKCLFERCTLGILSEGNSRVRHNVA  
SDCGCFMLVKSVAVIKHNMVCGNCEDRASQMLTCSDBGNCHLLKTI<sup>A</sup>VASHSRKAWPVFEHNILTRCSLHLGNRRGVFLPYQCNLSHTKILLEPESMSKVNNGVFDMTMKIWKVRLRYDETRTRCRPCEC  
GGKHIRNQPVMLDVTEELRPDHLVLACTRAEFGSDETD (SEQ ID NO: 2)

FIG. 19

MTTSGVPFGMTLRPTRSRLSRRTPTPSRDRLPPFETETRATILEDHPLLPECNTLTMHNVSVVRGLPC  
SVGFTLIQEWVVPWDMVLTREELVILRKCMHVCLCCANIDIMTSMMIHGYESWALHCHCSPGS  
LQCIAGGQVLASWFRMVVDGAMFNQRFIWIYREVVNYPKEVMFMSSVFMGRHLIYLRWL  
YDGHVGSVVPAMSGYSALHCGILNNIVVLCCSYCADLSEIRVRCCARRTRRLMLRAVRIIAEETTA  
MILYSCRTERRRQQFIRALLQHHRPILMHDYDSTPM (SEQ ID NO: 3)


FIG. 20

MERRNPSERGVPAGFSGHASVESGCETQESPATVVRPPGDNTDGGAAAAGGSQAAAAGAEPEPESRPGPSGMNVVQVAELYPELRRILTITEDGQGLKGVKRERGACEATEEARNLAFSLMTRHRP  
ECITFQQIKDNCANELDLLAQKYSIEQLTTYWLQPGDDFEEAIRVYAKVALRPDCKYKISKLVNIRNCCYISGNGAEVEIDTEDRVAFRCSMINMWPGLGMDGVVIMNVNFTGPNFSGTVFLANTNLILHG  
VSFYGFNNTCVEAWTDVRVRGCAFYCCWKGVVCRPKSRASIKKCLFERCTLGILSEGNSRVRHNVA  
SDCGCFMLVKSVAVIKHNMVCGNCEDRAGIPASQMLTCSDBGNCHLLKTIHVASHSRKAWPVFEH  
NIILTRCSLHLGNRRGVFLPYQCNLSHTKILLEPESMSKVNLNGLGVFDMTMKIWKVLRYDETRTRCRP  
CEGGGKHIRNQPVMLDVTEELRPDHLVLACTRAEFGSDEDDTD (SEQ ID NO: 4)




# FIG. 21


TCRa CRISPR guide#4 generates the highest TCRa-KO (knockout)  
Day 1 mCherry (mRNA transfection)



Day 7 mCherry (mRNA transfection)




Day 7 TCR-KO




*FIG. 21 (Con'd)*

TCRa CRISPR guide#4 generates the highest TCRa-KO (knockout)


Day 1 mCherry (mRNA transfection)



Day 7 mCherry (mRNA transfection)




Day 7 TCR-KO




**FIG. 21 (Con'd)**

TCRa CRISPR guide#4 generates the highest TCRa-KO (knockout)

Day 1 mCherry (mRNA transfection)



Day 7 mCherry (mRNA transfection)



Day 7 TCR-KO




FIG. 22

MDKKYSIGLAIGTNSVGWAVITDEYKVP SKFKVLGNTDRHSIKNKLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEFSN  
EMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV DSTDKADRLIYLALAHMIKFRGHFLIEGDLNP  
DNSDVKLFIQVLQTYNQ LFEENPINASGVDAKAIL SARLSKSRLENLIAQLPGEKKNLFGNLIALSLGLTPNFKSNFDLAEDAKL  
QLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQQLPEKYKEIFF  
DQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPLKDNREK  
IEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVVDKGASQAQSFIERMTNFDKNLPNEKVLPHKHSLLYEYFTVYNELTK  
VKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENE  
DILEDIVLTLTFEDREMIEERLKTYYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFQMQLIHDD  
SLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDLVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRI  
EEGIKELGSQILKEHPVENTQLQNEKLYLYLQNGRDMYVVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKKVLT RSDKNRGKSDNV  
PSEEVVKMKNYWRQLLNAKLITQRKFDNLTKAERGGELSELDKAGFIKRQIVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI  
TLKSKLVSDFRKDFQFYKVRINNYYHHAHDAYLNAVVG TALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIM  
NFFKTEITLANG EIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPK  
KYGGFDSPTVAYSVLVVAKVEKGSKKLKSVKELLGITIMERSFFEKNPIDFLEAKGYKEVKD LIKLPKYSLFELENGRKRMLASAG  
ELQKGNELALPSKYVNFILYLASHYEKLKGPEDNEQQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVL SAYNKH RDKPIREQA  
ENIIHLFTLNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSI TGLIYETRIDLSQLGGD (SEQ ID NO: 6)

FIG. 23

ACTGTA (SEQ ID NO: 7)

ATGGACAAGAAAGTACTCATTGGGCTCGCTATCGGCAACAACAGCGTGGCGCTCATTCAGGACGAGTACAAGGTGCCAGCAAAAATTCAAAGTTCTTGGGCAATA  
CCGATCGCCACAGCATAAAGAAGAAACCTCATTTGGCGCCCTCTGTTGCACTCGGGAGACGGCCGAAGCCAGCGGCTCAAAGAAGACAGCAGCGGCAGATATACCCGCA  
AAAAGAAATCGGATCTGCTACCTCGAGGAGATCTTTAGTAATGAGATGGCTAAGGTGGATGACTTTCTTCATAGGCTGGAGGAGTCTTTTTTGGTGGAGGAGTAAAAAGC  
AAGAGCGCCACCAATCTTTGGCAATATCTGTGGAGCGAGTGGCTACCATGAAAGATCCCAACCATATCATCTGAGGAAGAAGCTGTGATGAGACTGTAATAGGCTGA  
CTTGGGTGATCATCTCGGCTGGCGCATATGATCAAAATTCGGGAGACATCTCTATCGAGGGGACACTGAAACCCAGCAACGCGATGTGCAAAAACCTTTATCCAAT  
GGTTTCAGACTACAACTCAGCTTTTTCGAAGAGAACCCGATCAACGATCCGAGTTTGACGCCAAAGCAATCTGAGCGTAGGCTGCAAATCCCGCGCGCTCGAAAACCTCA  
TTCGACACGCTCCTGGGAGAAGAAAGACGGCTGTTTGGTAATCTTATCGCCCTGTCACTCGGCTGACCCCAACTTAAATCTAACTTCGACTTCGCGCGAAGATGCCAAG  
CTTCAACTGAGCAAGACACCTACGATGATGATCTCGACAATCTGCTGGCCAGATCGCGACACGACCTTTTTTTGGCGGCAAAAGAACCTGTGACAGCGCCATTCT  
GGCTGAGTGATAATCTCGAGTGAACACCGAGATCACAAAGCTCCGCTGAGCGTAGTATGATCAAGCGCTATGATGAGCACCAACAGACTGACTTTGCTGAAGGCCCTTG  
TCAGACAGCAACTGCCTGAGAAGTACAAGGAAATTTCTTCGATCAGTCTAAAAATGGCTACGCCGATACATTTGACGCCGAGCAAGCCAGGAGAAATTTTACAAATTTATTT  
TTCAGAGCCATCTTGGAAAAATGAGCGCACGAGGAGCTGCTGTAAGCTTAACAGAGAAGATCTGTTGCGCAAAACAGCGCACCTTCGACAAATGGAAGCATCCCCACCCAGA  
TTTCACTGGGCGAACTGCAGCTATTCAGTGGCGAAGAGGATTTCACTCCCTTTTGAAGATAACAGGGAAGATGTGAGAAATCTCTACAATTCGGATACCTACTATG  
TAGGCCCTCGCCGGGAAATTCAGATTCGCTGGATCGCAATCAGAGAGACCATCACTCCTCGAACTTCGAGGAATTCGAGGAATCGTGGAATAGGGGCTCGCCCA  
GTGCTCTCATCGAAGGATCAACTTTGATAAAAATCGCTAACGAAAAGGTGCTCTTAAACACTCTCTGCTGTACGATCTCTCACAGTTTATAACGAGCTCACCAAGGT  
CAAAATAGCTCAGAAGGATGAGAAGCCAGCATCTCTGTGGAGACGAGAAGAGTATCTGTGACCTCTCTTCAAGACGAACCCGGAAGTTTACCCTGGAACAGCTC  
AAAGAAGACTATTTCAAAGAGTTGAATGTTTCGACTCTGTGAATCAGCGGAGTGGAGATCGTTCACAGCATCTCTGGAAACGTATCAAGATCTCTGAAAAATCATTTAA  
AGACAAGGACTCTCGACAATGAGGAGAACGAGGACAATCTTGAGGACAATGTCTCACCTACCTTACGTTTGAAGATAGGAGATGATTTGAAGAAGCCTGTGAAAACTTAC  
GGGCTCATCTCTCGACGACAAAGTCATGAACAGCTCAAGAGCGCGATATACAGGATGGGCGGCTGTCAAGAAAAACTGATCAATGGGATCCGAGAACGACAGAGTGGA  
AAGACAATCTCGGATTTCTTAAGTCGATGGATTTGCCAACCGAACTTCATGCAGTTGATCCTCACTTAAAGGAGACATCCAGAAAGCACAAGATTTCT  
GGCAGGGGCGGAGCTTCACGAGCATCTGCTAAATCTTGCAAGTAGCCGACTCAAAAAGGAAATCACTGCAGACCTTAAAGGTCTGGATGAACCTGTCAAAGTAATGG  
GAAGGCATAAGCCGAGATATCGTTATCGAGATGGCCGAGAACCAAACTCCCAAGAGGACAGAAACAGTAGGGAAGAGGATGAAGAGATTTGAAGAGGGTATA  
AAAAAGAACTGGGCTCCAAATCTTAAAGAACACCCAGTTGAAAAACACCCAGTTCAGAAATGAGAAGCTCACTGTACTACCTGCAGAACGGGACATGTAAGTGGATC  
AGGAACTGGACATCAATCGGCTCGCACTAGCAGCTGGCTGATCGTGGCCAGCTTTTCTCAAAGATGATCTTATGATAAAGTGTGACAAGATCCGATAAAGCTA  
GAGGGAAGAGTGTAAACGCTCCCTCAGAAGAAGTTGTCAAGAAAAATGAAAAATTTATGGCGGACGCTGTGAACGCCAAACTGATCACACAGCGGAATTCGATAATCTGCAC  
TTAAGGCTGAACGAGTGGCTGCTGAGTTGGATTAAGCGCGCTTCATCAAAGGCGAGCTTTTGAGACACGCGAGATCCCAAGCAGCTGGCCCAAAATCTCTGATTTCACGC  
ATGAACCAAGTACGATGAATAATGACAAATGATTCGAGAGGTGAAGTTATTAAGTCTAAGCTGTAGCTGGTCTCAGATTTTCAAGAAAGGACTTCGATTTATAAGGTGAG  
ATGAGATCAAAATTTACCAATCGCGATGCTCTACCTGAATGCAATGAGTGTAGGCACTGCACTTCAAAAAATATCCCAAGTTGAATCTGAATTTGTTACCGGAGACTATAA  
AGTGTACGATTTAGGAAAAATGATCGCAAGTCTGAGCGAGAAATAGGCAAGGCCACCGTAACTGACTTCTTTACAGCAATATTTAGAAATTTTCAAGACCGAGATACACT  
GGCCCAATGGAGAGATTCGGAAGCGACCACTTATGAACAAACGGAGAAACAGGAAATCTGTGGACAAGGATAGGGAATTTCCGACAGTCCGGAAGGCTCTGTCCAT  
GGCGCAGGTGAACATCGTTTAAAGAACCGAAGTACAGCCGAGGCTTCTCCAAGGAAGTATCTCCCGAAAAGAACAGCAGACAGCTGATCGCAGCAAAAAGATTG  
GGACCCCAAGAAATACGGCGGATTCGATCTCTACAGTCGTTACAGTGTACTGGTTGCGCAAGGTGGAGAAAGGGAAGTCTAAAAAACTCAAAAGCGTCAAGGAACTG  
CTGTGGGCATCAATCATGTGGAGCATCAAGCTTCTGAAAAAAACCCCATCGACTTCTCGAGGCGAAGAGGATATAAGAGGTCAAAAAAGACCTCATCTTAAGCTTCCCAAGTA  
CTCTCTCTTTGAGCTTGAACACCGCGGAAACGAATGCTCGTAGTGGGCGAGCTCGAGAAAGGTAAACGAGCTGGCACTGCCCTCTAAATACGTTTAATTTCTGTATCTGG  
CCAGCAACTATGAAGAGTCCGAGAGATATGAGCAGAGTGTCTGGGAACAAACAAACACTACCTTGAATGAGATCATCGAGCAAAATAGCGGAATT  
TCTCCAAAAGAGTGAATCTCGCCGACGCTTCTGCTTCAATGAAGCAGGATAAGCCCATCAAGGAGGACGAGCAAAACATTATCCACTTGTTTA  
CTCTGACCAACTTGGGCGCGCTCGAGCTTCAAGTACTTGACACCCACCATAGACAAAGGCTACCTCTCAAAAGAGGTCCTGACGGCACTGATTCATCATGCTA  
TTTACGGGCTCTATGAACACAGAATCGACCTCTCTCAGCTCGGTGGAGACTAA (SEQ ID NO: 8)

[illegible]

ATGAGCGACCTGGTCTGGGCTGGCCATCGGCATCGGCAGCGTGGCGTGGGCATCTGAACAAGGTGACCGGGAGATCATCCAAGAACAAGTCGCATCTTCCCTGCTGCTC  
CTCAGGCTGAGAACAACTGGTGGCGGACCAACCGCAGGGTGGCGGCTTGTCCGCGCAAGAGCACGGGCGGTGGCTGAAACCGCTGTTTCGAGGAGAGCGGGCC  
TGATCACCGACTTACCAAGATCAGCATCAACTGAACCTACAGCTGCGGTGAAGGGCTGACCGACGAGTGAACAAGAGAGTGTTCATCGCCCTGAAGAACAT  
GGGTGAAGCACACCGGCATCAGTACTTGACGACGCGCAACAGCAGCGTGGCGACTACGCCAGATGTGAAGGAGAACAGCAAGCAGCTGGAGACCA  
AGAACCCCGGCAGATCCAGCTGGAGCTACAGACCTACGAGCTGCGCGGCACTTACCGTGAAGAAAGCGCAAGAACGCCCTGATCAACGTTGCCAC  
CAGCGCTACCGCAGCGAGGCCCTGGCATCTCGAGACCCAGCGAGTTCAACCCAGATCACCGACGATTCATCAACCGTACCTGGAGATCCTGACCGGCAAGCGC  
AAGTACTACCAAGCGCCCGCAACGAGAGCCGACCGACTACGGCCGTACCGCACCGGCGAGACCTTGGACAACATCTTCGGCATCTGATCGGCAAGTGCACT  
TCTACCCCGACGAGTTCGCGCCCAAGGCCAGCTACACCGCCAGGAGTTCAACTGTGAACGACCTGAACAACCTGACCTGCCAAGCTGTGAGCTGCGACGTGGCCGACATCAA  
GGGAGCAGAAGAACAGATCATCAACTACGTGAAGAACGAGAAGGCCATGGGCCCGCCAAAGCTGTCAAGTACATCGCAAGCTGTGAGCTGAGCAGATGGAACCGCGAGACCT  
GGGGTACCGCATCGACAAGAGCGGCAAGGCCGAGATCCACCTTCGAGGCTACCGCAAGATGAAGACCTTGGAGACCTTCCGCAACGAGTTCAGCCAGAAGCAGGTGGACGAGC  
GGGACAAGCTGGCTACGTGACCTTGAACACCGAGCGGAGGATCCAGGAGGCCCTGGAGCAGGATTCGCGACGGCAGCTTCAGCCAGAAGCAGGTGGACGAGC  
TGGTGCAGTTCGCAAGGCCAACAGCAGCATCTTCGCAAGGGCTGGCAAACTTCAGCGTGAAGCTGATGAGTGGAGCTGATCCCGAGCTGACGAGACAGCGAGGAGC  
AGATGACATCTGACCCGCTGGCAAGCAGAAACCAACAGCAGCAGCAACAAGACCAAGTATCATCGACAGAAAGCTGTGACCGAGGAGATCTACAACCCCGTGGTG  
CCAAGAGCGTGGCCAGGCCATCAAGATCGTGAACCGGCCATCAAGGAGTACGGCGACTTCGACAACATCTGTATCGAGATGGCCCGCGAGACCAACAGGACGACGAGA  
AAGAGGCCATCCAGAAGATCCAGAAGGCCAACAAAGGACGAGAAGGAGCGGCCATGCTGAAGGCCGCAACAGTACAACGGCAAGGCCGAGCTGCCCCACAGCGTGTTC  
ACGGCCACAAGCAGCTGGCCACCAAGATCGCCTGTGGCACCAAGCAGGGCGAGCGTCCCTGTACACGGCAAGACCATAGCATCCACGACTGATCAACAACAGCAACCA  
GTTGAGGCTGGTGCCATCTGCCCTGAGCATCACTTCGACGACAGCTGGCCAAACAAGTGTGTCGCGCACCGCGTCAAGGAGAAAGGCGCAGCGCACCCCTAC  
GTCAGCTTGACAGCATGACGACCGCTGGAGCTCCGCGAGTGAAGGCTTGTGGCGGACGCAAGCCGTGAGCAACAAGAAAGAGTACCTGCTGACCGGAG  
GGACATCAGCAAGTTCAGCTGCGCAAGAGTTTCAGAGCGCAACTGTTGGACACCCGCTACGCCAGCGCGTGGTGTGAACGCCCTGACGAGGACACTTCGCGGCCAC  
AAGATCAGACACCAAGTGAGCTGTGGCGGGCAGTTCAACAGCCAGCTGCGCCCATCGAAGAACCCGCGCATCGAAGAACCCGCGACACTACCAACCCGCTGAGCGCC  
CTGATCATTCGGCTTCTAGCAGCTGAACCTGTGAAGAAGCAGAAACACCTGTGTGAGCTACAGCGAGGACCCAGCTGTGACATCGAGACCGGCGAGTGTATCAGC  
GACGACGAGTACAAGGAGCGGTTCAGGGCCCTACAGCACTTCGTGGACACCTGAAGCAAGGATTCGAGGACAGCATCTGTTGAGTACCAAGTGGACAGC  
AAGTTCAACCGCAAGATCAGCGACGCCACCATCTACGCCACCCGCGGCAAGGTGGCAAGGACAAGGCCGACGAGACCTACGTGTGGCAAGATCAAGGACATCTAC  
ACCCAGGACGGCTACGACGCTTCATGAAGATCTACAAGAAGGACAAGAGCAAGTTCCTGATGTACCGCCACGACCCCGAGACCTTCGAGAAGGTGATCGAGCCCATCTG  
AGAAGTACCCCAACAGCAGATCAACGATAAAGGCAAGGAGGTGCCCTGCAACCCCTTCTGAAGTACAAGGAGGAGCAGCGGTACATCCGCAAGTACAGCAAGAAGGGCA  
ACGGCCCGCGAGATCAAGAGCTGAAGTACTACGACAGCAAGCTGGGCAACCATCGACATCAACCCCAAGGACAGCAACAAGGTTGGTGTGAGAGCGTGAGCCCT  
GGGCGCGCGACGTGTACTTCAACAAGACCAACCGGAAGTACGAGATCTTGGGCTGAAGTACCGGACCTGAGTTTGAAGGGCACCGGCACTACAAGATCAGCCAGGA  
GGAAGTACAACGACATCAAGAAGAGGAGGGCGTGGACAGCGACAGCGAGTTCAAGTTTCAACCTGTACAAGAACGACCTTCTGCTGTTGAAGGACACCGGACCAAGGAGCA  
ACAGCTGTTCCGCTTCTGAGCGCACCATGCCAAGCAGAGACACTACGTGAGCTGAAGCCCTACGACAAGCAAGATTCGAGGGCGGAGGCCCTGATCAAGGTGCTG  
GGCAACGTGGCCAAACAGCGGCGAGTGCAAGAAGGGCTGGCAAGAGCATCAGCATCAAGGTGGCGACCGACGCTGGGCAACCAACATCATCAAGAAACGA  
GGGCGCAAGGCCAAGCTGGACTTCTAA (SEQ ID NO: 10)



FIG. 27

ATGGCCGCTTCAAGCCCAACCCCATCACTACATCTCTGGGCTGGACATCGGCATCGCAGCGTGGGCTGGGCTGGATCGACGAGGACGAGAACCCCATCTGCC  
TGATCGACCTGGGTGCGGTGTTGAGCGCGCTGAGGTGCCAAGAGTGGTGACAGTGGCTATGGCTGCCGGCTTGTCTGCTGTTCGGGCGCTTACTGCCGGCGC  
GCTACCGCTTCTGGCGCTGCCGCTGTAAGCGGAGGTGTCTGAGGCTGCCGACTTCACGAGAACGGCTGATCAAGAGCTGCCAACACTCTTGGCAGC  
TGCGGCTGCCGCTGGACCGCAAGCTGACTCTCTGGAGTGGAGCGCTGTCTGCTGACCTGATCAAGCACCGCGGTACTGAGCCAGCGCAAGAACGAGGGGAGA  
CCGCCACAAGAGTGGGTCTCTGTGAAGGGGTGGCCGACACGCCCTGACACTTCCGCACTCTGCTGAGCTGGCCCTGAACAAGTCAGAAAGTCAGAGTTCGGA  
GGAGCGGCCACATCCGCAACCAGCGCGGACTACAGCCACACCTTCAGCCGCAAGGACTGACGGCCGAGCTGATCTGCTGTCGAGAAGCAGAAAGATTCCGGCAA  
CCCCACGTGAGCGCGGCTGAAGAGGGCATCAGACACCTTACACCCAGCGCCCTGAGCGCGACGCCGTGAGAAGTGCAGAAGATGCTGGGCCACTGACCTTCGA  
GCCAGCGAGCCCAAGCGCCAAAGAACCTACACCGCGAGCGCTTCACTGTGCTGACCAAGCTGAACAACCTGCGCATCTGGAGGACACCGCTTCTTCAAGGGCTGC  
GACACGAGCGCCACCTGATGAGCAGCCCTACCGCAAGAGCAAGCTGACTACGCCAGCGCCCTGAGAAAGGAGGCGCTGAAGGACACCGCATCCAGCCCGAGTCTCTG  
GCTACGGCAAGGACAACGCCGAGGCCAGCACCTGATGGAGATGAAGGCTTACAGCCCTTCAAGACCGACGAGGACATCACCGCGCTGAAGGACCGCATCCAGCCCGAGTCTGGAG  
AACCTGAGCCCGAGCTGCAGGACGAGATCGGCACCGCTTACAGCTTCAAGACCGACGAGGACATCACCGCGCTGAAGGACCGCATCCAGCCCGAGTCTGGAG  
GCCCTGTGAAGCATCAGCTTCGACAAAGTTCTGTCAGATCAGCTGAAGGCCCTGCGCGCATCTATCCCGCGCAGGATCCGCAACCCCTGTGTCTGCGCGCTGCGCCG  
AGATTACGGGACCACTACGGCAAGAAACACCGAGGAGAGATCTACCTGCCTCTATCCCGCGCAGGATCCGCAACCCCTGTGTCTGCGCGCTGAGCCAGGC  
CCGCAAGGTGATCAACGGCGTGTGCGCGCTACGGCAGCCCGCCGATCCACATCGACACCGCGCGAGGTGGGCAAGAGCTTCAAGGACCGCAAGGATCGAGAA  
GGCCAGGAGGAAACCGAACCGGAGAGCGCGCCCAAGTTCCGCGAGTACTTCCCAACTTCTGTGGCGAGCCCAAGAGCAAGGACATCTGAAAGTGCCT  
GTACGAGCAGCAGCACGGCAAGTGCCTGTACAGCGGCAAGGAGATCAACCTGGCGCGCTGAACGAGAGGGCTACGTGGAGATCGACCGCTGCCCTTTCAGCCGCAC  
CTGGGACGACAGCTTCAACAAGGTGTGTGTGGGCAAGGAGAACGAGAACGAGGCAACGAGACCCCTACGAGTACTTCAACGGCAAGGACAAAGCCCGGAGTG  
GCAGGTTCAAGGCCGCTGGAGACCAAGCGCTTCCCGCAGCAAGAACGAGCGCATCTGTCTGCAAGTTCGACGAGGACGGCTTCAAGGAGCGCAACCTGAACGA  
CACCGCTACGTGAACCGCTTCTGTGCCAGTTCTGTGGCCAGCGCATGCGCTGACGGCAAGGCAAGAGCGCTGTTCGCCAGCAACGGCCAGATCACCACTGCTG  
CGGGCTTCTGGGCTGCGCAAGGTGCGCGCAGAACCGCCACCGCTGGACCGCTGGAGTGTGTGGCTGACGACCGTGGCCATGCAGCAGAGATCACCCGC  
TTCGTGCGCTACAAGGAGATGAACGCTTCGACGGTAAACCATCGAACGAGACCGCGAGTGTCTGACCAAGAACCCACTTCCCCAGCCCTGGGAGTTCCTGCCCC  
AGGAGGTGATATCCGCGTGTTCGGCAAGCCCGACCGCAAGCCCGAGTTCGAGGAGCCGACACCCCGAAGCTGCGCACCTGTGCGCGAGAGCTGAGCAGCCGCTG  
CTGAGGCCGTGCACGAGTACGTACTCTTGTGTGAGCCGCGCCCAACCGCAAGATGAGCGGTGAGGTTCATGAGACCTGTAAGAGCGCAAGCGCTGAAGCGCCCTG  
AGGGCGTGAGCGTGTGCGGTGCCCTGACCCAGCTGAAGCTGAAGGACCTGGAGAAGTGGTAAACCGAGCGCGAGCCCAAGCTGTACGAGCCCTGAAGGCCCTGAAGGCCCGC  
CTGAGGCCCAAGGACACCCCGCAAGGCTTCGCGGAGCCCTTCAAGTACGACAAGCGCGGCAACCGCACCGCAGCGGTAAGGCGCTGCGCGTGGAGCAGGTG  
CAGAAGACCGCGTGTGGTGGCAACCAACGGCATCGCGCAACCGCCACCATGTTGCGGTGGACGTTCGAGAAGGGCGACAAGTACTACCTGGTGGCCATCTAC  
AGCTGGCAGGTGGCAAGGGCATCTGCGGACCGCGCGTGTGTCAGGGCAAGGACGAGGAGTGGAGTGGTGGCAAGGAGATCCGCCCTGCGCCCTGAAGA  
CCCAACGACCTGTGTGAGGTGATACCAAGAAGGCCCGCATGTCGGCTACTTCGCAAGTCCACCGCGCACCAATCAACATCCGATCCAGCTGACGACCA  
AGATCGGCAAGAACGGCATCTGGAGGGCATCGGCGTGAAGACCGCTGAGCTTCAGAAGTACCAAGTACGAGATCGACGATCGGCAAGGAGATCCGCCCTGCGCCCTGAAGA  
AGCGCCCTCTGTGCGCTAA (SEQ ID NO: 11)

FIG. 28

ATGGCCGCTTCAAGCCCAACCCCATCACTCTGGGCTGGCCATCGGCATCGGCAGCGTGGGCTGGGCCATGGTGGAGATCGACGAGGACGAGAACCCCATCTGCC  
TGATCGACCTGGGTGGCGGTTCGAGCGCGTGAAGTGCCCAAGACTGGTGACAGTCTGGCTATGGCTGCGCGCTTGCTGCTCTGTTGCGCGCTTACTGCGCGGC  
GCTACCGCTTCTGCGCGCTGCTGAAGCGGAGGGTGTGCTGACGGTGCAGTTCGACGAGAACGGCTGTAAAGAGCTGCCAACACTCTTGGCAGC  
TGGCGTGGCGCTCTGACCGCAAGCTGACTCTCTGGAGTGGAGCGCGTGTGCTGCACCTGATCAAGCACCGCGGTACTGAGCCAGCGCAAGAACGAGGGCGAGA  
CCGCGACAAGAGAGTGGTGTCTGAAGGGGTGGCGACAAAGCCACCGCTGCTGACCTGATCAAGCACCGCGGTGACTTCCGCACTCTGCTGAGCTGGCCCTGAACAAGTTCGAGAA  
GGAGCGGCCACATCCGCAACAGCGCGGCACTACGCCACACCTTCAGCCGCAAGGACTGAGCGGACCGCTGCGCATCTGGAGCGGGCAGCGCCCCCTGACC  
CCCCACGTGAGCGCGGCTGAAGAGGGCATCGAGACCTGTGATGACCCAGCGCCCGCTGAGCGGACCGCTGCGCATCTGGAGCGGGCAGCGCCCCCTGACC  
GCCAGCGAGCCCAAGCCCTACACCGCGAGCACTACCTGCTGACCAAGCTAACCACTGCGCATCTGGAGCGGGCAGCGCCCCCTTCTTCAAGGGCCTGC  
GACACCGAGCGCCACCTGATGGACGAGCCCTACCGCAAGAGCAAGTGAACCTACGCCAGCGCCCAAGTGTGGTCTGGAGACACCGCTTCTTCAAGGGCCTGC  
GCTACGGCAAGGACAACCGCGAGGCCAGCCCTGATGGAGATGAAGCCTACACGCCATCAGCGCGCCCTGGAGAAAGGGCTGAAGACAAGAGTCTCTG  
AACCTGAGCCCCGAGCTGAGGACGAGATCGGCACCGCTTCAAGACCGACGAGGACATCACCGCGCTGAAGGACCGCTGAAGGACCGCATCCAGCGCGAGATCTCTGGAG  
GCCCTGCTGAAGCACATCAGCTTCGACAAGTTCGTGACATCAGCCTGAAGGCCCTGCGCGCATCTGCCCCCTGATGGAGCAGGGCAAGCGCTACGACGAGGCTGCGCG  
AGATCTACGGCGACCACTACGGCAAGAAAGAACACCGAGGAGAAAGATCTACCTGCTCTATCCCCCGGACGAGATCCGCAACCCCGTGGTGTGCTGCGCGCTGAGCCAGGC  
CCGCAAGGTGATCAACGGCGTGTGGCGCTACGGCAGCGCCCGCATCCACATCGAGACCGCCCGAGGTGGGCAAGAGCTTCAAGGACCGCAAGGAGATCGAGAA  
GCGCGAGGAGAAACCGCAAGGACCGGAGAGCGCGCAAGTTCGCGAGTACTTCCCACTTCGTGGCGAGCGCAAGGGCTACGTGGAGATCGCGCTGCCCTTCAAGCGGCAC  
GTACGAGCAGCAGCGCAAGTGCCTGTACAGCGGCAAGGAGATCAACCTGGCGCGCTGAACGAGAGGGCTACGTGGAGATCGCGCTGCCCTTCAAGCGGCAC  
CTGGGACGACAGCTTCAACAACAGGTGCTGGTGGCAGCGAGGCTCAAGAACGGCAACCAAGCCCTACGAGTACTTCAAGGAGGCAAGGACCAAGCGCGAGTG  
GCAGGAGTTCAAGGCCCGCTGGAGACAGCGCTTCCCCCGCAGCAAGAAAGCAGCGCATCTCTGCTGCAAGTTCGACGAGGACGGCTTCAAGGAGCGCAACCTGAACGA  
CACCGCTACGTGAACCGTTCCTGTGCCAGTTCGTGGCCGACCGCATGCGCTGACCGGCAAGGCAAGCGCGTGTTCGCCAGCAACGGCCAGATCACCAACTGCTG  
CGCGCTTCTGGGCGCTGCGCAAGGTGCGCGCGAGAACACCGCCACCGCTGGACGCGCTGGTGGCTGCAAGCCTGCGCATGGCCATGCAAGAGATCACCCGC  
TTCGTGCGCTACAAGGAGATGAACGCTTTCGACGGTAAACCTACGACAGGACCGGCGAGTGTCAACGAGAACCCCTTCCCCCAGCTTCCCCCAGCTTCTTCTGCCCC  
AGGAGGTGATGATCCGCGTGTTCGGCAAGCCCGACGGCAAGCCCGAGTTCGAGGAGCGCGACACCCCGAGAAAGTGCACCTGCTGGCGGAGAAAGTGAAGCAAGCGGCC  
CTGAGGCGTGACGAGTACGTGACTCTCTGTTGAGCGCGCCCCAACCGCAAGATGAGCGGTACGGGTCACTGGAGACCGTCAATGGAGCGCGCAAGCGCTGGACG  
AGGCGTGAGCGTGCGCGTGCCTGACCCAGGCTGAAGCTGAAGGCTGGAGAAAGTGGTGAACCGCGAGCGCAACCGCAAGCGCTGAAGCGCTGAAGCGCGCGC  
CTGAGGCCCAAGGACACCGCCCAAGGCTTCGCCGAGCCCTTCAAGTACGACAAGCGCGCAACCGCAACCGCATGGTGGCGTGGAGCTGAAGCGCTGAAGCGCGCGC  
CAGAAGCCGGCTGTGGTGCGCAACCAACCGCATCGCGGACCAACCGCATGGTGGCGTGGAGCTGTTCGAGAAAGGGCGACAAGTACTACCTGGTGGAGCAGGTG  
AGCTGGCAGTGGCCAGGGCATCTGCCCCGACCGCGCTGTGCGAGCAAGGAGGAGGATGGCAGCTGATCGACGACAGTTCAACTCAAGTTCAGCTGCAC  
CCACGACCTGTTGGAGGTGATCACCAAGAGGCGCGATGTTGGCTACTTCCGAGTCCACCGCGGACCGGCAACATCAACATCCGATCCAGCAGCTGGACCA  
AGATCGGCAAGAACGGCATCTGGAGGGCATCGGCGTGAAGACCGCCCTGAGCTTCCAGAACTACAGATCGACGAGTGGGCAAGGAGATCGCGCCCTGCCCTTGAAGA  
AGCGCCCTCTGTGCGCTAA (SEQ ID NO: 12)

FIG. 29

ATGAAGAAGGAGATCAAGGACTACTTCTGGGCTGGACGTGGGACCGGACCGGAGCGTGGGCTGGGCGTGACCGACCGACTACAAGCTGCTGAAGGCCAACCGCAAGGAC  
CTGTGGGCGATGCGCTTCTGAGACTGCTGAGACCGCGAGGTGCGCGGCTGACCGGCTGCTCGCGCGCATCGAGCGCGCAAGAGCGCATCAAGCTGCTGCGAG  
GAGCTGTACCGCAGAGATCGCAAGACCGACGAGGCGTCTTCAGCGCATGAAGAGAGCGCCCTTACGCGGAGCAAGACATCTCTGAGGAGAACACCTGTTCAG  
AGCAAGGACTTGGCGACAAGACTACCAAGCGCTACCCACCATCAACCACTGATCAAGGCTGGATCGAAGAACAGGTGAAGCCCGACCTCGCTGCTGTACTG  
GCCTGCCACAACATCATCAAGAAGCGCGGCACTTCTGTTCCGAGGCGACTTCGACAGCGAGAACCAAGTTCGACACCGATCCAGGCCCTTCTGAGTACTCGCGGAGG  
ACATGAGGTTGACATCGACCGCGACAGCCAGAGGTTGAAGGAGATCTGAAGACAGCAGAGAGCGCGCTGAACAAGATCTTGGGCTG  
AAGCCAGCGACAAGAGAAGGCCATCAACCACTGATCAGCGGCAACAAGATCACTTGGCGACTGTAGACAAACCCGACTGAAGGACCGCGAGAAGAACAGC  
ATCAGCTTCAGCAAGGACGACTTCAGCCCTGAGCGACGACTGCGCCAGCATCTGGGCGACAGCTTCGAGCTGCTGCTGAAGGCCAAGGCCGTGTACAACCTGCGAGCTGC  
TGAGCAAGGTGATGGCGACGAGCTACCTGAGCTTCGCAAGGTGAAGATCTACGAGAAGCACAAGACCGACCTTACCAAGCTGAAGACGTGTACAAGAGCACTTCCC  
CAAGACTACAAGAAGGTGTTGGCTACAACAAGAGAGAGAAACAACAACACTACAGCGGCTACGTGGGCTGTGCAAGACCAAGAGCAAGAGTGTATCATCAACAA  
CAGCTGAACAGGAGGACTTCTACAAGTTCTGAAGACCATCTGAGCGCCAAGAGCGAGATCAAGGAGGTGAACGACATCTGACCGAGATCGAGACCGCACCTTCTCTG  
CCCAAGCAGATCAGCAAGAGCAACGCCGAGATCCCTACGAGCTGCGCAAGATGGAGCTGAGAGAAGATCTGAGCAACCGCGAGAGCACTTCTCTGAAGCAGAAAG  
GACGAGAGGCGCTGAGCCACAGCGAGAAGATCATGCTGCTGCTCAAGTCTTCAAGTCTTCACTGCGCCCATCAACGACCAACCAAGAAAGTTCCTCCCGACCGCTG  
CTGGTGTGAAGAAGAGAGCCCGAGAGAGCCACCCCTGGAACTTCTTCCGACATCGACAAGGAGAGAACCGCGAGGCTTATCACCAGCGCACCA  
CTTCTGCACATACCTGGTGGCGAGAGCGTGTGCTGACAGAGCAGCTGCTACAGCGAGTACACCGTGTGAACGAGATCAACACCTGACATCATCGACGCGCAAG  
AACATCTGCCAATCAAGCTGAAGCAGAAGATCTACGAGGAGCTGTTCAAGAGTACAAAGATCACCCAGACGATCAGCACCTTCAAGCACGAGGCGATCTGCA  
ACAAGCCGACGAGGTGATCATCTGGGCTGACAAGAGGTGACACGAGCTGAAGAGTACATCGAGTGAAGAACATCTTCGGCAAGCAGGTGGACGAGATCAGCA  
CCAAGAACATGCTGAGGAGATCATCGCTGGGCCACCATCTACGACGAGGCGAGGCAAGACCATCTGAAGACCAAGATCAAGGCCGAGTACGCGCAAGTACTGACGCG  
ACGAGCAGATCAAGAAGATCTGAACCTGAAGTTCAGCGGCTGGGCGGCTGAGCGCAAGTTCCTGAGACCGTGAACGAGAGTTCGCGGCTTACGCGAGCGGCTTCA  
ATCATCACCGCATTCGCGGAGACCCAGAACCACTGATGAGTGTGCTGAGCAGCGAGTTCACCTTACCGAGAACATCAAGAGATCAACAGCGGCTTCGAGGACCGCGA  
GAAGCAGTTACGACCGGCTGGTGAAGCCCTGTTCTGAGCCCGCGTGAAGAGATGCTGGCAGACCTGAAAGCTGTGAAGGAGATCAAGCGGATCAGCCACATCACCAG  
GCTCTCTTAAGAAAGATCTTATCGAGATGGCAAGGCGCGAGCTGGAGCCTGCTCGACCAAGACCGCTGAAGATCTCTGAGGAGCTGTACAACACTGCAAGAACG  
ACGCCGACGATTCAGCAGCGAGATCAAGGACTGAGCGGCAAGATCGAGAAGCAGGACAACCTGCGCTGCGCAGCGACAAGCTGTACTACCTGTACTACCCAGCTGGGCA  
AGTGCAATGACTCGGCAAGCCCATCGAGTCGGCACGTTTCGACACGAGCAACTACGACATCGACCACTACTACCCCGAGAGCAAGATCAAGGAGACAGCATCAGCAA  
CCGCGTGTGTCAGCAGCTGCAACAAGAAAGAGGAGCAAGTACCCTCTGAAGAGCGAGATCCAGCAAGCAGCGCGCTTCTGGAACCTCTCTGAGCGCGCAACAA  
CTTCATCAGCTTGAGAGGCTGAACCGCTGACCGCGCGCACCCCTACGACACGAGAGACCGCAAGTTCATCGCCCGCAGCTGGTGAGAGACTCGCAAGCTACCAAG  
GTGGCCCAAGGTGTGGAAAGATGTTCCCGAGACCAAGATCGTGTACAGCAAGGCGGAGACCGTGAGCATGTTCCGCAACAAGTTCGACATCGTGAAGTCCCGGAG  
ATCAAGGACTTCCACCGCCACGAGCTACCTGAACATGCTGTGGGCAACGTTGACACCAAGTTCACCAACAACCCCTGGAATTTCAITTAAGGAGAAGCGCGACAA  
CCCCAAGTCCCGACACCTACTACAGGTTTCGACTACGACGTGAAGCGCAACATCACCGCTGGAGAGAGGCAAGACCATCATCACCGTGAAGGACATG  
CTGAAGGCGAACACCCCATCTACACCCCGAGCGCTGCAAGAAGGGGAGCTGTTCACAGACCATCATGAAGAAGGGCTGGCGCAGCACCCCTGAAGAAGGAG  
GGCCCTTCAGCAACATCAGCAAGTACGCGGCTACAACAAGTGAAGCGCCCTACTACACCTGATCGAGTACGAGAGAGGCAACAAGATCCGCGACCTGGAGACC  
ATCCCTGTACCTGTTGAAGGACATCCAGAAGGACGAGGAGCTGCTGAAGAGCTACCTGACCGCAAGTTCGAGATCTGAGTTCGAGATCTGAGTTCGAGATCAAGGAGTCA  
TCAACAGCTGCTGAAGATCAAGGCTTCCCTGCCATCAACCGGCAAGCAACGACGATCTTCTGTGCGCCCGCGTGCACTTCTGTGAGCAACAAGAGGCTGTG  
TACTCAAGAAGATCATCCGCTTCAGCGAGATCCGCGAGCGAGAGATCGGCAAGACCATCAGGACCTTACGAGTTCGAGCTTCCGAGCTACATCAAGGAGAAC  
TGTGAAGAAGACCAAGAAGCAGAGATCGGCGAGAGGAGTTCTACGCTGTCGAGAAGAAGAACCTGGAGATCTACGATGCTGCTGACCAAGCAACAAGGACCA  
TCTACAAGAAGCGCCCAACAGCGCCACCATCGACATCTCTGTTGAAGGCAAGGAGAGTTCAAGAGCTGATCATCGAGAACCAAGTTCGAGGATGATCTGGAGATCTGAA  
GCTGTTAGCGCCACCCGCAACGTGAGCGACTGACGACATCGGCGGCGACCAAGTACAGCGGCTGGCCCAAGATCGGCAACAGATCAGCAGCTGGACAACTGCATCTCT  
GATCTACCAGAGCATCACCGGCATCTTCGAGAAGCGGCTCGACCTGCTGAAGGTGTA (SEQ ID NO: 13)

[illegible]

FIG. 31

GCCCACGACACCAACCACCA (SEQ ID NO: 18)

TCTTCCCTAGGAATGATGAC (SEQ ID NO: 19)

GCGGTCCCTGAGGTGCACCG (SEQ ID NO: 20)

AGAAGTGGAATACAGAGCGG (SEQ ID NO: 21)

FIG. 32A




FIG. 32B




FIG. 33

ATGAGAGAAGGAATCCTAGTGAGAGGGAGTGCCCGCGGGTTTTCTGTGCACGCCCTCCGTGGAATCCGGATGTGAGAC  
TCAGGAGTCCCCCGCACCGTGTGTTCGCGCCACCAAGGAGACAACACTGACGGTGGCGCGGCTGCTGCAGGTGGA  
AGCCAAGCCGCGCTGTGGGCGGAGCCGATGGAACCGAATCCAGACCCGGTCCCTCTGGCATGAACGTTGTGCAGGT  
CGCAGAACTTACCCCGAACTCCGCAGGATCTTGACAATCACGGAGGACGGCCAGGGCCTCAAGGGAGTGAAAGAGAGAG  
AGAGGGGCTTGTGAGGCCACTGAGGAAGCTCGCAATCTGGCGTTTTTCATTGATGACAAGGCACAGGCCGCGGAATGCATTAC  
ATTCCAACAGATTAAAGGACAACCTGCGCAAACGAGCTCGATCTCCTGGCCAGAAAGTATAGCATCGAGCAGCTGACAACCTAT  
TGGCTGAGCCCGGCGACGATTTTGAAGAGGCCATCCGCGTGTACGCAAAGGTGGCCCTGCGACCTGACTGCAAATATAAG  
ATTTCCAAACTGGTTAACATCCGGAATTGTTGTTATATTAGTGGAATGGCGCAGAAGTGAGATTGACACAGAGGATCGAG  
TCGCTTTCGGGTCTATGATCAACATGTGGCCCGGTGTGCTCGGCATGGATGGCGTAGTCATTATGAATGTGGCTTTCACC  
GGACCTAATTTTAGCGGAACCGTCTTCTGGCAAACACTAATCTGATCCTGCATGGAGTTTCTTTCTATGGATTAAATAACACC  
TGTGTTGAAGCTTGACCGACGTGGGTTAGAGGGTGTGCTTTTATTGCTGCTGGAAGGCGTCTGTGTAGACCCAAA  
AGTAGAGCTTCTATCAAGAAATGCCTGTTTCGAGAGGTGTAATCTGGGCATTCAGTGAAGGTAATAGCAGGGTCAGGCATA  
ACGTGGCCTCAGATTGCGGATGTTTATGTTGGTTAAATCCGTGGCTGTGATCAAGCACACAATGGTGTGGCAATTGTGA  
GGACCGGCATCTCAAATGCTGACATGTTCCGATGGCAACTGTCACTGTCTCAAACAATTCACGTTGCGAGCCATTCTCGG  
AAGGCTGGCCAGTTTTCGAGCATAACATCCTGACGCGCTGTAGTCTCCACCTGGGTAAACAGACGGCGTTTTCTCTGCCAT  
ATCAGTGTAAACCTGTACATACCAAGATACTCCTGGAAACCAGAAATCTATGAGTAAAGTGAACCTGAATGGTGATTCGATATG  
ACCATGAAGATATGAAAGTCTCCGCTATGACGAAACTAGGACTAGGTGTAGGCCCTGCGAGTGTGGCGGCAAGCATATC  
CGCAACCAACCCGTGATGTGGACGTGACCGAGGAGCTGCGCCCCGATCACCTGGTGTGCTGGCCTGCACCAGAGCAGAATT  
CGGGAGCTCAGACGAAGACACTGATTAA (SEQ ID NO: 22)



FIG. 34

ATGGGCACTAGTGGGTACCCCTTGGCATGACCCCTCCGCCCACTCGGTCAAGGCTCTCCGGAGAACTCCTTACTCTC  
GCGATAGGCTTCCTCCGTTCCGAACCGAACAACACGGGCAACCATTTCTGGAAGATCATCCACTGCTGCCAGAGTGTAATACCCCT  
GACGATGCATAACGTTTCTTACGTCCGGTCTGCCCTGTTCCTGGGTTTACTCTGATCCAGGAGTGGGTCGTGCCCTTGG  
GATATGGTCTCACACGCGAGAGCTGGTGATCCTGAGAAAGTGATGCAITGCTGCTTGTGTTGCGCAAAACATCGACATTAT  
GACCAGTATGATGATTGATGATACGAGAGCTGGCGCTTCACTGCCACTGCTCATCCCTGGCAGCCTGCAGTGTATTGCA  
GGGGGCCAGGTGCTCGCTTCCTGGTTTAGAATGGTAGTGGATGGCGCCATGTTTAATCAGAGATTTCATTTGGTATCGGGAG  
GTTGTGAACATAACATGCCAAAGGAAGTCAITGTTATGAGCAGCGTGTTCATGCGGGGGCGGCATCTGATATATCTGAGAC  
TGTGGTACGACGGTCACGTGGGCTCTGTCGTGCCTGCAATGTCTTCGGATACAGCGCCCTGCACGTGTGGGATCCTCAATAAT  
ATAGTCGTCTTGTGTTGCTCTTATTGCGCAGATCTCAGTGAGATAAGAGTCAGGTGCTGTGCAAGACGGACCGCAAGGGCG  
ATGCTCCGCGCGTCATCATTTGCCGAGGAGACAACCTGCCATGCTTTACAGCTGTAGAACAGAGCGCAGACGCCAGCAG  
TTTATCAGAGCCCTGCTGCAGCACCCACCGCCCCATACTCATGCTACTACGACAGTACGCCCAATGTAA (SEQ ID NO: 23)

## ENHANCING ENDONUCLEASE BASED GENE EDITING IN PRIMARY CELLS

### PRIORITY AND CROSS-REFERENCE TO RELATED APPLICATIONS

**[0001]** This application claims the benefit of priority to U.S. Provisional Application 62/161,104, filed on May 13, 2015, which is hereby incorporated by reference in its entirety.

### REFERENCE TO SEQUENCE LISTING

**[0002]** The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled SCRI\_094WO\_SEQLIST.txt which is 72,184 bytes in size, created on May 11, 2016 and last modified on May 11, 2016.

### FIELD

**[0003]** Aspects of the disclosure provided herein are generally related to endonuclease-based gene editing systems and methods. Some aspects of the disclosure provided herein are related to the CRISPR/Cas9 gene editing system.

### BACKGROUND

**[0004]** Endonuclease-based systems have rapidly become significant gene editing tools in biomedical research, with their application for gene disruption and/or gene targeting demonstrated in a variety of cultured cell and model organism systems.

**[0005]** Endonuclease-based systems for gene editing allow scientists to edit genomes with unprecedented precision, efficiency, and flexibility. Examples of endonuclease-based approaches for gene editing include systems comprising, without limitations, zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), meganucleases (such as MegaTALs), and CRISPR/Cas9.

### SUMMARY

**[0006]** The present disclosure provides several methods for applying CRISPR/Cas9 in primary cells in which an mRNA is used to express Cas9, and simultaneously, mRNA is used to transiently express two adenoviral proteins, E4ORF6 and an H373A or H354 mutant version of E1B55K. The wild type E4ORF6 and E1B55K proteins relieve post-entry defects for expression from AAV vectors; however, if the wild type E1B55K or E4ORF6 proteins are used, they disable an important protein complex involved in DNA repair (known as the MRN complex), which leads to cell cycle arrest and high toxicity due to lack of repair of DNA breaks. Instead of using the wild type proteins mutants of E1B55K, which do not disable the MRN complex are utilized. Co-expression of Cas9 with E4ORF6/E1B55K mutants results in sufficient relief of the post-entry restriction on AAV expression while maintaining intact DNA repair. This allows for a substantial improvement in Cas9-mediated gene editing efficiency with minimal toxicity when an AAV vector is used to express the guide RNA's necessary for Cas9 targeting.

**[0007]** Some alternatives of the system provided herein, comprise endonucleases so as to provide additional tools useful in gene disruption. Several alternatives, for example, relate to systems utilizing CRISPR/Cas9 systems and meth-

ods for enhancing the efficiency of inactivation of a target gene concurrently with endonucleases. More alternatives relate to the inactivation of a target gene for therapeutic, agricultural and/or other commercially useful purposes utilizing one or more of the systems described herein. Still more alternatives relate to the production of autologous and/or non-autologous primary cells having an inactivated target gene and the use of these cells for therapeutic and/or other commercial applications.

**[0008]** In some alternatives, a system for editing at least one target gene in a cell is provided, the system comprising a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector; a second nucleic acid sequence encoding a Cas9 protein, a derivative or fragment thereof; a third nucleic acid sequence encoding a first adenoviral protein; and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives of the system, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives of the system, the cell is not a transformed cell. In some alternatives of the system, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

**[0009]** In some alternatives of the system, the vector is a viral vector. In some alternatives of the system, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the system, the second nucleic acid encoding the Cas9 protein, a derivative or fragment thereof is an mRNA. In some alternatives of the system, the second nucleic acid sequence encoding the Cas9 protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the Cas9 protein, a derivative or fragment thereof is from *S. pyogenes*. In some alternatives of the system, the third nucleic acid encoding the first adenoviral protein is an mRNA. In some alternatives of the system, the mRNA is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first adenoviral protein is E4ORF6. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is an mRNA. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the second adenoviral protein is an E1B55K mutant. In some alternatives of the system, the first, second, third and fourth nucleic acid sequences are joined to regulatory elements that are operable in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a regulatory element. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a promoter, for example, a U6 promoter. In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is constitutively expressed.

**[0010]** In some alternatives, a method of editing at least one target gene in a cell is provided, the method comprising introducing into a cell a first vector that comprises a first nucleic acid sequence encoding a CRISPR guide RNA,

wherein the CRISPR guide RNA is complimentary to at least one target gene in said cell; introducing into said cell a second nucleic acid sequence encoding a Cas9 protein, a derivative or fragment thereof; introducing into said cell a third nucleic acid sequence encoding a first adenoviral protein; and introducing into said cell a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives of the method, the cell is a mammalian cell. In some alternatives of the method, the cell is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the method, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

**[0011]** In some alternatives of the method, the first vector comprising the first nucleic acid sequence encoding the CRISPR guide RNA is a viral vector. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the second, third and fourth nucleic acid sequences are mRNA. In some alternatives of the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human. In some alternatives of the method, the Cas9 protein, a derivative or fragment thereof is from *S. pyogenes*. In some alternatives of the method, the first adenoviral protein is E4ORF6. In some alternatives of the method, the second adenoviral protein is a E1B55K mutant. In some alternatives of the method, the CRISPR guide RNA is complimentary to a target gene of interest. In some alternatives of the method, the CRISPR guide RNA is complimentary to a target gene of interest. In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are transiently introduced into the cell. In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, the introducing of the first, second, third and fourth nucleic acid sequences into the cell does not transform the cell. In some alternatives of the method, the target gene is a selected or identified gene of interest. In some alternatives of the method and/or the system, the second, third, or fourth nucleic acid sequence is provided on a vector. In some alternatives, a method of editing at least one target gene in a cell is practiced by introducing into a cell any of the alternatives of the system described herein.

**[0012]** In some alternatives, a method of treating, ameliorating, or inhibiting a disease and/or a condition in a subject is practiced by providing to a subject having a disease and/or a condition any of the alternatives of the system described herein.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0013]** FIG. 1A shows a schematic of mRNA and AAV vector constructs used for TCR locus targeting.

**[0014]** FIG. 1B shows T7 assay of editing-induced insertions-deletions (indels) at TCR $\alpha$  locus.

**[0015]** FIG. 1C shows the effect of Cas9-T2A-mCherry mRNA dose on expression at 24 h post transfection.

**[0016]** FIG. 1D shows the effect of increasing AAV dose on TCR $\alpha$  knockout.

**[0017]** FIG. 1E shows flow cytometry data related to comparison of TCR $\alpha$  knockout with single stranded (ss) versus self-complementary (sc) AAV for guide expression in T-cells.

**[0018]** FIG. 2A shows data related to relief of post-entry restriction of AAV-mediated gene expression.

**[0019]** FIG. 2B shows data related to comparison of effect of E4ORF6/E1B55K proteins on self-complementary and single-stranded AAV6-mediated gene expression

**[0020]** FIG. 2C shows data related to MRN inactivation and its effect of relief of post-entry restriction on AAV-mediated expression.

**[0021]** FIG. 3A shows the effect of E4ORF6/E1B55K mutants on AAV-driven GFP expression.

**[0022]** FIG. 3B shows the effect of E4ORF6/E1B55K-H373 expression on AAV transduction.

**[0023]** FIG. 3C shows a comparison of E1B55K, E4ORF6 mutants effects on AAV transduction.

**[0024]** FIG. 3D shows a comparison of E1B55K, E4ORF6 mutants effects on AAV-driven GFP expression.

**[0025]** FIG. 4A-FIG. 4C show data related to CRISPR-mediated gene knockout in primary human T-cells through use of adenoviral E4ORF6/E1B55K proteins.

**[0026]** FIG. 5A-FIG. 5C show data related to the effect of E4ORF6/E1B55K MRN mutants on indel spectra.

**[0027]** FIG. 6 shows the effect of E4ORF6/E1B55K proteins on non-homologous AAV insertion.

**[0028]** FIG. 7A-FIG. 7B show data related to implementation of CRISPR/Cas9 with mRNA/AAV delivery to achieve knockout at multiple genomic sites.

**[0029]** FIG. 8A-FIG. 8D show data related to implementation of Cas9 mRNA/AAV guide delivery to generate CRISPR-mediated double knockout in primary human T-cells with E4ORF6/E1B55K H373A expression.

**[0030]** FIG. 9 shows data related to implementation of Cas9 mRNA/AAV guide delivery to generate CRISPR-mediated knockout of more than two genes in primary human T-cells with E4ORF6/E1B55K H373A expression.

**[0031]** FIG. 10A-FIG. 10C show data related the effect of using E1B55K mutants (E4ORF6/E1B55K) enhance targeted CRISPR knock-in.

**[0032]** FIG. 11 shows data related to the effect of addition of E4ORF6/E1B55K H373A or H354 on homology directed repair (HDR) when using shorter homology arms for gene knock-in with CRISPR-Cas9 at the CCR5 locus.

**[0033]** FIG. 12A-FIG. 12C show data related to the effect of addition of E4ORF6/E1B55K H354 on HDR when using shorter homology arms for gene knock-in with CRISPR-Cas9 at the TCR locus.

**[0034]** FIG. 13A-FIG. 13B show data related to surface marker phenotype and Ca<sup>2+</sup> signaling in edited primary T-cells with E4ORF6/E1B55K H373A.

**[0035]** FIG. 14A-FIG. 14B show data related to cell karyotype following multiplex CRISPR editing.

**[0036]** FIG. 15A-FIG. 15C show data related to molecular confirmation of HDR events following CRISPR-Cas9 breaks with E4ORF6/E1B55K H373A or H354.

**[0037]** FIG. 16A shows alternatives of polynucleotide sequences of guide RNAs guide1 (SEQ ID NO: 15), guide2 (SEQ ID NO: 16), guide3 (SEQ ID NO: 17), and guide4 (SEQ ID NO: 5) used for generating TCR knockout using the CRISPR/Cas9 system.

[0038] FIG. 16B shows flow cytometry data comparing the efficiency of Cas9-mCherry expression from mRNA in primary T-cells from donor 1 when using guide RNAs guide1-guide4.

[0039] FIG. 16C shows flow cytometry data comparing the efficiency of generation of TCR knockout in primary T-cells from donor 1 when using guide RNAs guide1-guide4.

[0040] FIG. 16D shows flow cytometry data comparing Cas9-mCherry expression levels in primary T-cells from donor 1 when using different volumes of Cas9/guide sample.

[0041] FIG. 16E shows flow cytometry data comparing the efficiency of generation of TCR knockout in primary T-cells from donor 1 when using different volumes of sample containing guide RNA guide4.

[0042] FIG. 16F shows flow cytometry data comparing Cas9-mCherry expression levels in primary T-cells from donor 2 when using different volumes of Cas9/guide sample containing guide RNA guide4.

[0043] FIG. 16G shows flow cytometry data comparing the efficiency of generation of TCR knockout in primary T-cells from donor 2 when using different volumes of sample containing guide RNA guide4.

[0044] FIG. 16H shows flow cytometry data comparing the efficiency of Cas9-mCherry expression from mRNA in Jurkat T-cells when using guide RNAs guide1-guide4.

[0045] FIG. 16I shows flow cytometry data comparing the efficiency of generation of TCR knockout in Jurkat T-cells when using guide RNAs guide1-guide4.

[0046] FIG. 17 shows the protein sequence of an alternative of a wild type adenoviral protein E1B55K (SEQ ID NO: 1).

[0047] FIG. 18 shows the protein sequence of an alternative of a mutant adenoviral protein E1B55K with an H373A polymorphism (SEQ ID NO: 2). The mutation is shown in bold and underlined.

[0048] FIG. 19 shows the protein sequence of an alternative of a wild type adenoviral protein E4ORF6 (SEQ ID NO: 3).

[0049] FIG. 20 shows the protein sequence of an alternative of a mutant adenoviral protein E1B55K with an H354 (SEQ ID NO: 4). The mutation/insertion is shown in bold and underlined.

[0050] FIG. 21 shows flow cytometry data of generation of TCR $\alpha$  knockout with CRISPR guide RNAs guide1 (G1), guide2 (G2), guide3 (G3) and guide4 (G4).

[0051] FIG. 22 shows the protein sequence of an alternative dCas9 variant of Cas9 protein of *Streptococcus pyogenes* (SEQ ID NO: 6).

[0052] FIG. 23 shows the nucleotide sequence of an alternative Cas9-SP variant from *Streptococcus pyogenes* (SEQ ID NO: 7).

[0053] FIG. 24 shows the nucleotide sequence of an alternative Cas9-SPm4 variant from *Streptococcus pyogenes* (SEQ ID NO: 8).

[0054] FIG. 25 shows the nucleotide sequence of an alternative Cas9-ST1 variant from *Streptococcus thermophilus* (SEQ ID NO: 9).

[0055] FIG. 26 shows the nucleotide sequence of an alternative Cas9-ST1m4 variant from *Streptococcus thermophilus* (SEQ ID NO: 10).

[0056] FIG. 27 shows the nucleotide sequence of an alternative Cas9-NM variant from *Neisseria meningitidis* (SEQ ID NO: 11).

[0057] FIG. 28 shows the nucleotide sequence of an alternative Cas9-NMm4 variant from *Neisseria meningitidis* (SEQ ID NO: 12).

[0058] FIG. 29 shows the nucleotide sequence of an alternative Cas9-TD variant from *Treponema denticola* (SEQ ID NO: 13).

[0059] FIG. 30 shows the nucleotide sequence of an alternative Cas9-TDm4 variant from *Treponema denticola* (SEQ ID NO: 14).

[0060] FIG. 31 shows alternatives of polynucleotide sequences of PD1 guide RNA (SEQ ID NO: 18), TIGIT guide RNA (SEQ ID NO: 19), Lag3 guide RNA (SEQ ID NO: 20) and Tim3 guide RNA (SEQ ID NO: 21).

[0061] FIG. 32A shows the effect of TALENs on HDR for the CCR5 locus.

[0062] FIG. 32B shows the effect of TALENs on HDR for the CD40L locus.

[0063] FIG. 33 shows the nucleotide sequence of an alternative of an R240A mutant of the adenoviral protein E1B55K (SEQ ID NO: 22).

[0064] FIG. 34 shows the nucleotide sequence of an alternative of an AXA mutant of the adenoviral protein E4ORF6 (SEQ ID NO: 23).

#### DETAILED DESCRIPTION

[0065] In some alternatives, nuclease-based gene editing systems and methods are provided. Examples of nuclease-based approaches for gene editing include systems comprising nucleases such as, without limitations, ZFNs, TALENs, meganucleases (e.g., MegaTALs) and CRISPR/Cas9.

[0066] The gene-editing systems and methods provided herein can be applied to any nuclease-based gene editing approach comprising, without limitations, gene disruption and/or gene targeting. For example, aspects of the present disclosure are related to CRISPR/Cas9-based gene editing. In some alternatives, Cas9 nuclease-mediated enhancement of gene editing is provided.

[0067] An important aspect of applying CRISPR/Cas9 for gene editing is the need for a system to express the guide RNA's efficiently in a wide variety of cell types. An important system for expressing guide RNAs is based on the use of adeno-associated virus vectors (AAV). AAV vectors are able to transduce a wide range of primary cells.

[0068] However, in many cell types, there is a post-entry restriction on AAV vectors that renders AAV-mediated expression of transgenes, including guide RNAs, very inefficient, thus substantially compromising the utility of AAV vectors for this purpose. Therefore, an approach to substantially improve and expand the potential applications of the CRISPR/Cas9 system in primary cells is contemplated.

[0069] In some alternatives, Cas9-based approach enhances gene editing efficiency with minimal toxicity when adeno-associated virus vectors (AAV) are used to express the guide RNA's necessary for Cas9 targeting.

[0070] CRISPR/Cas9 and related programmable endonuclease systems have rapidly become significant gene editing tools of the biomedical research laboratory, with their application for gene disruption and/or gene targeting demonstrated in a variety of cultured cell and model organism systems. Although the flexibility with which the Cas9 nuclease can be re-programmed to target new sites is a major advantage for genome engineering in the research setting, several practical barriers limit the direct extension of

research-based gene editing methods to editing of primary human cells for therapeutic purposes.

**[0071]** Examples of some of these practical barriers include limited opportunities to identify and enrich for cells that have incurred a desired editing event; the requirement for transient (e.g. a few days) nuclease delivery due to safety and immunogenicity issues associated with longer term and/or in vivo nuclease expression; and limitations in vector systems for nuclease or recombination template delivery posed by primary cells' robust capacity to detect the presence of cytosolic DNA and consequent generation of anti-viral or pro-apoptotic signals.

**[0072]** Driven by the practical barriers delineated herein, therapeutic gene editing strategies utilizing zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), and meganucleases, have gravitated towards delivery approaches that ensure transient nuclease expression, most notably mRNA transfection, and the use of viral vectors for recombination template delivery. For these same reasons, mRNA-based CRISPR component expression has recently been extended to human primary cells for the purpose of gene disruption through the use of electroporation to deliver Cas9 mRNA or protein in conjunction with either native or degradation-resistant guide RNAs.

**[0073]** While RNA or protein/RNA-based nuclease delivery are straightforward methods for disrupting individual genes, applications of CRISPR-based gene editing that involve gene targeting require efficient delivery of three components: Cas9, guide RNA, and a recombination template.

**[0074]** In some alternatives, an electroporation/transduction co-delivery method for CRISPR/Cas9 gene editing that utilizes mRNA electroporation-mediated expression of Cas9 in conjunction with variants of two adenoviral serotype 5 proteins, E4ORF6 and E1B55K is provided, that transiently enhance both primary cells' capacity for transduction by AAV and gene editing efficiency.

**[0075]** In some alternatives, using a cell culture/manufacturing protocol compatible with clinical translation, the application of this method for efficient gene disruption and homology-directed gene targeting in primary human T-cells is provided.

#### Definitions

**[0076]** In the description that follows, a number of terms are used extensively. The following definitions are provided to facilitate understanding of the present alternatives.

**[0077]** As used herein, "a" or "an" may mean one or more than one.

**[0078]** As used herein, the term "about" indicates that a value includes the inherent variation of error for the method being employed to determine a value, or the variation that exists among experiments.

**[0079]** As used herein, "nucleic acid" or "nucleic acid molecule" refers to polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have altera-

tions in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like. The term "nucleic acid molecule" also includes so-called "peptide nucleic acids," which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded. The basic components of CRISPR/Cas9 system comprise a target gene, a guide RNA, and a Cas9 endonuclease, derivative, or fragment thereof. An important aspect of applying CRISPR/Cas9 for gene editing is the need for a system to deliver the guide RNAs efficiently to a wide variety of cell types. This could for example involve delivery of an in vitro generated guide RNA as a nucleic acid (the guide RNA generated by in vitro transcription or chemical synthesis). In some alternatives the nucleic acid encoding the guide RNA is rendered nuclease resistant by incorporation of modified bases, such as 2'O-methyl bases. In some alternatives, the CRISPR/Cas9 system described herein, whereby the polynucleotide encoding the Cas9 nuclease or a derivative or functional fragment thereof (e.g., SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14) is provided with a poly(T) or poly(A) tail of a desired length and prepared in accordance with the teachings described herein, for example, is provided with a guide RNA that comprises one or more modified bases, such as any one or more of the modified bases described herein.

**[0080]** Exemplary guide RNAs useful with the alternatives described herein, which may contain one or more of the modified bases set forth herein are provided in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21. Furthermore, an important system for expressing guide RNAs in this context is based on the use of adeno-associated virus (AAV) vectors because AAV vectors are able to transduce a wide range of primary cells. AAV vectors do not cause infection and are not known to integrate into the genome. Therefore, the use of AAV vectors has the benefits of being both safe and efficacious.

**[0081]** The term "complementary to" means that the complementary sequence is homologous to all or one or more portions of a reference polynucleotide sequence. For illustration, the nucleotide sequence "CATAG" corresponds to a reference sequence "CATAG" and is complementary to a reference sequence "GTAATC."

**[0082]** A "promoter" is a nucleotide sequence that directs the transcription of a structural gene. In some alternatives, a promoter is located in the 5' non-coding region of a gene, proximal to the transcriptional start site of a structural gene. Sequence elements within promoters that function in the

initiation of transcription are often characterized by consensus nucleotide sequences. These promoter elements include RNA polymerase binding sites, TATA sequences, CAAT sequences, differentiation-specific elements (DSEs; McGehee et al., *Mol. Endocrinol.* 7:551 (1993); incorporated by reference in its entirety herein), cyclic AMP response elements (CREs), serum response elements (SREs; Treisman, *Seminars in Cancer Biol.* 1:47 (1990); incorporated by reference in its entirety herein), glucocorticoid response elements (GREs), and binding sites for other transcription factors, such as CRE/ATF (O'Reilly et al., *J. Biol. Chem.* 267:19938 (1992)), AP2 (Ye et al., *J. Biol. Chem.* 269:25728 (1994)), SP1, cAMP response element binding protein (CREB; Loeken, *Gene Expr.* 3:253 (1993)) and octamer factors (see, in general, Watson et al., eds., *Molecular Biology of the Gene*, 4th ed. (The Benjamin/Cummings Publishing Company, Inc. 1987), and Lemaigre and Rousseau, *Biochem. J.* 303:1 (1994); all references incorporated by reference in their entireties herein). As used herein, a promoter may be constitutively active, repressible or inducible. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter. Repressible promoters are also known. In some alternatives, a regulatory element can be an untranslated region. In some alternatives, an untranslated region is a 5' untranslated region. In some alternatives, an untranslated region is a 3' untranslated region. In some alternatives, either 5' or 3' untranslated region is used. In some alternatives, both 5' and 3' untranslated regions are used. One skilled in the art will understand the meaning of an untranslated region as used in the alternatives here.

**[0083]** A "regulatory element" is a nucleotide sequence that modulates the activity of a core promoter. For example, a regulatory element may contain a nucleotide sequence that binds with cellular factors enabling transcription exclusively or preferentially in particular cells, tissues, or organelles. These types of regulatory elements are normally associated with genes that are expressed in a "cell-specific," "tissue-specific," or "organelle-specific" manner. In some alternatives, a system for editing at least one target gene in a cell is provided, wherein the system comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complementary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector; said system also comprising a second nucleic acid sequence encoding a Cas9 protein, a third nucleic acid sequence encoding a first adenoviral protein, and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, the first, second, third and fourth nucleic acid sequences are joined to regulatory elements that are operable in a eukaryotic cell, such as a human cell.

**[0084]** A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides." A polypeptide can be considered as a protein.

**[0085]** A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptide components, such as carbohydrate groups. Carbohydrates and other non-peptide substituents may be added to a protein by the cell in which the protein is produced, and

will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless. In some embodiments, a system for editing at least one target gene in a cell is provided, wherein the method comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complementary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector; said system also comprising a second nucleic acid sequence encoding a Cas9 protein, a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein.

**[0086]** As used herein, "transient transfection" refers to the introduction of exogenous nucleic acid(s) into a host cell by a method that does not generally result in the integration of the exogenous nucleic into the genome of the transiently transfected host cell. In some alternatives, the nucleic acid is RNA. In some alternatives, the nucleic acid is DNA. In some alternatives, when the nucleic acid is RNA, the nucleic acid does not generally integrate in the genome of the transiently transfected cell. In some alternatives, when the nucleic acid is DNA, the nucleic acid can integrate in the genome of the transiently transfected cell.

**[0087]** By the term "host cell" is meant a cell that is introduced with Cas9-mRNA/AAV-guide RNA according to the present alternatives, as well as, cells that are provided with the systems herein. Host cells can be prokaryotic cells or eukaryotic cells. Examples of prokaryotic host cells include, but are not limited to *E. coli*, nitrogen fixing bacteria, *Staphylococcus aureus*, *Staphylococcus albus*, *Lactobacillus acidophilus*, *Bacillus anthracis*, *Bacillus subtilis*, *Bacillus thuringiensis*, *Clostridium tetani*, *Clostridium botulinum*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Mycoplasmas*, and *Cyanobacteria*. Examples of eukaryotic host cells include, but are not limited to, protozoa, fungi, algae, plant, insect, amphibian, avian and mammalian cells. In some alternatives, a system for editing at least one target gene in a cell is provided, wherein the cell is a eukaryotic cell. In some alternatives, the cell is a mammalian cell. In some alternatives, the cell is a human cell. In some alternatives, the cell is a primary cell. In some alternatives, the cell is not a transformed cell. In some alternatives, the cell is a primary lymphocyte. In some alternatives, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

**[0088]** The term "gene expression" refers to the biosynthesis of a gene product. For example, in the case of a structural gene, gene expression involves transcription of the structural gene into mRNA and the translation of mRNA into one or more polypeptides.

**[0089]** The term "endonuclease" refers to enzymes that cleave the phosphodiester bond within a polynucleotide chain. The polynucleotide may be double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), RNA, double-stranded hybrids of DNA and RNA, and synthetic DNA (for example, containing bases other than A, C, G, and T). An endonuclease may cut a polynucleotide symmetrically, leaving "blunt" ends, or in positions that are not directly opposing, creating overhangs, which may be referred to as "sticky ends." The methods and compositions described herein may be applied to cleavage sites generated by endonucleases. In some alternatives of the system, the system can further

provide nucleic acids that encode an endonuclease, such as Cas9, TALEN, or MegaTAL, or a fusion protein comprising a domain of an endonuclease, for example, Cas9, TALEN, or MegaTAL, or one or more portion thereof. These examples are not meant to be limiting and other endonucleases and alternatives of the system and methods comprising other endonucleases and variants and modifications of these exemplary alternatives are possible without undue experimentation. All such variations and modifications are within the scope of the current teachings.

**[0090]** The term “TAL Effector Nuclease” (TALEN) refers to a nuclease comprising a TAL-effector domain fused to a nuclease domain. TAL-effector DNA binding domains, isolated from the plant pathogen *Xanthomonas* have been described (see Boch et al., (2009) Science 29 Oct. 2009 (10.1126/science.117881) and Moscou and Bogdanove, (2009) Science 29 Oct. 2009 (10.1126/science.1178817); both references incorporated by reference in their entireties herein). These DNA binding domains may be engineered to bind to a desired target and fused to a nuclease domain, such as the FokI nuclease domain, to derive a TAL effector domain-nuclease fusion protein. The methods and systems described herein may be applied to cleavage sites generated by TAL effector nucleases. In some alternatives of the systems provided herein, the systems can further comprise a TALEN nuclease or a vector or nucleic acid encoding a TALEN nuclease. In some alternatives of the methods provided herein, the method can further comprise providing a nuclease, such as a TALEN nuclease.

**[0091]** MegaTALs are derived from the combination of two distinct classes of DNA targeting enzymes. Meganucleases (also referred to as homing endonucleases) are single peptide chains that have the advantage of both DNA recognition and nuclease functions in the same domain. In some alternatives of the systems provided herein, the systems can further comprise a MegaTAL nuclease or a vector or nucleic acid encoding a MegaTAL nuclease. In some alternatives of the methods provided herein, the methods can further comprise providing MegaTAL nuclease or a vector or nucleic acid encoding a MegaTAL nuclease.

**[0092]** Cas9 (CRISPR associated protein 9) is an RNA-guided DNA endonuclease enzyme associated with the CRISPR (Clustered Regularly Interspersed Palindromic Repeats) adaptive immunity system in *Streptococcus pyogenes*, among other bacteria. *S. pyogenes* utilizes Cas9 to memorize and later interrogate and cleave foreign DNA, such as invading bacteriophage DNA or plasmid DNA. Cas9 performs this interrogation by unwinding foreign DNA and checking for if it is complementary to the 20 base pair spacer region of the guide RNA. If the DNA substrate is complementary to the guide RNA, Cas9 cleaves the invading DNA.

**[0093]** CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of “spacer DNA” from previous exposures to a bacterial virus or plasmid. CRISPR/Cas system has been used for gene editing (adding, disrupting or changing the sequence of specific genes) and gene regulation in species throughout the tree of life. By delivering the Cas9 protein, a derivative, or fragment thereof and appropriate guide RNAs into a cell, the organism’s genome can be cut at any desired location. It can be possible to use CRISPR to build RNA-guided gene drives capable of altering the genomes of entire populations. In some alternatives,

a system for editing at least one target gene in a cell is provided, wherein the method comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector, a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof, a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. Exemplary guide RNAs useful with the alternatives described herein, which may contain one or more modified bases, are provided in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and/or SEQ ID NO: 21.

**[0094]** In some alternatives, the use of chemically modified guide RNAs is contemplated. Chemically-modified guide RNAs have been used in CRISPR-Cas genome editing in human primary cells (Hendel, A. et al., Nat Biotechnol. 2015 September; 33(9):985-9). Chemical modifications of guide RNAs can include modifications that confer nuclease resistance. Nucleases can be endonucleases, or exonucleases, or both. Some chemical modification, without limitations, include 2'-fluoro, 2'-O-methyl, phosphorothioate dithiol 3'-3' end linkage, 2-amino-dA, 5-methyl-dC, C-5 propynyl-C, C-5 propynyl-U, morpholino, etc. These examples are not meant to be limiting and other chemical modifications and variants and modifications of these exemplary alternatives are also contemplated.

**[0095]** The term “exonuclease” refers to enzymes that cleave phosphodiester bonds at the end of a polynucleotide chain via a hydrolyzing reaction that breaks phosphodiester bonds at either the 3' or 5' end. The polynucleotide may be double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), RNA, double-stranded hybrids of DNA and RNA, and synthetic DNA (for example, containing bases other than A, C, G, and T). The term “5' exonuclease” refers to exonucleases that cleave the phosphodiester bond at the 5' end. The term “3' exonuclease” refers to exonucleases that cleave the phosphodiester bond at the 3' end. Exonucleases may cleave the phosphodiester bonds at the end of a polynucleotide chain at endonuclease cut sites or at ends generated by other chemical or mechanical means, such as shearing (for example by passing through fine-gauge needle, heating, sonicating, mini bead tumbling, and nebulizing), ionizing radiation, ultraviolet radiation, oxygen radicals, chemical hydrolysis and chemotherapy agents. Exonucleases may cleave the phosphodiester bonds at blunt ends or sticky ends. *E. coli* exonuclease I and exonuclease III are two commonly used 3'-exonucleases that have 3'-exonucleolytic single-strand degradation activity. Other examples of 3'-exonucleases include Nucleoside diphosphate kinases (NDKs), NDK1 (NM23-H1), NDK5, NDK7, and NDK8 (Yoon J-H, et al., Characterization of the 3' to 5' exonuclease activity found in human nucleoside diphosphate kinase 1 (NDK1) and several of its homologues. (Biochemistry 2005: 44(48):15774-15786.), WRN (Ahn, B., et al., Regulation of WRN helicase activity in human base excision repair. J. Biol. Chem. 2004, 279:53465-53474) and Three prime repair exonuclease 2 (Trex2) (Mazur, D. J., Perrino, F. W., Excision of 3' termini by the Trex1 and TREX2 3'→5' exonucleases. Characterization of the recombinant proteins. J. Biol. Chem. 2001, 276:17022-17029; both references incorporated by reference in their entireties herein). *E. coli*

exonuclease VII and T7-exonuclease Gene 6 are two commonly used 5'-3' exonucleases that have 5% exonucleolytic single-strand degradation activity. The exonuclease can be originated from prokaryotes, such as *E. coli* exonucleases, or eukaryotes, such as yeast, worm, murine, or human exonucleases. In some alternatives of the systems provided herein, the systems can further comprise an exonuclease or a vector or nucleic acid encoding an exonuclease. In some alternatives, the exonuclease is Trex2. In some alternatives of the methods provided herein, the methods can further comprise providing exonuclease or a vector or nucleic acid encoding an exonuclease, such as Trex2.

**[0096]** The term “cleavage” refers to the breakage of the covalent backbone of a polynucleotide. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. Double stranded DNA, RNA, or DNA/RNA hybrid cleavage can result in the production of either blunt ends or staggered ends.

**[0097]** “Prokaryotic” cells lack a true nuclease. Examples of prokaryotic cells are bacteria (e.g., *cyanobacteria*, *Lactobacillus acidophilus*, Nitrogen-Fixing Bacteria, *Helicobacter pylori*, *Bifidobacterium*, *Staphylococcus aureus*, *Bacillus anthrax*, *Clostridium tetani*, *Streptococcus pyogenes*, *Staphylococcus pneumoniae*, *Klebsiella pneumoniae* and *Escherichia coli*) and archaea (e.g., *Crenarchaeota*, *Euryarchaeota*, and *Korarchaeota*). The Cas9 protein described herein is a protein from a prokaryotic cell.

**[0098]** “Eukaryotic” cells include, but are not limited to, algae cells, fungal cells (such as yeast), plant cells, animal cells, mammalian cells, and human cells (e.g., T-cells).

**[0099]** The term “subject” as used herein includes all members of the animal kingdom including non-human primates and humans. In some alternatives, a system for editing at least one target gene in a cell is provided, wherein the method comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector, a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof, a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, the cell that comprises an edited gene is delivered to a subject in need.

**[0100]** The homing endonucleases, also known as meganucleases, are sequence specific endonucleases that generate double strand breaks in genomic DNA with a high degree of specificity due to their large (e.g., >14 bp) cleavage sites. While the specificity of the homing endonucleases for their target sites allows for precise targeting of the induced DNA breaks, homing endonuclease cleavage sites are rare and the probability of finding a naturally occurring cleavage site in a targeted gene is low. In some alternatives of the systems provided herein, the systems can further comprise a meganuclease or a vector or nucleic acid encoding a meganuclease. In some alternatives of the methods provided herein, the methods can further comprise providing a meganuclease or a vector or nucleic acid encoding a meganuclease.

**[0101]** Another class of artificial endonucleases is the engineered meganucleases. Engineered homing endonu-

cleases are generated by modifying the specificity of existing homing endonucleases. In one approach, variations are introduced in the amino acid sequence of naturally occurring homing endonucleases and then the resultant engineered homing endonucleases are screened to select functional proteins which cleave a targeted binding site. In another approach, chimeric homing endonucleases are engineered by combining the recognition sites of two different homing endonucleases to create a new recognition site composed of a half-site of each homing endonuclease. In some alternatives of the systems provided herein, the systems can further comprise an engineered meganuclease or a vector or nucleic acid encoding an engineered meganuclease.

**[0102]** Targeted DNA double-strand breaks introduced by rare-cleaving endonucleases can be harnessed for gene disruption applications in diverse cell types by engaging non-homologous end joining DNA repair pathways. However, endonucleases create chemically clean breaks that are often subject to precise repair, limiting the efficiency of targeted gene disruption. Several alternatives described herein relate to a method of improving the rate of targeted gene disruptions caused by imprecise repair of endonuclease-induced site-specific DNA double-strand breaks. In some alternatives, systems can further comprise site specific endonucleases that are coupled with end-processing enzymes to enhance the rate of targeted gene disruption. Coupling may be, for example, physical, spatial, and/or temporal.

**[0103]** Not to be bound by any particular theory, the resolution of a double-strand DNA breaks by “error-prone” non-homologous end-joining (NHEJ) can be harnessed to create targeted disruptions and genetic knockouts, as the NHEJ process can result in insertions and deletions at the site of the break. NHEJ is mediated by several sub-pathways, each of which has distinct mutational consequences. The classical NHEJ pathway (cNHEJ) requires the KU/DNA-PKcs/Lig4/XRCC4 complex, and ligates ends back together with minimal processing. As the DNA breaks created by designer endonuclease platforms (zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), and homing endonucleases (HEs)) all leave chemically clean, compatible overhang breaks that do not require processing prior to ligation, they are excellent substrates for precise repair by the cNHEJ pathway. In the absence or failure of the classical NHEJ pathway to resolve a break, alternative NHEJ pathways (altNHEJ) can substitute: however, these pathways are considerably more mutagenic.

**[0104]** Not to be bound by any particular theory, modification of DNA double-strand breaks by end-processing enzymes may bias repair towards an altNHEJ pathway. Further, different subsets of end-processing enzymes may enhance disruption by different mechanisms. For example, Trex2, an exonuclease that specifically hydrolyzes the phosphodiester bonds which are exposed at 3' overhangs, biases repair at break sites toward mutagenic deletion. By contrast, terminal deoxynucleotidyl transferase (TdT), a non-templative polymerase, is expected to bias repair at break sites toward mutagenic insertions by promoting the addition of nucleotide bases to alter DNA ends prior to ligation. Accordingly, one of skill in the art can use end-processing enzymes with different activities to provide for a desired engineering outcome with any of the systems or methods provided herein. Further one of skill in the art may use the synergy between different end-processing enzymes so as to achieve maximal or unique types of effects.



**[0105]** Several alternatives described herein couple DNA breaks created by endonucleases with end-processing enzymes, which can improve the rates of targeted disruption in a variety of cell types and species, without associated toxicity to the host. This is an important advance at least because: 1) Double-strand breaks (DSBs) trigger cell cycle checkpoints to arrest division until the break has been resolved; in the case of a “persistent break” (a repetitive cycle of cleaving and precise repair), cells may arrest indefinitely, leading to apoptosis. 2) Engineering applications often utilize transient delivery of an endonuclease, providing only a short window in which enzyme concentration is sufficient to achieve breaks. 3) Persistent breaks can be a source of translocations. Coupling endonucleases to end-processing enzymes prevents the establishment of a persistent break and reduces the incidence of gross chromosomal rearrangements, thereby improving the safety of endonuclease-induced targeted disruption. 4) Multiple changes in a single round of mutagenesis can be achieved, for use for example, in multi-allelic knockouts and multiplexing, as data described herein provides evidence that coupling endonucleases to end-processing enzymes improves the mutagenic rate of two given endonucleases 5-fold at their respective targets, a 25-fold improvement can be realized in disrupting both targets simultaneously.

**[0106]** The system can further comprise endonucleases, end-processing enzymes, and/or fusion proteins having endonuclease and end-processing activity, for delivery to host cells. In some alternative of the system described herein, the system can further comprise a protein such as one or more polypeptides having endonuclease and/or end-processing activity may be provided directly to cells. In some alternatives, expression of endonucleases, end-processing enzymes and/or fusion proteins having endonuclease and end-processing activity in a host cell can result from delivery of one or more polynucleotides encoding one or more endonucleases, end-processing enzymes, and/or fusion proteins having endonuclease and end-processing activity to the host cell. In some alternatives, one or more polynucleotides is a DNA expression vector. In some alternatives, one or more polynucleotides is an RNA expression vector. In some alternatives, trans-splicing, polypeptide cleavage and/or polypeptide ligation can be involved in expression of one or more proteins in a cell.

**[0107]** The systems and methods described herein are useful for generating targeted disruptions of the coding sequences of genes and in some alternatives, creating gene knockouts. Targeted cleavage by the compositions and methods described herein can also be used to alter non-coding sequences (e.g., regulatory sequences such as promoters, enhancers, initiators, terminators, splice sites) to alter the levels of expression of a gene product. Such methods can be used, for example, for biological research, for biotechnology applications such as crop modification, for therapeutic purposes, functional genomics, and/or target validation studies.

**[0108]** Some alternatives of the system are coupled to the activity of one or more site-specific endonucleases with one or more end-processing enzymes. In some alternatives, the endonucleases and end-processing enzymes are provided as separate proteins with the system. In some alternatives, the endonucleases and end-processing enzymes are co-expressed in a cell. If expression of the separate endonucleases and end-processing enzymes is by polynucleotide delivery,

each of the endonucleases and end-processing enzymes can be encoded by separate polynucleotides, or by a single polynucleotide. In some alternatives, the endonucleases and end-processing enzymes are encoded by a single polynucleotide and expressed by a single promoter. In some alternatives, an endonuclease and end-processing enzymes are linked by a T2A sequence, which allows for two separate proteins to be produced from a single translation. In some alternatives, a different linker sequence can be used. In other alternatives a single polynucleotide encodes the endonucleases and end-processing enzymes separated by an Internal Ribosome Entry Sequence (IRES).

**[0109]** Several alternatives of the system comprises coupling the system with endonucleases selected from the group consisting of: I-Anil, I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-PanII, I-PanMI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-LtrI, I-GpiI, I-GZeI, I-OnuI, I-HjeMI, I-TevI, I-TevII, and I-TevIII with one or more DNA end-processing enzymes selected from the group consisting of: Trex2, Trex1, Trex1 without transmembrane domain, Apollo, Artemis, DNA2, Exo1, ExoT, ExoIII, Fen1, Fan1, MreII, Rad2, Rad9, TdT (terminal deoxynucleotidyl transferase), PNKP, RecE, RecJ, RecQ, Lambda exonuclease, Sox, Vaccinia DNA polymerase, exonuclease I, exonuclease III, exonuclease VII, NDK1, NDK5, NDK7, NDK8, WRN, T7-exonuclease Gene 6, avian myeloblastosis virus integration protein (IN), Bloom, Antartic Phosphatase, Alkaline Phosphatase, Poly nucleotide Kinase (PNK), Apel, Mung Bean nuclease, Hex1, TTRAP (TDP2), Sgs1, Sae2, CtIP, Pol mu, Pol lambda, MUS81, EME1, EME2, SLX1, SLX4 and UL-12. In some alternatives, the homing endonucleases and DNA end-processing enzymes are provided as a fusion protein. In some alternatives, the endonucleases and DNA end-processing enzymes are provided as separate proteins. In some alternatives, the endonucleases and DNA end-processing enzymes are co-expressed in a host cell.

**[0110]** Several alternatives relate to coupling the system described herein, with DNA end-processing enzymes selected from the group consisting of: Trex2, Trex1, Trex1 without transmembrane domain, Apollo, Artemis, DNA2, Exo1, ExoT, ExoIII, Fen1, Fan1, MreII, Rad2, Rad9, TdT (terminal deoxynucleotidyl transferase), PNKP, RecE, RecJ, RecQ, Lambda exonuclease, Sox, Vaccinia DNA polymerase, exonuclease I, exonuclease III, exonuclease VII, NDK1, NDK5, NDK7, NDK8, WRN, T7-exonuclease Gene 6, avian myeloblastosis virus integration protein (IN), Bloom, Antartic Phosphatase, Alkaline Phosphatase, Poly nucleotide Kinase (PNK), Apel, Mung Bean nuclease, Hex1, TTRAP (TDP2), Sgs1, Sae2, CtIP, Pol mu, Pol lambda, MUS81, EME1, EME2, SLX1, SLX4 and UL-12. In some alternatives of the system, the end-processing enzymes are provided as separate proteins. In some alternatives of the system, the end-processing enzymes are co-expressed in a host cell.

**[0111]** In several alternatives, the activity of one or more site-specific homing endonucleases selected from the group consisting of: I-Anil, I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-PanII, I-PanMI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-LtrI, I-GpiI, I-GZeI, I-OnuI, I-HjeMI, I-TevI, I-TevII, and I-TevIII is coupled with the activity of one or more DNA end-processing enzymes selected from the group consisting of: Artemis, Trex1, Flap endonuclease, terminal deoxynucleotide transferase, Trex2, Vaccinia DNA polymerase, MreII, exonuclease I, exonuclease III, NDK1,

NDK5, NDK7, NDK8, and WRN. In some alternatives, the homing endonucleases and DNA end-processing enzymes are provided as a fusion protein. In some alternatives, the endonucleases and DNA end-processing enzymes are provided as separate proteins. In some alternatives, the endonucleases and DNA end-processing enzymes are co-expressed in a host cell.

**[0112]** Several alternatives of the system further comprise a heterologous fusion protein, which comprises an endonuclease domain and an end-processing domain or one or more portions thereof. Several alternatives relate to a heterologous fusion construct, which encodes a fusion protein having endonuclease and end-processing activity. The present alternatives also relate to systems and methods that further comprise the heterologous fusion construct, as well as, methods for producing a fusion protein having endonuclease and end-processing activity and compositions thereof. In one alternative, the endonuclease domain is coupled to the end-processing domain by recombinant means (e.g., the fusion protein is generated by translation of a nucleic acid in which a polynucleotide encoding all or one or more portions of an endonuclease is joined in-frame with a polynucleotide encoding all or one or more portions of an end-processing enzyme). In other alternatives, the endonuclease domain and end-processing domain of a fusion protein are linked chemically. This chemical linkage can be carried out, for example, by using bifunctional linker molecules, such as, BS3 (Bis[sulfosuccinimidyl] suberate).

**[0113]** Some alternatives of the system further comprise a protein comprising an endonuclease domain and exonuclease domain in which it is provided as a protein or a vector or nucleic acid encoding the protein comprising an endonuclease domain and exonuclease domain as a fusion protein. In some alternatives, the fusion protein comprises at least a fragment or variant of a homing endonuclease and at least a fragment or variant of an exonuclease, for example a 3' exonuclease, which are associated with one another by genetic or chemical conjugation to one another. In several alternatives, the 3' exonuclease is a Trex2 monomer, dimer, or a variant thereof. In other alternatives, the fusion protein comprises at least a fragment or variant of a zinc finger endonuclease and at least a fragment or variant of a 5' exonuclease, which are associated with one another, by genetic fusion or chemical conjugation to one another. The endonuclease and exonuclease, once part of the fusion protein, may be referred to as a "portion", "region," "domain" or "moiety" of the endo/exonuclease fusion protein. In some alternatives, the exonuclease domain comprises Trex or one or more portions thereof.

**[0114]** An endonuclease/end-processing enzyme fusion protein may optionally include a linker peptide between the endonuclease and end-processing enzyme domains to provide greater physical separation between the moieties and thus maximize the accessibility of the endonuclease portion, for instance, for binding to its target sequence. The linker peptide may consist of amino acids selected to make it more flexible or more rigid depending on the relevant function. The linker sequence can be cleavable by a protease or cleavable chemically to yield separate endonuclease and end-processing enzyme moieties. Examples of enzymatic cleavage sites in the linker include sites for cleavage by a proteolytic enzyme, such as enterokinase, Factor Xa, trypsin, collagenase, and thrombin. In some alternatives, the protease is one, which is produced naturally by the host or

it is exogenously introduced. Alternatively, the cleavage site in the linker may be a site capable of being cleaved upon exposure to a selected chemical, e.g., cyanogen bromide, hydroxylamine, or low pH. The optional linker sequence may serve a purpose other than the provision of a cleavage site. The linker sequence should allow effective positioning of the endonuclease moiety with respect to the end-processing enzyme moiety so that the endonuclease domain can recognize and cleave its target sequence and the end-processing domain can modify the DNA ends exposed at the cleavage site. The linker may also be a simple amino acid sequence of a sufficient length to prevent any steric hindrance between the endonuclease domain and the end-processing domain. In addition, the linker sequence may provide for post-translational modification including, but not limited to, e.g., phosphorylation sites, biotinylation sites, sulfation sites,  $\gamma$ -carboxylation sites, and the like. In some alternatives, the system can further comprise a fusion with an endonuclease/end-processing protein.

**[0115]** In some alternatives, the linker sequence comprises from 4 to 30 amino acids, more preferably from 8 to 22 amino acids. That is, the linker sequence can be any number of amino acids from 4 to 30, such as at least or equal to 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids or a length that is within a range defined by any two of the aforementioned lengths. In some alternatives, the linker sequence is flexible so as not to hold the biologically active peptide in a single undesired conformation. The linker may be predominantly comprised of amino acids with small side chains, such as glycine, alanine, and serine, so as to provide for flexibility. In some alternatives about 80 or 90 percent or greater of the linker sequence comprises glycine, alanine, or serine residues, particularly glycine and serine residues. In several alternatives, a G4S linker peptide separates the end-processing and endonuclease domains of the fusion protein. In other alternatives, a T2A linker sequence allows for two separate proteins to be produced from a single translation. Suitable linker sequences can be readily identified empirically. Additionally, suitable size and sequences of linker sequences also can be determined by conventional computer modeling techniques.

**[0116]** Expression of a fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein. Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are well known in the art.

**[0117]** A variety of DNA molecules encoding the endonucleases described herein, end-processing enzymes and fusion proteins may be constructed for providing the selected proteins or peptides to a cell. The DNA molecules encoding the endonucleases, end-processing enzyme, and fusion proteins may be modified to contain different codons to optimize expression in a selected host cell, as is known in the art.

**[0118]** A variety of RNA molecules encoding the endonucleases described herein, end-processing enzymes and fusion proteins may be constructed for providing the selected proteins or peptides to a cell. The RNA molecules encoding the endonucleases, end-processing enzyme, and

fusion proteins may be modified to contain different codons to optimize expression in a selected host cell, as is known in the art. In some alternatives, the RNA can comprise a poly(A) tail of 50, 100, 150, 200, 250, 300, 350, 400, 450, 500 covalently linked adenosine residues, or an amount of residues within a range defined by any two of the aforementioned values.

**[0119]** Several alternatives of the system further comprise a vector or nucleic acid for the simultaneous expression of a site-specific endonuclease and an end-processing enzyme to improve the efficiency of targeted gene disruption by up to 70 fold, essentially fixing a mutagenic outcome in 100% of a population of cells containing the target site in less than 72 hours.

**[0120]** In some alternatives of the system, an additional vector or nucleic acid is provided for effective amounts of endonucleases and end-processing enzymes or an effective amount of a fusion protein for delivery to a cell either directly by contacting the cell with the protein(s) or by transient expression from an expression construct. In such alternatives of the system, in which the system is delivered to a cell, cell division reduces the concentration of the nucleases to sub-active levels within a few cell divisions.

**[0121]** Several alternatives of the systems and methods provided herein, further provide a fusion protein for conferring site specificity on a DNA end-processing enzyme by physically tethering an end-processing enzyme domain to a site specific DNA binding domain. In some alternatives, the end-processing enzyme domain is tethered to a DNA binding domain through a linker peptide. The composition and structure of the linker peptide is not especially limited and in some alternatives the linker may be chemically or enzymatically cleavable. The linker peptide may be flexible or rigid and may comprise from about 4 to 30 amino acids. In other alternatives, the end-processing enzyme domain is chemically fused to a DNA binding domain. Not wishing to be bound by a particular theory, imparting site specificity to an end-processing enzyme through tethering the end-processing enzyme to a site specific DNA binding domain decreases toxicity associated with indiscriminate end-processing activity, such as exonuclease activity, and reduces the effective amount of end-processing enzyme required for efficient modification of the exposed double stranded DNA break caused by endonuclease activity compared to untethered end-processing enzyme. In some alternatives, the end-processing enzyme is tethered to a homing endonuclease. In other alternatives, the end-processing enzyme is tethered to zinc finger endonuclease. In some alternatives, an end-processing enzyme domain is tethered to a zinc finger DNA binding domain which binds to a DNA sequence adjacent to the cleavage site of a homing endonuclease or zinc finger endonuclease.

**[0122]** Several alternatives of the system and methods relate to coupling the activity of the CRISPR/Cas9 system with one or more site-specific endonucleases with Trex2, in order to promote gene knockout efficiently when coupled with the systems provided herein. Trex2 may be provided as a monomer or dimer. The Trex2 enzyme specifically hydrolyzes the phosphodiester bonds, which are exposed at 3' overhangs. While homing endonucleases can generate 3' overhangs, which are susceptible to Trex2 exonuclease activity, the zinc finger nucleases, which utilize the FokI cleavage domain, generate double strand DNA breaks with 5' overhangs. The homing endonucleases and zinc finger

nucleases generate mutations at their cleavage sites at a baseline rate. Co-expression of Trex2 with homing endonucleases increased the mutation rate ~70 fold. Co-expression of Trex2 with zinc finger endonucleases was also observed to effect on the rate of mutation. Some alternatives of the methods relate to providing the system described herein, with co-expression of an exonuclease, Trex2.

**[0123]** As used herein, an Ad5 adenoviral protein, and Ad5 viral protein or an Ad5 protein refers to a protein that is encoded by adenovirus serotype 5. Non-limiting examples include E4ORF6 and E1B55K. The protein sequence of an alternative of the wild type E1B55K protein is shown in FIG. 17 (SEQ ID NO: 1). The protein sequence of an alternative of the wild type E4ORF6 protein is shown in FIG. 19 (SEQ ID NO: 3). In some alternatives, a mutant form of an Ad5 protein is used. Non-limiting examples include the H373A mutant of E1B55K and the H354 mutant of E1B55K. In some alternatives, Ad5 refers to a combination of two or more Ad5 viral proteins. In some alternatives, Ad5 refers to a combination two or more wild type Ad5 viral proteins. In some alternatives, Ad5 refers to a combination two or more Ad5 viral proteins at least one of which is a wild type form. In some alternatives, Ad5 refers to a combination two or more Ad5 viral proteins at least one of which is a mutant form. In some alternatives, Ad5<sup>wt</sup> refers to one or more wild type Ad5 viral proteins. In some alternatives, Ad5<sup>MRN-</sup> refers to one or more mutant Ad5 viral proteins that do not disable the MRN complex. In some alternatives, at least one Ad5 viral protein is used in combination with or not in combination with a nuclease. In some alternatives, the nuclease is an endonuclease. In some alternatives, the endonuclease is Cas9, a derivative, or fragment thereof. In some alternatives, the nuclease is an exonuclease. In some alternatives, the exonuclease is Trex2. In some alternatives, at least one Ad5 viral protein is used in combination with more than one a nuclease. In some alternatives, at least one Ad5 viral protein is used in combination with Cas9, a derivative, or fragment thereof and Trex2.

#### Expression Vectors

**[0124]** Expression constructs can be readily designed using methods known in the art. Examples of nucleic acid expression vectors include, but are not limited to: recombinant viruses, lentiviruses, adenoviruses, plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, human artificial chromosomes, minicircle DNA, episomes, cDNA, RNA, and PCR products. In some alternatives, nucleic acid expression vectors encode a single peptide (e.g., an endonuclease, an end-processing enzyme, or a fusion protein having endonuclease and end-processing activity). In some alternatives, nucleic acid expression vectors encode one or more endonucleases and one or more end-processing enzymes in a single, polycistronic expression cassette. In some alternatives of the system, one or more endonucleases and one or more end-processing enzymes are provided, wherein they are linked to each other by a 2A peptide sequence or an "autocleavage" or self-cleavage sequence. In some alternatives, the nucleic acid expression vectors are DNA expression vectors. In some alternatives, the nucleic acid expression vectors are RNA expression vectors. In some alternatives, the expression vectors are viral vectors. In some alternatives of the systems provided herein, the viral vector is an Adeno-associated virus (AAV) vector.

**[0125]** In some alternatives, a nucleic acid expression vector further comprises one or more selection markers that facilitate identification or selection of host cells that have received and express the endonuclease(s), end-processing enzyme(s), and/or fusion protein(s) having endonuclease and end-processing activity along with the selection marker. Examples of selection markers include, but are not limited to, genes encoding fluorescent proteins, e.g., EGFP, DS-Red, YFP, and CFP; genes encoding proteins conferring resistance to a selection agent, e.g., PuroR gene, ZeoR gene, HygroR gene, neoR gene, and the blasticidin resistance gene. In some cases, the selection marker comprises a fluorescent reporter and a selection marker.

**[0126]** In some alternatives, a DNA expression vector comprises a promoter capable of driving expression of one or more endonuclease(s), end-processing enzyme(s), and/or fusion protein(s) having endonuclease and end-processing activity. Examples of promoters include, but are not limited to, retroviral LTR elements; constitutive promoters such as CMV, HSV1-TK, SV40, EF-1 $\alpha$ ,  $\beta$ -actin; inducible promoters, such as those containing Tet-operator elements; and tissue specific promoters. Suitable bacterial and eukaryotic promoters are well known in the art and described, e.g., in Sambrook et al., *Molecular Cloning, A Laboratory Manual* (2nd ed. 2001); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (2010), the references are incorporated by reference in their entirety herein. Non-limiting examples of plant promoters include promoter sequences derived from *A. thaliana* ubiquitin-3 (ubi-3).

**[0127]** In some alternatives, a nucleic acid encoding one or more endonucleases, end-processing enzymes, and/or fusion proteins having endonuclease and end-processing activity or exonuclease activity are cloned into a vector for transformation into eukaryotic cells along with the vectors and nucleic acid of the systems provided herein. In some alternatives, nucleic acids encoding different endonucleases and end-processing enzymes are cloned into the same vector. In such cases, the nucleic acids encoding different endonucleases and end-processing enzymes may optionally be separated by T2A, self-cleavage sequences, protease cleavage sites, or IRES sequences. Vectors can be prokaryotic vectors, e.g., plasmids, or shuttle vectors, insect vectors, or eukaryotic vectors, including plant vectors described herein. Expression of the nucleases and fusion proteins may be under the control of a constitutive promoter or an inducible promoter. In some alternatives, the vector comprises a nucleic acid sequence that encodes Cas9, a derivative, or fragment thereof. In some alternatives, the vector comprises a nucleic acid sequence that encodes Trex. In some alternatives, the genes and/or nucleic acids in the vector are codon optimized for expression in a mammalian cell, such as a human cell. In some alternatives, the vector is an mRNA. In some alternatives, the vector is an mRNA encoding a Cas9 protein, a derivative, or fragment thereof. In some alternatives, the nucleic acid encoding Cas9 protein, a derivative, or fragment thereof is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives, the Cas9 protein, a derivative, or fragment thereof is from *S. pyogenes* or is a consensus sequence made from other Cas9 proteins from other organisms.

**[0128]** Introduction of polypeptides having endonuclease and/or end-processing activity and/or polynucleotides encoding polypeptides having endonuclease and/or end-

processing activity into host cells may use any suitable methods for nucleic acid or protein delivery as described herein or as would be known to one of ordinary skill in the art. The polypeptides and polynucleotides described herein can be delivered into cultured cells in vitro, as well as in situ into tissues and whole organisms. Introduction of the polypeptides and polynucleotides of the present alternatives into a host cell can be accomplished chemically, biologically, or mechanically. This may include, but is not limited to, electroporation, sonoporation, use of a gene gun, lipotransfection, calcium phosphate transfection, use of dendrimers, microinjection, polybrene, protoplast fusion, the use of viral vectors including adenoviral, AAV, and retroviral vectors, and group II ribozymes.

#### Immune Response Against AAV Vectors

**[0129]** Adeno-associated viral (AAV) vectors are widely used for gene therapy-based treatment genetic diseases. However, generation of immune responses against the AAV vector can undermine the therapeutic efficacy of the vector. Similarly, generation of immune responses against the AAV vector used in CRISPR/Cas9-based (or one or more other nucleases-based) genome editing can undermine the efficacy of gene targeting.

**[0130]** In some alternatives, it is contemplated that the AAV vectors used for CRISPR/Cas9-based (and/or one or more other nucleases-based) genome editing will possess reduced immunogenicity. In some alternatives, it is contemplated that the AAV vectors used for CRISPR/Cas9-based (and/or one or more other nucleases-based) genome editing will possess no immunogenicity. In some alternatives, because of the reduced immunogenicity, the likelihood of development of resistance against the AAV vector will be minimal. In some alternatives, because of the lack of immunogenicity, the likelihood of development of resistance against the AAV vector will be non-existent.

#### Organisms

**[0131]** The alternatives described herein are applicable to any eukaryotic organism in which it is desired to edit a gene. Examples of eukaryotic organisms include, but are not limited to, algae, plants, animals (e.g., mammals such as mice, rats, primates, pigs, cows, sheep, rabbits, dogs, cats, or horses etc.), fish, and insects. In some alternatives, isolated cells from the organism are genetically modified as described herein. In some alternatives, the modified cells develop into reproductively mature organisms. Eukaryotic (e.g., algae, yeast, plant, fungal, piscine, avian, and mammalian cells) cells can be used. Cells from organisms containing one or more additional genetic modifications can also be used.

**[0132]** Examples of mammalian cells include any cell or cell line of the organism of interest, for example oocytes, somatic cells, K562 cells, CHO (Chinese hamster ovary) cells, HEP-G2 cells, BaF-3 cells, Schneider cells, COS cells (monkey kidney cells expressing SV40 T-antigen), CV-1 cells, HuTu80 cells, NTERA2 cells, NB4 cells, HL-60 cells and HeLa cells, 293 cells and myeloma cells like SP2 or NS0. Peripheral blood mononucleocytes (PBMcs) or T-cells can also be used, as can embryonic and adult stem cells. For example, stem cells that can be used include embryonic stem cells (ES), induced pluripotent stem cells (iPSC), mesenchymal stem cells, hematopoietic stem cells, muscle stem

cells, skin stem cells, adipose derived stem cells, and neuronal stem cells. In some alternatives, a system for editing at least one target gene in a cell is provided, wherein the system comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector, wherein said system further comprises a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof, a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, the cell is a eukaryotic cell. In some alternatives, the cell is a mammalian cell, such as a human cell. In some alternatives, the cell is a primary cell. In some alternatives the cell is not a transformed cell. In some alternatives, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

**[0133]** Examples of target plants and plant cells include, but are not limited to, monocotyledonous and dicotyledonous plants, such as crops including grain crops (e.g., wheat, maize, rice, millet, barley), fruit crops (e.g., tomato, apple, pear, strawberry, orange), forage crops (e.g., alfalfa), root vegetable crops (e.g., carrot, potato, sugar beets, yam), leafy vegetable crops (e.g., lettuce, spinach); flowering plants (e.g., petunia, rose, chrysanthemum), conifers and pine trees (e.g., pine fir, spruce); plants used in phytoremediation (e.g., heavy metal accumulating plants); oil crops (e.g., sunflower, rape seed) and plants used for experimental purposes (e.g., *Arabidopsis*). Thus, the disclosed methods and compositions have use over a broad range of plants, including, but not limited to, species from the genera *Asparagus*, *Avena*, *Brassica*, *Citrus*, *Citrullus*, *Capsicum*, *Cucurbita*, *Daucus*, *Erigeron*, *Glycine*, *Gossypium*, *Hordeum*, *Lactuca*, *Lolium*, *Lycopersicon*, *Malus*, *Manihot*, *Nicotiana*, *Orychophragmus*, *Oryza*, *Persea*, *Phaseolus*, *Pisum*, *Pyrus*, *Prunus*, *Raphanus*, *Secale*, *Solanum*, *Sorghum*, *Triticum*, *Vitis*, *Vigna*, and *Zea*. The term plant cells include isolated plant cells as well as whole plants or one or more portions of whole plants such as seeds, callus, leaves, roots, etc. The present disclosure also encompasses seeds of the plants described herein. The present disclosure further encompasses the progeny, clones, cell lines, or cells of the plants described.

#### Generating Homozygously Modified Organisms

**[0134]** Cells in which systems are provided with one or more vectors or nucleic acids encoding endonucleases for co-expression with one or more fusion proteins comprising endonuclease and end-processing activity are expressed and are assayed for site specific cleavage. Such modified cells can be identified using any suitable method known to the skilled artisan, including sequencing, PCR analysis, southern blotting, and the like. In some alternatives, an amplicon spanning the endonuclease target site is generated by PCR.

#### Pharmaceutical Compositions and Administration

**[0135]** Cells manufactured by the systems or methods provided herein can be administered directly to a patient for targeted cleavage of a DNA sequence and for therapeutic or prophylactic applications, for example, for treating, inhibiting, or ameliorating cancer, ischemia, diabetic retinopathy, macular degeneration, rheumatoid arthritis, psoriasis, HIV

infection, sickle cell anemia, Alzheimer's disease, muscular dystrophy, neurodegenerative diseases, vascular disease, cystic fibrosis, stroke, hyper IGE syndrome, or hemophilia. In some alternatives, cells are manufactured by the systems provided herein. In some alternatives, a method of editing at least one target gene in a cell is provided, wherein the method comprises introducing into a cell a first vector that comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in said cell, introducing into said cell a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof; introducing into said cell a third nucleic acid sequence encoding a first adenoviral protein; and introducing into said cell a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, a cell is provided, wherein the cell is manufactured by the said methods. In some alternatives, a composition is provided, wherein the composition comprises the cell. In some alternatives, the compositions described herein, can be used in methods of treating, preventing, ameliorating, or inhibiting a disease (e.g., cancer, ischemia, diabetic retinopathy, macular degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell anemia, Alzheimer's disease, muscular dystrophy, neurodegenerative diseases, vascular disease, cystic fibrosis, stroke, hyper IGE syndrome, hemophilia) or ameliorating a disease condition or symptom associated with a disease, such as, cancer, ischemia, diabetic retinopathy, macular degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell anemia, Alzheimer's disease, muscular dystrophy, neurodegenerative diseases, vascular disease, cystic fibrosis, stroke, hyper IGE syndrome, or hemophilia. In some alternatives, the cells or compositions are administered to treat, prevent, ameliorate, or inhibit an autosomal dominant disease, such as achondroplasia, pseudoachondroplasia, the multiple epiphyseal dysplasias, chondrodysplasias, osteogenesis imperfecta, Marfan syndrome, polydactyly, hereditary motor sensory neuropathies I and II (Charcot-Marie-Tooth disease), myotonic dystrophy, and neurofibromatosis or ameliorate a disease condition or symptom associated with an autosomal dominant disease, such as achondroplasia, pseudoachondroplasia, the multiple epiphyseal dysplasias, chondrodysplasias, osteogenesis imperfecta, Marfan syndrome, polydactyly, hereditary motor sensory neuropathies I and II (Charcot-Marie-Tooth disease), myotonic dystrophy, and/or neurofibromatosis. In some alternatives, the cells or compositions provided herein, are administered to treat, prevent, ameliorate, or inhibit a disease caused by misregulation of genes. In some alternatives, the cells or compositions provided herein, are administered to treat, prevent, ameliorate, or inhibit a cancer, such as BCL-2, Bcl-XI, and FLIP, or ameliorate a disease condition or symptom associated with a cancer, such as BCL-2, Bcl-XI, and FLIP.

**[0136]** The compositions comprising the cells are administered in any suitable manner, and in some alternatives with pharmaceutically acceptable carriers. Suitable methods of administering such proteins or polynucleotides are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

**[0137]** Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer

the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions that are available (see, e.g., Remington's Pharmaceutical Sciences).

**[0138]** Formulations suitable for parenteral administration, such as, for example, by intravenous, intramuscular, intradermal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The disclosed compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials. Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

**[0139]** In some alternatives, one or more of parenteral, subcutaneous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal routes of administration are contemplated. In some embodiments, the composition to be administered can be formulated for delivery via one or more of the above noted routes.

#### Additional Alternatives

**[0140]** RNA-guided endonuclease (RGEN) technology has great promise for enabling efficient editing of a target genomic locus. In some alternatives, the application of *S. pyogenes* Cas9 for gene editing in primary human cells such as primary human T-cells using mRNA-mediated delivery of a first generation spCas9 and adeno-associated virus (AAV) to drive guide RNA expression has been evaluated. In some alternatives, spCas9-mediated editing using mRNA-mediated delivery of a first generation spCas9 and adeno-associated virus (AAV) to drive guide RNA expression achieves targeted gene disruption rates at the TCR $\alpha$  locus of up to 30%. In some alternatives, the evaluation of the dose response of editing efficiency at different Cas9 mRNA doses and over a range of AAV MOI provided evidence that editing efficiency is limited primarily by AAV-driven guide RNA expression. In some alternatives, the evaluation of several approaches to achieve higher editing efficiencies led to the development of approaches that achieve up to 90% TCR $\alpha$  disruption at reduced AAV MOI in selected cell populations. In some alternatives, the results provide evidence that a Cas9-mRNA/AAV-guide approach can be applied to effectively disrupt multiple individual genes in primary human T-cells, and resulted in an innovative method through which CRISPR/Cas9 technology has enhanced efficiency.

**[0141]** The basic components of CRISPR/Cas9 system comprise a target gene, a protospacer adjacent motif (PAM), a guide RNA, Cas9 endonuclease. An important aspect of applying CRISPR/Cas9 for gene editing is the need for a

system to deliver the guide RNAs efficiently to a wide variety of cell types. This could, for example, involve delivery of an in vitro generated guide RNA as a nucleic acid (the guide RNA generated by in vitro transcription or chemical synthesis). In some alternatives the nucleic acid could be rendered nuclease resistant by incorporation of modified bases. An important system for expressing guide RNAs is based on the use of adeno-associated virus (AAV) vectors because AAV vectors are able to transduce a wide range of primary cells. AAV vectors do not cause infection and are not known to integrate into the genome. Therefore, the use of AAV vectors has the benefits of being both safe and efficacious.

**[0142]** In some alternatives, an AAV vector is used to deliver one or more components of the CRISPR/Cas9 system for gene editing. In some alternatives, an AAV vector is used to deliver one or more components of CRISPR/Cas9 system for gene editing in primary cells. In some alternatives, an AAV vector is used to deliver a CRISPR guide RNA for gene editing. In some alternatives, an AAV vector is used to deliver a CRISPR guide RNA for gene editing in primary cells. In some alternatives, a primary cell, is a cell directly derived from a host donor, which is not transformed or cancerous and which cannot be propagated indefinitely outside the host.

**[0143]** In many cell types, there is a post-entry or post-delivery restriction on AAV vectors. This renders AAV-mediated expression of transgenes, including guide RNAs, very inefficient, thus substantially compromising the utility of AAV vectors for this purpose. Certain adenoviral proteins facilitate expression and replication of AAV and AAV vectors. In particular, in some alternatives, E4ORF6 and E1B55K are used as helper proteins in AAV vector production and/or as helper proteins in replication of AAV vector encoding guide RNA.

**[0144]** Previous work has shown that wild type E1B55K or wild type E4ORF6 proteins can disable an important protein complex involved in DNA repair (known as the MRN complex). This leads to cell cycle arrest and high toxicity due to lack of repair of DNA breaks. On the other hand, it has been realized that neither the H373A mutant of E1B55K nor the H354 mutant of E1B55K disable the MRN complex. This leaves the DNA repair machinery intact and provides increased safety and efficacy when using the mutant form of ad proteins for AAV replication in cells. Thus, in some alternatives, the wild type E1B55K is used in combination with the H373A mutant of E1B55K protein. In some alternatives, the wild type E4ORF6 is used in combination with the H354 mutant of E1B55K protein. In some alternatives, the use of wild type E4ORF6 in combination with the H373A mutant of E1B55K protein does not disable the MRN complex. In some alternatives, the use of wild type E4ORF6 in combination with the H354 mutant of E1B55K protein does not lead to cell cycle arrest. In some alternatives, the use of wild type E4ORF6 in combination with the H373A mutant of E1B55K protein does not lead to toxicity due to lack of repair of DNA breaks. In some alternatives, the use of wild type E4ORF6 in combination with the H354

mutant of E1B55K protein does not lead to toxicity due to lack of repair of DNA breaks.

**[0145]** In some alternatives, the use of mutant adenoviral proteins for AAV transduction resulted in lower transduction efficiency of primary cells, as compared to wild type adenoviral proteins. However, the use of mutant adenoviral proteins resulted in dramatic enhancement of CRISPR/Cas9-based gene editing. In some alternatives, this is likely due to enhancing gRNA expression from the AAV vector. In some alternatives, this is likely due to modulation of the DNA repair environment of the cell to promote mutagenic repair of double strand breaks created by CRISPR. In some alternatives, this is likely due to both enhancing gRNA expression from the AAV vector as well as modulation of the DNA repair environment of the cell to promote mutagenic repair of double strand breaks created by CRISPR.

**[0146]** In some alternatives, expression of E4ORF6 and mutant E1B55K-H373A results in sufficient relief of the post-entry restriction on AAV expression while maintaining intact DNA repair. In some alternatives, expression of E4ORF6 and mutant E1B55K-H354 results in sufficient relief of the post-entry restriction on AAV expression while maintaining intact DNA repair. In some alternatives, expression of E4ORF6 and E1B55K-H373A allows for a substantial improvement in gene editing efficiency. In some alternatives, expression of E4ORF6 and E1B55K-H354 allows for a substantial improvement in gene editing efficiency. In some alternatives, expression of E4ORF6 and E1B55K-H373A allows for a substantial improvement in CRISPR/Cas9-mediated gene editing efficiency. In some alternatives, expression of E4ORF6 and E1B55K-H354 allows for a substantial improvement in CRISPR/Cas9-mediated gene editing efficiency. In some alternatives, expression of E4ORF6 and E1B55K-H373A allows a substantial improvement in gene editing efficiency in primary cells. In some alternatives, expression of E4ORF6 and E1B55K-H354 allows a substantial improvement in gene editing efficiency in primary cells. In some alternatives, expression of E4ORF6 and E1B55K-H373A allows for a substantial improvement in CRISPR/Cas9-mediated gene editing efficiency in primary cells. In some alternatives, expression of E4ORF6 and E1B55K-H354 allows for a substantial improvement in CRISPR/Cas9-mediated gene editing efficiency in primary cells.

**[0147]** In some alternatives, a system of introducing CRISPR/Cas9 in primary cells using an AAV-mRNA split system approach is provided. In some alternatives of the split system, Cas9, a derivative, or fragment thereof and adenoviral proteins are expressed from mRNA and expressed transiently, and gRNA is expressed constantly and expressed from AAV. In some alternatives, the split system increased the efficiency of gene editing in primary human cells.

**[0148]** Some alternatives relate to a method of introducing CRISPR guide RNA in primary cells using an AAV vector. More alternatives relate to a method of introducing Cas9, a derivative, or fragment thereof in primary cells encoded by an mRNA. In some alternatives, a method of introducing Cas9, a derivative, or fragment thereof in primary cells encoded as a fusion protein by an mRNA is provided. In some alternatives, Cas9 is fused with a fluorophore at the C terminus. In some alternatives, Cas9, a derivative, or fragment thereof is fused with a fluorophore at the N terminus. In some alternatives, Cas9, a derivative, or fragment thereof

is fused with a fluorophore and the Cas9, a derivative, or fragment thereof and fluorophore are separated by a self-cleavage sequence, such as a T2A sequence. In some alternatives, Cas9, a derivative, or fragment thereof is fused to an NLS. In some alternatives, the NLS is fused at the N terminus of Cas9, a derivative, or fragment thereof. In some alternatives, the NLS is fused at the C terminus of Cas9, a derivative, or fragment thereof. In some alternatives, the NLS is fused at both the N and the C terminus of Cas9, a derivative, or fragment thereof. In some alternatives, Cas9, a derivative, or fragment thereof is tagged with an mCherry fluorophore.

**[0149]** In some alternatives, the mRNA comprises a poly A tail. In some alternatives, the poly A tail confers stability to the mRNA. In some alternatives, the length of the poly A tail is greater than or equal to 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 base pairs or a length that is within a range defined by any two of the aforementioned lengths. In some alternatives, the mRNA is encoded by a vector. In some alternatives, the mRNA is expressed from the vector by in vitro transcription. In some alternatives, the mRNA encodes a nuclease, helicase and/or an adenoviral protein. In some alternatives, the mRNA encodes Cas9, a derivative, or fragment thereof. In some alternatives, the mRNA encodes MegaTAL or TALEN. In some alternatives, the mRNA encodes E4ORF6. In some alternatives, the mRNA encodes E1B55K. In some alternatives, the mRNA encodes H373A E1B55K. In some alternatives, the mRNA encodes H354 E1B55K. In some alternatives, the mRNA encodes Trex2.

**[0150]** In some alternatives, the expression of adenoviral proteins is desired along with the Cas9 protein. mRNAs with poly A tails that are greater than or equal to 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 base pairs or a length that is within a range defined by any two of the aforementioned lengths, wherein said mRNAs encode Cas9, a derivative, or fragment thereof, TALEN, or MegaTAL, can be efficiently co-expressed in primary human cells. In some alternatives, said mRNA is used to express Cas9, a derivative, or fragment thereof. In some alternatives, said mRNA is used to express wild type adenoviral proteins. In some alternatives, said mRNA is used to express mutant adenoviral proteins. In some alternatives, AAV is used to express guide RNA. Some alternatives relate to methods of introducing adenoviral proteins in primary cells encoded by an mRNA. In some alternatives, mRNA is used to introduce the wild type adenoviral protein E4ORF6. In some alternatives, mRNA is used to introduce the mutant adenoviral protein H373A E1B55K. In some alternatives, mRNA is used to introduce the mutant adenoviral protein H354 E1B55K. In some alternatives, separate mRNAs are used to introduce both wild type E4ORF6 and the mutant H373A E1B55K. In some alternatives, separate mRNAs are used to introduce both wild type E4ORF6 and the mutant H354 E1B55K. In some alternatives, the mRNAs are on a vector. In some alternatives, AAV with guide RNA and mRNA encoding Cas9, a derivative, or fragment thereof, and E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, E4ORF6 and mutant H354 E1B55K are simultaneously introduced. In some alternatives, AAV with guide RNA and mRNA encoding Cas9, a derivative, or fragment thereof, and E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, E4ORF6 and mutant H354 E1B55K

are sequentially introduced. In some alternatives, AAV with guide RNA and mRNA encoding Cas9, a derivative, or fragment thereof, and E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, E4ORF6 and H354 E1B55K are present in a cell at the same time. In some alternatives, mRNA is used to transiently express wild type adenoviral proteins. In some alternatives, mRNA is used to transiently express mutant adenoviral proteins. In some alternatives, mRNA is used to simultaneously albeit transiently to express Cas9, a derivative, or fragment thereof, wild type adenoviral proteins and mutant adenoviral protein. In some alternatives, guide RNA is prone to degradation. In some alternatives, therefore AAV is used to constantly express guide RNA. In some alternatives, AAV with guide RNA and mRNA encoding Cas9, a derivative, or fragment thereof, and E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, and E4ORF6 and H354 E1B55K are present transiently. In some alternatives, AAV with guide RNA and mRNA encoding Cas9, a derivative, or fragment thereof, E4ORF6 and mutant H373A E1B55K or AAV with guide RNA and mRNA encoding Cas9, E4ORF6 and H354 E1B55K are not present permanently.

**[0151]** In some alternatives, co-expressing Cas9, a derivative, or fragment thereof with E4ORF6/E1B55K-H373A results in sufficient relief of post-entry restriction on AAV expression while maintaining intact DNA repair. This allows substantial improvement in Cas9-mediated gene editing efficiency with minimal toxicity when an AAV vector is simultaneously used to express the guide RNAs necessary for Cas9 targeting, thus yielding results counterintuitive to what one might have expected from the use of AAV vectors and substantially improving and expanding the potential applications of the CRISPR/Cas9 system in primary cells.

**[0152]** In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in primary cells is provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in primary T-cells is provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in Jurkat T-cells is provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in primary cells using a combined mRNA/AAV approach is provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in primary T-cells using a combined mRNA/AAV approach is provided. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout in Jurkat T-cells using a combined mRNA/AAV approach is provided. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout is provided. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout in primary cells is provided. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout in primary T-cells is provided. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout in Jurkat T-cells is provided.

**[0153]** In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout and enhanced homologous recombination in primary T-cells is described. In some alternatives, the use of adenoviral proteins to enhance CRISPR-mediated gene knockout and enhanced

homologous recombination in primary T-cells using a combined mRNA/AAV approach is described. In some alternatives, the use of mutant adenoviral proteins to enhance CRISPR-mediated gene knockout and enhanced homologous recombination is provided. In some alternatives, the mutant adenoviral proteins enhance CRISPR-mediated gene knockout and enhance homologous recombination in primary T-cells.

**[0154]** The application of this technology is not limited to primary human cells. In some alternatives, a system for targeting of non-human sequences, for example pathogenic organisms, is provided. In some alternatives, a method for targeting of non-human sequences, for example pathogenic organisms, is provided. In some alternatives, a system for targeting diseases is provided. In some alternatives, a method for targeting diseases is provided. In some alternatives, the disease can be an infectious disease caused by a pathogenic organism. In some alternatives, the disease can be a non-infectious disease.

**[0155]** Double strand DNA break repair through the NHEJ pathway is often not mutagenic. The majority of endonuclease-induced breaks repaired by the NHEJ pathway involve precise re-ligation, resulting in the restoration of the original DNA sequence. HDR, in contrast to NHEJ, requires a repair template and imprecise repair through this pathway can result in mutations at the break site, such as DNA base deletions and insertions, as well as, translocations and telomere fusion.

**[0156]** In some alternatives, the use of Cas9-mRNA/AAV-guide system results in increased NHEJ rates. Thus, in some alternatives of the Cas9-mRNA/AAV-guide system, a repair template is introduced into the cell. In some alternatives the repair template is RNA. In some alternatives, the repair template is DNA. In some alternatives, the Cas9-mRNA/AAV-guide system is driven towards HDR to achieve greater mutation rate. In some alternatives, the mRNA-AAV system is implemented with another nuclease without providing a repair template. In some alternatives, the mRNA-AAV system implemented with another nuclease without providing a repair template allows for NHEJ. In some alternatives, the system further comprises a nuclease, wherein the nuclease is MegaTAL.

#### Additional Preferred Alternatives

**[0157]** In some alternatives, a system for editing at least one target gene in a cell, comprising a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in a cell and, wherein said first nucleic acid sequence is present in a vector, wherein said system further comprises a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof; a third nucleic acid sequence encoding a first adenoviral protein, and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives, the cell is not a transformed cell. In some alternatives of the system, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the system, the vector is a viral vector. In some alternatives of the system, the viral vector is an



Adeno-associated virus (AAV) vector. In some alternatives of the system, the second nucleic acid encoding the Cas9 protein, a derivative, or fragment thereof is an mRNA. In some alternatives of the system, the second nucleic acid sequence encoding the Cas9 protein, a derivative, or fragment thereof is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the Cas9 protein, a derivative, or fragment thereof is from *S. pyogenes*. In some alternatives of the system, the third nucleic acid encoding the first adenoviral protein is an mRNA. In some alternatives of the system, the mRNA is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first adenoviral protein is E4ORF6. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is an mRNA. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the second adenoviral protein is an E1B55K mutant. In some alternatives of the system, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the system, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 4. In some alternatives of the system, the first, second, third and fourth nucleic acid sequences are joined to regulatory elements that are operable in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a regulatory element. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a U6 promoter. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is constitutively expressed.

**[0158]** In some alternatives, a method of editing at least one target gene in a cell, comprises introducing into a cell a first vector that comprises a first nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complimentary to at least one target gene in said cell; introducing into said cell a second nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof; introducing into said cell a third nucleic acid sequence encoding a first adenoviral protein; and introducing into said cell a fourth nucleic acid sequence encoding a second adenoviral protein.

**[0159]** In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives of the method, the cell is a mammalian cell. In some alternatives of the method, the cell is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the method, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the method, the first vector comprising the first nucleic acid sequence encoding the CRISPR guide RNA is a viral vector. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the second, third and fourth nucleic acid sequences are mRNA. In some alternatives of the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human. In some alternatives of the method, the Cas9 protein, a derivative, or fragment thereof

is from *S. pyogenes*. In some alternatives of the method, the first adenoviral protein is E4ORF6. In some alternatives of the method, the second adenoviral protein is an E1B55K mutant. In some alternatives of the method, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the method, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 4.

**[0160]** In some alternatives of the system, the CRISPR guide RNA is any and all guide RNAs that are complimentary to a gene of interest. In some alternatives of the system, the CRISPR guide RNA is complimentary to a target gene of interest. Some non-limiting examples of target genes of interest include TCR $\alpha$ , TCR $\beta$ , PD-1, Tim3, Lag3, TIGIT or HBB.

**[0161]** In some alternatives of the system, the CRISPR guide RNA sequence targeting TCR comprises a sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 5. These sequences are described in FIG. 16A. In some alternatives of the system, polynucleotide sequence alternatives of PD1 guide target comprises a sequence set forth in SEQ ID NO: 18, TIGIT guide target comprises a sequence set forth in SEQ ID NO: 19, Lag3 guide target comprises a sequence set forth in SEQ ID NO: 20 and Tim3 guide target comprises a sequence set forth in SEQ ID NO: 21. These sequences are provided in FIG. 31.

**[0162]** In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, introducing the first, second, third and fourth nucleic acid sequences into the cell does not transform the cell. In some alternatives of the method and/or the system, the second, third, or fourth nucleic acid sequence is provided on a vector. In some alternatives, a method of editing at least one target gene in a cell, the method comprising introducing into the cell any of the alternatives of the system described herein.

**[0163]** In some alternatives, a method of treating, ameliorating, or inhibiting a disease and/or a condition in a subject, the method comprising providing to the subject having a disease and/or a condition and in need thereof, any of the alternatives of the system described herein. Some non-limiting examples of diseases and/or conditions can be sickle cell disease, hypercholesterolemia, cancer, autoimmune disease, inherited disorder of metabolism, immunodeficiency or genetic disease such as any disease due to a functional deficit in a gene product due to an alteration in the genome of the cell relative to a reference human genome.

#### More Alternatives

**[0164]** In more alternatives, a system for editing at least one target gene in a cell is provided, the system comprising a nucleic acid encoding Cas9 protein, at least one nucleic acid encoding at least protein, which alone or together with other proteins modifies the substrate specificity of at least one ubiquitin ligase enzyme or enzyme complex in the cell, and a vector that comprises at least one nucleic acid sequence encoding a CRISPR guide RNA, wherein the one or more CRISPR guide RNAs is/are complimentary to at least one target gene in a cell and in some alternatives of the system a vector that comprises a nucleic acid template for homologous gene targeting.

**[0165]** In some alternatives of the system, the Cas9 protein, a derivative, or fragment thereof and the ubiquitin

ligase substrate specificity modifying proteins are encoded on the same nucleic acid. In some alternatives of the system, the Cas9 protein, a derivative, or fragment thereof and the ubiquitin ligase substrate specificity modifying proteins are encoded on two or more nucleic acids. In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives of the system, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives of the system, the cell is not a transformed cell. In some alternatives of the system, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the system, the vector encoding the guide RNA(s) is a viral vector. In some alternatives of the system, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives, the viral vector is a lentiviral vector.

**[0166]** In some alternatives of the system, the nucleic acid encoding the Cas9 protein, a derivative, or fragment thereof is an mRNA the second nucleic acid encoding the Cas9 protein, a derivative, or fragment thereof is an mRNA. In some alternatives of the system, the nucleic acid sequence encoding the Cas9 protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the Cas9 protein, a derivative, or fragment thereof is from *S. pyogenes*.

**[0167]** In some alternatives of the system, the nucleic acid or nucleic acids encoding any of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins are mRNA. In some alternatives of the system, the one or more mRNA's encoding ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins are codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is the adenoviral protein E4ORF6 of any adenoviral serotype. In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is E1B55K of any adenovirus serotype.

**[0168]** In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is an E1B55K mutant, said mutant having an one or more amino acid changes or additions relative to the wild type E1B55K protein, which cause an alteration in the mutant protein's ability to modify cellular ubiquitin ligase substrate specificity relative the wild type E1B55K protein.

**[0169]** In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 2.

**[0170]** In some alternatives of the system, one of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 4.

**[0171]** In some alternatives of the system, the nucleic acid sequences are joined to regulatory elements that are operable in a eukaryotic cell, such as a human cell. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is operably linked to a regulatory element. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is operably

linked to a U6 promoter. In some alternatives of the system, the nucleic acid sequence encoding the CRISPR guide RNA is constitutively expressed. In some alternatives, the nucleic acid sequence encoding the CRISPR guide RNA is operably linked to the U6 promoter and constitutively expressed.

**[0172]** In some alternatives, a method of editing at least one target gene in a cell is provided, the method comprising introducing into the cell a nucleic acid sequence encoding a Cas9 protein, a derivative, or fragment thereof; introducing into said cell at least one nucleic acid sequence encoding a ubiquitin ligase enzyme/enzyme complex substrate specificity modifying protein; introducing into said cell a vector that comprises at least one nucleic acid sequence encoding a CRISPR guide RNA, wherein the CRISPR guide RNA is complementary to at least one target gene in said cell; and in some alternative of the method, introducing into said cell a vector that comprises a nucleic acid template for homologous gene targeting.

**[0173]** In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives of the method, the cell is a mammalian cell. In some alternatives of the method, the cell is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the method, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the method, the vector comprising the first nucleic acid sequence encoding the endonuclease is a viral vector. In some alternatives, Cas9 is encoded in a viral vector. In some alternatives, a guide RNA is encoded in a viral vector. In some alternatives, a Cas9 and a guide RNA are encoded together in a viral vector. In some alternatives, a Cas9 and a guide RNA encoded together in a viral vector is used in combination with one or more Ad5 protein encoded by mRNA.

**[0174]** In some alternatives of the method, the vector comprising the nucleic acid sequence encoding the one or more CRISPR guide RNAs is a viral vector. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the viral vector is a lentiviral vector. In some alternatives of the method, the nucleic acids encoding Cas9, a derivative, or fragment thereof and/or the ubiquitin ligase substrate specificity modifying proteins are mRNA. In some alternatives of the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human.

**[0175]** In some alternatives of the method, the Cas9 protein, a derivative, or fragment thereof is from *S. pyogenes*. In some alternatives of the method, the ubiquitin ligase substrate specificity modifying proteins is E4ORF6 of any adenoviral serotype. In some alternatives of the method, the ubiquitin ligase substrate specificity modifying proteins is E1B55K of any adenoviral serotype. In some alternatives of the method, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the method, the second adenoviral protein comprises the amino acid sequence set forth in SEQ ID NO: 4.

**[0176]** In some alternatives of the system, the CRISPR guide RNA is any and all guide RNAs that are complementary to a gene of interest. In some alternatives of the system, the CRISPR guide RNA is complementary to a target gene

on interest. Some non-limiting examples of target genes of interest include TCR $\alpha$ , TCR $\beta$ , PD-1, Tim3, Lag3, TIGIT or HBB.

**[0177]** In some alternatives of the system, alternatives of the CRISPR guide RNA sequence targeting TCR comprise a sequence set forth in SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 5. These sequences are shown in FIG. 16A. In some alternatives of the system, a polynucleotide sequence comprises alternatives of PD1 guide target (SEQ ID NO: 18), TIGIT guide target (SEQ ID NO: 19), Lag3 guide target (SEQ ID NO: 20) or Tim3 guide target (SEQ ID NO: 21). These sequences are provided in FIG. 31.

**[0178]** In some alternatives of the method, the nucleic acid sequences are transiently introduced into the cell. In some alternatives of the method, the nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, introducing the nucleic acid sequences into the cell does not permanently transform the cell.

**[0179]** Any of the alternatives of the system or the method described herein, wherein said second, third, or fourth nucleic acid sequence is provided on a vector.

**[0180]** In some alternatives, a method of editing at least one target gene in a cell, the method comprising introducing into the cell any of the alternatives of the system described herein.

**[0181]** In some alternatives, a method of treating, ameliorating, or inhibiting a disease and/or a condition in a subject, the method comprising providing to the subject having a disease and/or a condition and in need thereof, any of the alternatives of the system described herein. Some non-limiting examples of diseases and/or conditions can be sickle cell disease, hypercholesterolemia, cancer, autoimmune disease, inherited disorder of metabolism, immunodeficiency or genetic disease such as any disease due to a functional deficit in a gene product due to an alteration in the genome of the cell relative to a reference human genome.

**[0182]** In some alternatives, a system for editing at least one target gene in a cell is provided, the system comprising a nucleic acid encoding an endonuclease protein that targets at least one sequence in a cell, and at least one nucleic acid encoding at least one protein, which alone or together with other proteins modifies the substrate specificity of at least one ubiquitin ligase enzyme or enzyme complex in the cell, and, optionally, a vector that comprises a nucleic template for homologous gene targeting. In some alternatives of the system, the nuclease protein and the ubiquitin ligase substrate specificity modifying proteins are encoded on the same nucleic acid. In some alternatives of the system, the nuclease protein and the ubiquitin ligase substrate specificity modifying proteins are encoded on two or more nucleic acids. In some alternatives of the system, the nucleic template for homologous gene targeting is a DNA. In some alternatives of the system, the nucleic template for homologous gene targeting is an RNA. In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives of the system, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives of the system, the cell is not a transformed cell. In some alternatives of the system, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the system, the vector is a viral vector. In

some alternatives of the system, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the system, the viral vector is a lentiviral vector.

**[0183]** In some alternatives of the system, the nucleic acid encoding the Cas9 nuclease, a derivative, or fragment thereof is an mRNA. In some alternatives of the system, the nucleic acid sequence encoding the nuclease is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the nucleic acid or nucleic acids encoding any of the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins are mRNA. In some alternatives of the system, the one or more mRNAs encoding ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins are codon optimized for expression in a eukaryotic cell, such as a human cell.

**[0184]** In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is the adenoviral protein E4ORF6 of any adenoviral serotype. In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is E1B55K of any adenovirus serotype. In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins is an E1B55K mutant, said mutant having an one or more amino acid changes relative to the wild type E1B55K protein which cause an alteration in the mutant protein's ability to modify cellular ubiquitin ligase substrate specificity relative the wild type E1B55K protein. In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the system, the ubiquitin ligase enzyme/enzyme complex substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 4. In some alternatives of the system, the ubiquitin ligase substrate specificity modifying proteins are one or more viral proteins.

**[0185]** In some alternatives of the system, the nucleic acid sequence encoding the endonuclease RNA is operably linked to a regulatory element. In some alternatives of the system, the nucleic acid sequence encoding the endonuclease RNA is operably linked to a U6 promoter. In some alternatives of the system, the nucleic acid sequence encoding the endonuclease RNA is constitutively expressed. In some alternatives, the nucleic acid sequence encoding the endonuclease RNA is operably linked to the U6 promoter and constitutively expressed.

**[0186]** In some alternatives, a method of editing at least one target gene in a cell is provided, the method comprising introducing into a cell a nucleic acid sequence encoding an endonuclease, introducing into said cell at least one nucleic acid sequence encoding a ubiquitin ligase enzyme/enzyme complex substrate specificity modifying protein; and optionally introducing into said cell a vector that comprises a nucleic acid template capable of homologous gene targeting of at least one genomic sequence in the cell. In some alternatives of the method, the nucleic template for homologous gene targeting is a DNA. In some alternatives of the method, the nucleic template for homologous gene targeting is an RNA.

**[0187]** In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives, a method the cell is a mammalian cell. In some alternatives of the method, the cell

is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the method, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell. In some alternatives of the method, the vector comprising the first nucleic acid sequence encoding the endonuclease is a viral vector. In some alternatives, Cas9, a derivative, or fragment thereof is encoded in a viral vector. In some alternatives, a guide RNA is encoded in a viral vector. In some alternatives, a Cas9, a derivative, or fragment thereof and a guide RNA are encoded together in a viral vector. In some alternatives, a Cas9, a derivative, or fragment thereof and a guide RNA encoded together in a viral vector is used in combination with one or more Ad5 protein encoded by mRNA. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the viral vector is a lentiviral vector. In some alternatives of the method, the nucleic acids encoding the nuclease and/or the ubiquitin ligase substrate specificity modifying proteins are mRNA. In some alternatives of the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human. In some alternatives of the method, the endonuclease protein is a meganuclease, a TALEN, a zinc finger nuclease, or a MegaTAL. In some alternatives of the method, one of the ubiquitin ligase substrate specificity modifying proteins is E4ORF6 of any adenoviral serotype. In some alternatives of the method, one of the ubiquitin ligase substrate specificity modifying proteins is E1B55K of any adenoviral serotype. In some alternatives of the method, one of the ubiquitin ligase substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 2. In some alternatives of the method, one of the ubiquitin ligase substrate specificity modifying proteins comprises the amino acid sequence set forth in SEQ ID NO: 4. In some alternatives of the system, the nuclease targets a gene of interest. Some non-limiting examples of target genes of interest include TCR $\alpha$ , TCR $\beta$ , PD-1, Tim3, Lag3, TIGIT or HBB.

**[0188]** In some alternatives of the method, the nucleic acid sequences are transiently introduced into the cell. In some alternatives of the method, the nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, introducing the nucleic acid sequences into the cell does not transform the cell. In some alternatives of the system, the target gene intended for homologous gene targeting is a gene of interest. Some non-limiting examples of target genes of interest include TCR $\alpha$ , TCR $\beta$ , PD-1, Tim3, Lag3, TIGIT or HBB. In some alternatives of any of the system or any of the method described herein, the nucleic acid sequences are provided on a vector. In some alternatives, a method of editing at least one target gene in a cell is provided, the method comprising introducing into the cell any of the alternatives of the system described herein.

**[0189]** In some alternatives, a method of treating, ameliorating, or inhibiting a disease and/or a condition in a subject, the method comprises providing to the subject having a disease and/or a condition in need thereof, any of the alternatives of the system described herein. Some non-limiting examples of diseases and/or conditions can be sickle cell disease, hypercholesterolemia, cancer, autoimmune disease, inherited disorder of metabolism, immuno-

deficiency or genetic disease such as any disease due to a functional deficit in a gene product due to an alteration in the genome of the cell relative to a reference human genome.

**[0190]** While the foregoing written description enables one of ordinary skill to make and use what is considered presently to be the best mode thereof, those of ordinary skill will understand and appreciate the existence of variations, combinations, and equivalents of the specific embodiment, method, and examples herein. The present alternatives should therefore not be limited by the herein described embodiment, method, and examples, but by all alternatives and methods within the scope and spirit of the present alternatives. The following examples are presented for illustrative purposes and should not be construed as being limiting.

#### Further Alternatives

**[0191]** Alternative of Cas9 described herein can be used in any and all of the alternatives of the system and/or method described herein. Some alternatives of Cas9 are disclosed in the following references which are hereby incorporated by reference in their entirety (Gilbert et al, Cell, July 18, 154(2): 442-451, 2013; Hilton et al, Nat Biotechnol. April 6, doi: 10.1038/nbt.3199, 2015; Qi et al, Cell, February 28; 152(5): 1173-1183, 2013; Esvelt et al, Nature Methods 10, 1116-1121, 2013; Zetsche et al, Nature Biotechnology, 33, 139-142, 2015; all references incorporated by reference in their entirety herein). The ability of Cas9 to co-localizing RNA, DNA and protein to a target region of a genome offers unprecedented control over cellular organization, regulation and behavior using the Cas9 system (Mali et al).

**[0192]** The CRISPR-associated catalytically inactive variant of *S. pyogenes* Cas9 (dCas9 or nuclease null Cas9) can be used for RNA-guided DNA targeting (Gilbert et al; incorporated by reference in its entirety herein). Fusion of dCas9 to effector domains of regulatory proteins (for example, a transcriptional activator (hereinafter, activator domain) or a transcriptional repressor (hereinafter, repressor domain) enables stable and efficient transcriptional regulation in human and yeast cells (Gilbert et al; incorporated by reference in its entirety herein). The site-specific delivery of dCas9 is determined solely by a guide RNA (Gilbert et al). CRISPR interference (CRISPRi)-mediated transcriptional repression, which entails coupling dCas9 to a transcriptional repressor domain, can robustly and specifically silence gene expression in eukaryotic cells (Gilbert et al; incorporated by reference in its entirety herein) and *Escherichia coli* (Qi et al; incorporated by reference in its entirety herein).

**[0193]** Thus, in some alternatives, a catalytically inactive Cas9 (dCas9) is used which does not cause a double stranded DNA break. In some alternatives, a dCas9 is fused to an activator domain. In some alternatives, a dCas9 is fused to a repressor domain. In some alternatives, a dCas9-activator domain is encoded by an mRNA. In some alternatives, a dCas9-repressor domain is encoded by an mRNA. In some alternatives, an mRNA encoding dCas9-activator domain is used in combination an AAV vector encoding a guide RNA. In some alternatives, an mRNA encoding dCas9-repressor domain is used in combination an AAV vector encoding a guide RNA. In some alternatives, an mRNA encoding dCas9-activator domain is used in combination an mRNA encoding an Ad5 protein and an AAV vector encoding a guide RNA. In some alternatives, an mRNA encoding dCas9-repressor domain is used in combination an mRNA

encoding an Ad5 protein and an AAV vector encoding a guide RNA. In some alternatives, a dCas9-activator domain activates transcription. In some alternatives, a dCas9-repressor domain represses transcription. In some alternatives, one or more Ad5 proteins further increases activation of transcription by a dCas9-activator domain fusion. In some alternatives, one or more Ad5 proteins further increases repression of transcription by dCas9-repressor domain fusion.

**[0194]** Creating a fusion of dCas9 with a catalytic core of a human acetyltransferase led to acetylation of histone H3, resulting in robust transcriptional activation of target genes from promoters and both proximal and distal enhancers (Hilton et al; incorporated by reference in its entirety herein). Thus, in some alternatives, dCas9 is fused to a functional catalytic domain of a histone modifying enzyme. In some alternatives, dCas9 is fused to a functional catalytic domain, for example, a catalytic core of a histone acetyltransferase. In some alternatives, dCas9 is fused to a functional catalytic domain of a histone deacetylase. In some alternatives, dCas9 is fused to a functional catalytic domain of a histone methyl transferase. In some alternatives, dCas9 fused to a functional catalytic domain of a histone modifying enzyme can activate transcription. In some alternatives, dCas9 fused to a functional catalytic domain of a histone modifying enzyme can repress transcription.

**[0195]** A set of fully orthogonal Cas9 proteins mediated simultaneous and independently targeted gene regulation and editing in bacteria and in human cells (Esvelt et al). In some alternatives, the Cas9 variants recognize different variants of PAM (Kleinstiver et al). A PAM is a DNA sequence immediately following a DNA sequence targeted by Cas9. Thus, in some alternatives, Cas9 is from *S. pyogenes*. In some alternatives, an *S. pyogenes* Cas9 variant can recognize an NGG protospacer PAM. In some alternatives, an *S. pyogenes* Cas9 variant can recognize a PAM that is not NGG. In some alternatives, Cas9 variants can be from *Staphylococcus aureus*. In some alternatives, Cas9 variants can be from *Streptococcus thermophiles*. In some alternatives, Cas9 variants can be from *Neisseria meningitidis*. In some alternatives, Cas9 variants can be from *Treponema denticola*. In some alternatives, the sequence of Cas9 can be a Cas9 consensus sequence derived from two or more of the organisms provided herein, for example, *Staphylococcus aureus* and *Streptococcus thermophiles*. In some alternatives, the sequence of Cas9 can be from any of the organisms provided herein and codon optimized for expression in any of the other organisms provided herein.

**[0196]** Examples of desirable alternatives of Cas9 include Cas9 from *S. pyogenes* and variants thereof. In some alternatives, Cas9 can be from *S. pyogenes*. In some alternatives, Cas9 can be a variant of Cas9 from *S. pyogenes*. In some alternatives, Cas9 can be an ortholog of Cas9 from *S. pyogenes*. In some alternatives, Cas9 can be a variant of an ortholog of Cas9 from *S. pyogenes*. In some alternatives, Cas9 is catalytically inactive. In some alternatives, a dCas9 is inactive because of mutations. In some alternatives, a dCas9 is inactive because of mutations D10A and H841A in the protein sequence.

**[0197]** A modular Cas9 architecture for inducible genome editing and transcription modulation was reported in which Cas9 was split into an N terminal piece and a C terminal piece, each catalytically active and fused to a dimerization domain. The two dimerization domains of each of the two

Cas9 pieces were brought together by a small molecule (for example, a drug) to generate a functional Cas9 capable of generating a double strand break (Zetsche et al; incorporated by reference in its entirety herein). Thus, in some alternatives, an N terminal fragment of Cas9 is used. In some alternatives, a C terminal fragment of Cas9 is used. In some alternatives, an N terminal fragment of Cas9 is used in combination a C terminal fragment of Cas9. In some alternatives, an N terminal fragment of Cas9 is fused to a dimerization domain. In some alternatives, a C terminal fragment of Cas9 is fused to a dimerization domain. In some alternatives, the dimerization domains dimerize. In some alternatives, the dimerization domains do not dimerize. In some alternatives, the dimerization domains dimerize in the presence of a small molecule, for example, a drug. In some alternatives, the dimerization domains do not dimerize in the presence of a small molecule, for example, a drug. In some alternatives, the dimerization domains dimerize in the absence of a small molecule, for example, a drug. In some alternatives, the dimerization domains do not dimerize in the absence of a small molecule, for example, a drug. In some alternatives, dimerization of the dimerization domains brings the N and C terminal fragments of Cas9 into close proximity. In some alternatives, a double stranded DNA break is created at a target genomic locus when the two Cas9 fragments are brought into close proximity. Examples of desirable alternatives of N terminal fragments of Cas9 can be Cas9 fragments extending from amino acids 1-203, 1-256, 1-311, 1-535, 1-573, 1-714, 1-1004, 1-1055, 1-1115, 1-1153 or 1-1246. Examples of desirable alternatives of C terminal fragments of Cas9 can be Cas9 fragments extending from amino acids 204-1368, 257-1368, 312-1368, 536-1368, 574-1368, 715-1368, 1005-1368, 1056-1368, 1116-1368, 1154-1368 or 1247-1368.

#### Endonuclease-Based Gene Editing in Primary Human T-Cells

**[0198]** Many future therapeutic applications of RNA-guided endonucleases are likely to require their use to promote gene targeting, thus necessitating development of methods that provide for delivery of three components—endonuclease, guide RNAs and recombination templates—to primary cells rendered proficient for homology-directed repair to achieve gene disruption and/or gene targeting for recombination.

**[0199]** For example, many future therapeutic applications of CRISPR/Cas9 and related RNA-guided endonucleases are likely to require their use to promote gene targeting, thus necessitating development of methods that provide for delivery of three components—Cas9, guide RNAs and recombination templates—to primary cells rendered proficient for homology-directed repair. Thus, in some alternatives, a CRISPR gene editing in primary human T-cells using mRNA/AAV co-delivery is contemplated.

**[0200]** In some alternatives, a high efficiency CRISPR/Cas9-mediated gene editing in primary human T-cells using mutant adenoviral E4ORF6/E1B55K “helper” proteins are provided.

**[0201]** In some alternatives, an electroporation/transduction co-delivery method that utilizes mRNA to express Cas9 in conjunction with mutant adenoviral E4ORF6 and E1B55K helper proteins is provided. In some alternatives, the mutant adenoviral E4ORF6 and E1B55K helper proteins

serve to transiently enhance both the target cells' permissiveness to AAV transduction and its gene editing efficiency.

**[0202]** In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption at one or more loci and/or simultaneously at multiple loci in cells in general is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient homologous gene targeting at one or more loci and/or simultaneously at multiple loci in cells in general is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption and homologous gene targeting at one or more loci and/or simultaneously at multiple loci in cells in general is contemplated.

**[0203]** In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption at one or more loci and/or simultaneously at multiple loci in primary cells is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient homologous gene targeting at one or more loci and/or simultaneously at multiple loci in primary cells is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption and homologous gene targeting at one or more loci and/or simultaneously at multiple loci in primary cells is contemplated.

**[0204]** In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption at one or more loci and/or simultaneously at multiple loci in primary T-cells is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient homologous gene targeting at one or more loci and/or simultaneously at multiple loci in primary T-cells is contemplated. In some alternatives, the system and/or method provided herein can be applied for efficient gene disruption and homologous gene targeting at one or more loci and/or simultaneously at multiple loci in primary T-cells is contemplated.

**[0205]** In some alternatives, the system and/or method provided herein can be applied for both efficient gene disruption and/or homologous gene targeting at one or more loci and/or simultaneously at multiple loci in human cells in general, illustrating its broad potential for application in translational gene editing. For example, in some alternatives, this method can be applied for both efficient gene disruption and/or homologous gene targeting at multiple loci in primary human T-cells, illustrating its broad potential for application in translational gene editing.

#### Preferred Alternatives

**[0206]** In some alternatives, a system for editing at least one target gene in a cell, the system comprising a first nucleic acid sequence, or a set of nucleic acid sequences, encoding one or more CRISPR guide RNA, wherein the one or more CRISPR guide RNA is complimentary to the at least one target gene in a cell and, wherein the first nucleic acid sequence, or the set of nucleic acid sequences, may be comprised in one or more vectors, but not required to be comprised in one or more vectors; a Cas9 protein or a second nucleic acid sequence encoding a Cas9 protein; a third nucleic acid sequence encoding a first adenoviral protein; and a fourth nucleic acid sequence encoding a second adenoviral protein.

**[0207]** In some alternatives of the system, the cell is a eukaryotic cell. In some alternatives of the system, the cell is a mammalian cell. In some alternatives of the system, the cell is a human cell. In some alternatives of the system, the cell is a primary cell. In some alternatives of the system, the cell is not a transformed cell. In some alternatives of the system, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

**[0208]** In some alternatives of the system, the vector is a viral vector. In some alternatives of the system, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the system, the AAV vector is a self-complementary vector. In some alternatives of the system, the AAV vector is a single stranded vector. In some alternatives of the system, the AAV vector is a combination of a self-complementary vector and a single stranded vector.

**[0209]** In some alternatives of the system, the second nucleic acid encoding the Cas9 protein is an mRNA. In some alternatives of the system, the second nucleic acid sequence encoding the Cas9 protein is codon optimized for expression in a eukaryotic cell, such as a human cell.

**[0210]** In some alternatives of the system, the Cas9 protein is from *S. pyogenes*.

**[0211]** In some alternatives of the system, the third nucleic acid encoding the first adenoviral protein is an mRNA. In some alternatives of the system, the third nucleic acid encoding the first adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the first adenoviral protein is from an AAV of serotype 5.

**[0212]** In some alternatives of the system, the first adenoviral protein is a wild type E4ORF6. In some alternatives of the system, the sequence of the wild type E4ORF6 is set forth in SEQ ID NO: 3. In some alternatives of the system, the first adenoviral protein is a mutant E4ORF6. In some alternatives of the system, the mutant E4ORF6 protein is an AXA mutant. In some alternatives of the system, the AXA mutant is set forth in SEQ ID NO: 23.

**[0213]** In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is an mRNA. In some alternatives of the system, the fourth nucleic acid encoding the second adenoviral protein is codon optimized for expression in a eukaryotic cell, such as a human cell. In some alternatives of the system, the second adenoviral protein is from an AAV of serotype 5.

**[0214]** In some alternatives of the system, the second adenoviral protein is a wild type E1B55K. In some alternatives of the system, the sequence of the wild type E1B55K is set forth in SEQ ID NO: 1. In some alternatives of the system, the second adenoviral protein is a mutant E1B55K. In some alternatives of the system, the mutant E1B55K is an H373A mutant. In some alternatives of the system, the sequence of the H373A mutant is set forth in SEQ ID NO: 2. In some alternatives of the system, the mutant E1B55K is an H354 mutant. In some alternatives of the system, the sequence of the H354 mutant is set forth in SEQ ID NO: 4. In some alternatives of the system, the mutant E1B55K is an R240A mutant. In some alternatives of the system, the sequence of R240A mutant is set forth in SEQ ID NO: 22.

**[0215]** In some alternatives of the system, the first, second, third and fourth nucleic acid sequences are operably linked to regulatory elements that are operable in a eukaryotic cell, such as a human cell.

[0216] In some alternatives of the system, the first nucleic acid sequence encoding one or more CRISPR guide RNA is operably linked to a regulatory element. In some alternatives of the system, the first nucleic acid sequence encoding one or more CRISPR guide RNA is operably linked to a U6 promoter. In some alternatives of the system, when the first nucleic acid sequence encodes more than one CRISPR guide RNA, each guide RNA is operably linked to a separate regulatory element.

[0217] In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is constitutively expressed. In some alternatives of the system, the first nucleic acid sequence encoding the CRISPR guide RNA is transiently expressed.

[0218] In some alternatives of the system, the CRISPR guide RNA sequences for the TCR $\alpha$  gene are set forth in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16 and/or SEQ ID NO: 17.

[0219] In some alternatives of the system, the CRISPR guide RNA sequence for the PD1 gene is set forth in SEQ ID NO: 18, for the TIGIT gene is set forth in SEQ ID NO: 19, for the Lag3 gene is set forth in SEQ ID NO: 20, and for the Tim3 gene is set forth in SEQ ID NO: 21.

[0220] In some alternatives of the system, the system can be used for gene knockout, gene knock-in, or both.

[0221] In some alternatives of the system, the first nucleic acid sequence, or the set of nucleic acid sequences, and the Cas9 protein or the second nucleic acid sequence encoding the Cas9 protein, are collectively replaced by a fifth nucleic acid sequence and a sixth nucleic acid sequence, wherein the fifth and sixth nucleic acid sequences comprise mRNAs encoding a left component and a right component of a TALEN nuclease, respectively.

[0222] In some alternatives, a method for editing at least one target gene in a cell, the method comprising introducing into a cell a first nucleic acid sequence, or a set of nucleic acid sequences, encoding one or more CRISPR guide RNA, wherein the one or more CRISPR guide RNA is complementary to at least one target gene in the cell; introducing into the cell a Cas9 protein or a second nucleic acid sequence encoding a Cas9 protein; introducing into the cell a third nucleic acid sequence encoding a first adenoviral protein; and introducing into the cell a fourth nucleic acid sequence encoding a second adenoviral protein.

[0223] In some alternatives of the method, the cell is a eukaryotic cell. In some alternatives of the method, the cell is a mammalian cell. In some alternatives of the method, the cell is a human cell. In some alternatives of the method, the cell is a primary cell. In some alternatives of the method, the cell is not a transformed cell. In some alternatives of the method, the cell is a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

[0224] In some alternatives of the method, the vector comprising the first nucleic acid sequence, or a set of nucleic acid sequences, encoding the one or more CRISPR guide RNAs, may be comprised in one or more vectors, but not required to be comprised in one or more vectors. In some alternatives of the method, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives of the method, the AAV vector is a self-complementary vector. In some alternatives of the method, the AAV vector is a single

stranded vector. In some alternatives of the method, the AAV vector is a combination of a self-complementary vector and a single stranded vector.

[0225] In some alternatives of the method, the second, third and fourth nucleic acid sequences are mRNA. In some alternatives of the method, the mRNAs are codon optimized for expression in a eukaryotic cell, such as a human.

[0226] In some alternatives of the method, the Cas9 protein is from *S. pyogenes*.

[0227] In some alternatives of the method, the first adenoviral protein is from an AAV of serotype 5. In some alternatives of the method, the first adenoviral protein is a wild type E4ORF6. In some alternatives of the method, the sequence of the wild type E4ORF6 is set forth in SEQ ID NO: 3.

[0228] In some alternatives of the method, the first adenoviral protein is a mutant E4ORF6. In some alternatives of the method, the mutant E4ORF6 protein is an AXA mutant. In some alternatives of the method, the sequence of the AXA mutant is set forth in SEQ ID NO: 23.

[0229] In some alternatives of the method, the second adenoviral protein is from an AAV of serotype 5. In some alternatives of the method, the second adenoviral protein is a wild type E1B55K. In some alternatives of the method, the sequence of the wild type E1B55K is set forth in SEQ ID NO: 1. In some alternatives of the method, the second adenoviral protein is a mutant E1B55K. In some alternatives of the method, the mutant E1B55K is an H373A mutant. In some alternatives of the method, the sequence of the H373A mutant is set forth in SEQ ID NO: 2. In some alternatives of the method, the mutant E1B55K is an H354 mutant. In some alternatives of the method, the sequence of the H354 mutant is set forth in SEQ ID NO: 4. In some alternatives of the method, the mutant E1B55K is an R240A mutant. In some alternatives of the method, the sequence of R240A mutant is set forth in SEQ ID NO: 22. In some alternatives of the method, wherein any one of the E4ORF6 variants can be used in combination with any one the E1B55K variants.

[0230] In some alternatives of the method, the number of genes that are simultaneously knocked out is 2-10. In some alternatives of the method, the number of genes that are simultaneously knocked out is 2-5. In some alternatives of the method, the dose of mRNA is 0.01  $\mu$ g to 1  $\mu$ g. In some alternatives of the method, there is a 1.5 fold to 9 fold increase in the rate of mutations.

[0231] In some alternatives of the method, the CRISPR guide RNA sequences for the TCR $\alpha$  gene are set forth in SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16 and/or SEQ ID NO: 17.

[0232] In some alternatives of the method, the CRISPR guide RNA sequence for the PD1 gene is set forth in SEQ ID NO: 18, for the TIGIT gene is set forth in SEQ ID NO: 19, for the Lag3 gene is set forth in SEQ ID NO: 20, and for the Tim3 gene is set forth in SEQ ID NO: 21.

[0233] In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are transiently introduced into the cell. In some alternatives of the method, the first, second, third and fourth nucleic acid sequences are not permanently introduced into the cell. In some alternatives of the method, introducing the first, second, third and fourth nucleic acid sequences into the cell do not transform the cell.

[0234] In some alternatives of the system, the target gene is a gene of interest. In some alternatives of the method, the target gene is a gene of interest.

[0235] In some alternatives of the system and/or method provided herein, the third nucleic acid sequence and fourth nucleic acid sequence are comprised in the AAV vector.

[0236] In some alternatives of the method, the second nucleic acid sequence is introduced into the cell first followed by the AAV vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence.

[0237] In some alternatives of the method, the AAV vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence is introduced into the cell first followed by second nucleic acid sequence.

[0238] In some alternatives of the method, the second nucleic acid sequence and the AAV vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence are co-delivered and introduced into the cell at the same time.

[0239] In some alternatives of the method, the system can be used for gene knockout, gene knock-in, or both.

[0240] In some alternatives of the method, the first nucleic acid sequence, or the set of nucleic acid sequences, and the Cas9 protein or the second nucleic acid sequence encoding the Cas9 protein, are collectively replaced by a fifth nucleic acid sequence and a sixth nucleic acid sequence, wherein the fifth and sixth nucleic acid sequences comprise mRNAs encoding a left component and a right component of a TALEN nuclease, respectively.

[0241] In some alternatives, a method for editing at least one target gene in a cell, comprising introducing into a cell any of the alternatives of the system provided herein.

[0242] In some alternatives, a method for treating, ameliorating, and/or inhibiting a disease and/or a condition in a subject, the method comprising providing to a subject having a disease and/or a condition any of the alternatives of the system provided herein.

[0243] In some alternatives, a system for editing at least one target gene in a cell and a method of using the system for genome editing are contemplated. In some alternatives, the target gene is a gene of interest, which is edited by can be either gene disruption. In some alternatives, the cell is a primary T-cell.

[0244] In some alternatives, the system comprises a first nucleic acid sequence encoding one or more guide RNA and a second nucleic acid sequence encoding an endonuclease protein. In some alternatives, the endonuclease can be any of the endonucleases disclosed herein and/or alternative variants and modifications of that are within the scope of the current disclosure. In some alternatives, the second nucleic acid is an mRNA and encodes any of the endonuclease protein. In some alternatives, the second nucleic acid sequence encoding the endonuclease protein is codon optimized for expression in a eukaryotic cell. In some alternatives, the one or more guide RNA is complimentary to the at least one target gene in a cell. In some alternatives, the one or more guide RNA is provided in a vector. In some alternatives, the vector can be a viral vector. In some alternatives, the viral vector is an Adeno-associated virus (AAV) vector. In some alternatives, the AAV vector can be

a self-complementary vector, or a single stranded vector, or a combination of a self-complementary vector and a single stranded vector.

[0245] As many cell types possess a post-entry restriction on AAV vectors that renders AAV-mediated expression of transgenes, including guide RNAs, very inefficient, proteins that suppress the post-entry restriction on AAV vectors are provided on additional nucleic acid sequences. Thus, in some alternatives, the system comprises a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. In some alternatives, the third nucleic acid and the fourth nucleic acid are mRNAs, which are codon optimized for expression in a eukaryotic cell. In some alternatives, the nucleic acid sequences can either be introduced into the cell sequentially and in any order or be introduced into the cell simultaneously.

[0246] In some alternatives, the first and second adenoviral proteins are from an AAV of serotype 5. In some alternatives, the first adenoviral protein is a wild type E4ORF6, or an AXA mutant of E4ORF6. In some alternatives, the second adenoviral protein is a wild type E1B55K, or an H373A mutant of E1B55K, or an H354 mutant of E1B55K, or an R240A mutant of E1B55K. While the mutant proteins are not as efficient as wild type proteins at suppressing at post-entry restriction on AAV vectors, they are relatively more efficient at enhancing gene targeting.

[0247] In some alternatives, the first, second, third and fourth nucleic acid sequences are operably linked to regulatory elements that are operable in a eukaryotic cell. In some alternatives, the first nucleic acid sequence can encode one or more guide RNA and each guide RNA is operably linked to a separate regulatory element. In some alternatives, the first nucleic acid sequence encoding the guide RNA is transiently expressed in the cell. In some alternatives, the one or more guide RNA sequences are complementary to the TCR $\alpha$  gene, the PD1 gene, the TIGIT gene, the Lag3 gene, and/or the Tim3 gene. In some alternatives, the system also comprises nucleic acid sequences regions that bear homology to the gene of interest.

[0248] In some alternatives, the system comprising the above-mentioned components is introduced into the primary T cell. These nucleic acid sequence regions that bear homology to the gene of interest direct the endonuclease-based system to be targeted to a specific gene. Targeting to the specific gene can result in a gene knockout, a gene knock-in, or both.

[0249] Depending on the nature of gene targeting approach (knockout or knock-in) the result can be determined by flow cytometry, or sequencing or both. For example, if the system is used for knocking out a gene of interest that encodes a cell surface-expressed protein, flow cytometry can be used to check for suppressed and/or lack of cell surface expression of the protein. Or, if the system is used for knocking out a gene of interest that encodes an intracellularly-expressed protein, flow cytometry can be used to check for suppressed and/or lack of intracellular expression of the protein. Or, if the system is used for knock-in, for example, knock-in of a dominant epitope of an antigen into a gene of interest that encodes a cell surface-expressed protein, flow cytometry can be used to check for cell surface expression of the dominant epitope. Or, if the system is used for knock-in, for example, knock-in of a dominant epitope of an antigen into a gene of interest that



encodes an intracellularly-expressed protein, flow cytometry can be used to check for intracellular expression of the dominant epitope. In any of the above cases, the DNA sequencing of genomic DNA can also be used to confirm the desired gene targeting event. In some alternatives, the number of genes that can be simultaneously targeted for knock-out, knock-in or both can be 2-5.

**[0250]** In some alternatives, the T-cells in which the gene of interest has been targeted are enriched by cell sorting or other cell enrichments methods. If the enriched cells are intended to be used for treating, ameliorating, and/or inhibiting a disease and/or a condition in a subject, the enriched cells are administered to the subject. For example, in some alternatives, the subject may have a disease and/or a condition because the T-cells in the subject are “exhausted,” and therefore, are not effective at clearing one or more antigens from the disease and/or condition.

**[0251]** By targeting one or more “exhaustion” markers (e.g., PD1, TIGIT, Lag3 and Tim3), the “exhausted” condition of T-cells can be reversed. In some alternatives, the targeted T-cells are administered to the subject (e.g., via the intravenous route). Follow-up testing is performed on the subject to assess the status of the targeted T-cells and their effect on the disease and/or condition. For example, in some alternatives, blood is drawn from the subject at various intervals following administration of the targeted T-cells. In some alternatives, testing is performed to determine whether the administered T-cells are activated, for example, by assessing their secretion of the cytokine (e.g., IL-2, TNF $\alpha$ ). In some alternatives, testing is also performed to determine the effect of administration of the targeted T-cells on the disease and/or condition.

**[0252]** Any of the systems and/or methods provided herein in regard to humans can also be provided to one or more companion animals or animals domesticated for commercial interest. A companion animal, without limitations, can be dog, cat, guinea pig, mouse, rat, rabbit or hamster. An animal domesticated for commercial interest, without limitations, can be goat, sheep, cow, pig, monkey or elephant.

**[0253]** Detailed below are some non-limiting examples with references to figures illustrating how CRISPR gene editing can be implemented. These examples are not meant to be limiting and other endonucleases and alternatives of the system and methods comprising other endonucleases and variants and modifications of these exemplary alternatives are possible without undue experimentation. All such variations and modifications are within the scope of the current teachings.

#### Example 1: An mRNA/AAV Delivery Method Effects Cas9-Mediated Gene Disruption in Primary Human T-Cells

**[0254]** In some alternatives, CRISPR gene editing in primary human T-cells using mRNA/AAV co-delivery is provided.

**[0255]** AAV6 capsid-based AAV vectors are able to achieve sufficient transduction efficiencies of human primary T-cells and CD34+ cells to serve as templates for TALEN and other nuclease-catalyzed homologous recombination. Thus, it was hypothesized that AAV vectors might serve as safe and effective vectors for transient expression of guide RNAs as well as delivery of recombination templates for Cas9-induced gene targeting.

**[0256]** In some alternatives, cell used can be, without limitations, a primary lymphocyte, a CD34+ stem cell, a hepatocyte, a cardiomyocyte, a neuron, a glial cell, a muscle cell or an intestinal cell.

**[0257]** In some alternatives, the duration of transient expression of guide RNAs can be 1 min to 1 week or within a range defined by any two of the aforementioned values.

**[0258]** In some alternatives, the size of the recombination template can range from 0.05 kb to 1 kb. In some alternatives, the length of the homology arm can be 0.05, 0.075, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95 or 1 kb or within a range defined by any two of the aforementioned values.

**[0259]** Through this series of experiments and our previous experience with other nuclease platforms, it was observed that performing the mRNA electroporation step first appeared to work most reliably. Thus, in some alternatives, mRNA electroporation followed by AAV transduction was adopted as our standard approach. In some preferred alternatives, mRNA electroporation is performed before AAV transduction.

**[0260]** In some alternatives, to evaluate the potential of an mRNA/AAV delivery method in which spCas9 was expressed through mRNA electroporation, and an AAV vector was used to provide guide RNA expression, an AAV construct was generated which included both a U6 promoter driven guide RNA cassette and an MND promoter driven GFP cassette—the latter provides for tracking of AAV transduction efficiency.

**[0261]** FIG. 1A, top panel, shows a schematic of mCherry and Cas9-T2A-mCherry constructs that were cloned in different in-house backbones to generate mRNA. FIG. 1A, middle and bottom panels, show schematic of guide position (s) within the TCR genomic locus. Self-complementary and single-stranded AAV vector backbones were used for expression of guides.

**[0262]** In some alternatives, one or more nucleases can be delivered using a single or a plurality of mRNAs. In some alternatives, 1 to 5 nucleases can be delivered using a single mRNA or a plurality of mRNAs. In some alternatives, 1, 2, 3, 4 or 5 nucleases can be delivered using a single mRNA or a plurality of mRNAs.

**[0263]** In some alternatives, delivery of nuclease(s), guide RNA(s), helper protein(s), template with homologous region (s), and any additional component(s) as may be required by AAV is contemplated. In some alternatives, delivery of any one of nuclease(s), guide RNA(s), helper protein(s), template with homologous region(s), and any additional component(s) as may be required by mRNA and the rest by AAV is contemplated. In some alternatives, delivery of any two of nuclease(s), guide RNA(s), helper protein(s), template with homologous region(s), and any additional component(s) as may be required by mRNA and the rest by AAV is contemplated. In some alternatives, delivery of any three of nuclease(s), guide RNA(s), helper protein(s), template with homologous region(s), and any additional component(s) as may be required by mRNA and the rest by AAV is contemplated. In some alternatives, delivery of any four of nuclease (s), guide RNA(s), helper protein(s), template with homologous region(s), and any additional component(s) as may be required by mRNA and the rest by AAV is contemplated. In some alternatives, delivery of nuclease(s), guide RNA(s), helper protein(s) and template with homologous region(s) by mRNA is contemplated.

**[0264]** In some alternatives, one or more reporters can be delivered using a single mRNA or a plurality of mRNAs. In some alternatives, 1 to 5 reporters can be delivered using a single mRNA or a plurality of mRNAs. In some alternatives, 1, 2, 3, 4 or 5 reporters can be delivered using a single mRNA or a plurality of mRNAs.

**[0265]** In some alternatives, one or more reporters can be delivered using AAV transduction. In some alternatives, 1 to 5 reporters can be delivered using AAV transduction. In some alternatives, 1, 2, 3, 4 or 5 reporters can be delivered AAV transduction.

**[0266]** In some alternatives, one or more nucleases and one or more reporters can be delivered using a single mRNA or a plurality of mRNAs. In some alternatives, 1 to 5 nucleases and 1 to 5 reporters can be delivered using a single mRNA or a plurality of mRNAs. In some alternatives, 1, 2, 3, 4 or 5 nucleases and 1, 2, 3, 4 or 5 reporters can be delivered using a single mRNA or a plurality of mRNAs.

**[0267]** In some alternatives, mRNA electroporation of Cas9 (as a Cas9-T2A-mCherry fusion) was tested both before and after AAV transduction for guide delivery, and moderately efficient Cas9 cleavage was achieved within the constant region of the TCR $\alpha$  gene using several protocols with two different guides.

**[0268]** In some alternatives, one or more guide RNAs can be delivered using AAV transduction. In some alternatives, 1 to 5 guide RNAs can be delivered using AAV transduction. In some alternatives, 1, 2, 3, 4 or 5 guide RNAs can be delivered AAV transduction.

**[0269]** In some alternatives, the use of chemically modified guide RNAs is contemplated. In some alternatives, chemically modified guide RNAs can be provided as separate RNAs. Thus, in some alternatives when one or more guide RNAs are designed against one or more target genes of interest, each guide RNA is provided as a separate chemically-modified guide RNA. For example, when the use of 10 guide RNAs is contemplated against 10 separate target genes of interest, each guide RNA is a chemically-modified guide RNA and each guide RNA is separate and distinct RNA molecule from the other guide RNAs. In some alternatives, the 10 different guide RNAs can be introduced into a cell either sequentially in any order or simultaneously.

**[0270]** In some alternatives, when the use of Cas9 protein pre-complexed with guide RNAs in conjunction with adenoviral proteins is contemplated, the guide RNAs are provided as chemically modified guide RNAs, wherein when one or more guide RNAs are designed against one or more target genes of interest, each guide RNA is provided as a separate chemically-modified guide RNA.

**[0271]** Thus, in some alternatives, mRNA electroporation can be performed before AAV transduction. In some alternatives, mRNA electroporation can be performed after AAV transduction. In some alternatives, mRNA and AAV can be co-delivered.

**[0272]** In some alternatives, for optimization of Cas9 mRNA transfection in primary human T-cells, CD4+ T-cells were transfected with varying concentrations of Cas9-T2A-mCherry mRNA using the Neon electroporation system and cultured at 30° C. for the initial 24 hrs, after which they were transferred to 37° C. Flow cytometry analysis of T-cells 24 hrs after electroporation with the indicated amounts of Cas9-T2A-mCherry mRNA (FIG. 1C). Percentages of mCherry positive cells are indicated in FIG. 1C.

**[0273]** In some alternatives, analysis of AAV-guide doses in primary human T-cells was performed by transfecting CD4+ T-cells with 1  $\mu$ g of Cas9-T2A-mCherry mRNA. Two hours post-electroporation, cells were transduced with AAV expressing TCR $\alpha$  guide at MOI 600 and 6000 (corresponding to culture volume of 1% and 10%, respectively). Cells were cultured at 30° C. for the initial 24 hrs, after which cells were transferred to 37° C. and kept there for the duration of the experiment. Cells were analyzed by flow cytometry for loss of surface CD3 expression as an index of TCR $\alpha$  gene knockout on day 7 post EP/transduction (FIG. 1D).

**[0274]** In some alternatives, using the mRNA/AAV transduction protocol, a range of Cas9 mRNA and AAV-guide doses were evaluated (FIG. 1C and FIG. 1D) to determine ranges that maximize Cas9 cleavage efficiency and minimize toxicity. In some alternatives, while mRNA dose appeared to saturate (1  $\mu$ g in our standard electroporation conditions). In some alternatives, the mRNA dose can range from 0.05 to 3  $\mu$ g. In some alternatives, the mRNA dose can be 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75 or 3  $\mu$ g or within a range defined by any two of the aforementioned doses.

**[0275]** In some alternatives, a dose-dependent increase in knockout with AAV up to the maximum tolerated MOI was observed. In some alternatives, the AAV dose can range from 60 to 60,000. In some alternatives, the AAV dose can range from 60, 125, 250, 500, 1,000, 2,000, 4,000, 8,000, 16,000, 30,000 or 60,000 or within a range defined by any two of the aforementioned doses.

**[0276]** In some alternatives, for T7 endonuclease I assay (T7EI) for cleavage following Cas9/AAV.sgRNA delivery into primary human T-cells, primary CD4+ T-cells were electroporated with Cas9 mRNA followed by AAV.sgRNA transduction 2 hours later. Ten days following electroporation/transduction, genomic DNA was isolated from the cells, and T7 endonuclease assay was performed (FIG. 1B). Arrow indicates the expected position of DNA bands cleaved by T7EI (FIG. 1B).

**[0277]** In some alternatives, Cas9 cleavage was detected as indel formation demonstrated by T7 assay of amplicons surrounding the predicted target site in TCR $\alpha$  (FIG. 1B). In some alternatives, loss of surface TCR/CD3 complex expression by flow cytometry (TCR/CD3 complex expression requires expression of a functional TCR $\alpha$  chain (FIG. 1D).

**[0278]** In some alternatives, T7 Endonuclease I assay yielded similar levels of cutting efficiency for both TCR $\alpha$  and CCR5 loci.

**[0279]** In some alternatives, both single stranded and self-complementary AAV vectors were compared (FIG. 1E). sgTCR $\alpha$  in FIG. 1E indicates single guide TCR $\alpha$ . In some alternatives, flow cytometric comparison was performed of TCR $\alpha$  knockout with scAAV and ssAAV-GFP by electroporating primary T-cells with mRNA encoding for control mCherry or Cas9-T2A-mCherry proteins, rested for 3 hours, and transduced with AAV driving guide RNA expression. Cells were cultured at 30° C. for the initial 24 hours, after which cells were transferred to 37° C. Cells were analyzed using flow cytometry for mCherry and GFP expression 24 and 96 hours following electroporation/transduction, and surface CD3 expression was analyzed at 7 days post electroporation/transduction.

**[0280]** In some alternatives, no significant differences was observed between self-complementary and single stranded AAV in the efficiency of Cas9 target cleavage as assessed by loss of surface CD3 (FIG. 1E). Thus, in some alternatives, Cas9-mRNA and guide-AAV mediated efficient TCR knock-out in primary cells and both self-complementary and single stranded guide RNA yielded similar levels of CD3 knock-out.

**[0281]** Thus, in some alternatives the AAV vector can be single stranded. In some alternatives the AAV vector can be self-complementary. In some alternatives the AAV vector can be both single stranded and self-complementary.

Example 2: Adenoviral Serotype 5 E4ORF6 and E1B55K Helper Proteins Enhance Permissiveness of Primary Human T-Cells to AAV Transduction

**[0282]** In some alternatives, enhanced AAV-mediated gene expression in primary human T-cells using adenoviral E4ORF6/E1B55K proteins to relieve post-entry AAV restriction mechanisms is provided.

**[0283]** The dependence of Cas9 cleavage efficiency on AAV dose observed in our initial analyses suggested to us that efficiency of AAV transduction is a key limiting factor for application of the mRNA/AAV method in T-cells. AAV transduction in many human cell types is known to be subject to restriction at the cell entry stage by surface receptor expression binding properties of the capsid, and post-entry based on multiple mechanisms. In cultured transformed cells, plasmid-based expression of E4ORF6 and E1B55K proteins from multiple adenoviral serotypes is effective at relieving post-entry restrictions on AAV expression, among them genome concatamerization by DNA damage response proteins, activation of cell cycle DNA damage checkpoints, and pro-apoptotic DNA damage signaling.

**[0284]** Thus, in some alternatives, E4ORF6 and E1B55K proteins can be from multiple adenoviral serotypes. In some alternatives, the adenoviral serotypes can be Ad1, Ad2, Ad3, Ad4, Ad5, Ad6 or Ad7. Additional alternative serotypes are also contemplated and are within the scope of the current disclosure. In some alternatives, E4ORF6 and E1B55K proteins can be from the same adenoviral serotype. In some alternatives, E4ORF6 can be from one adenoviral serotype and E1B55K from a different serotype.

**[0285]** As DNA plasmid-based expression is toxic to primary T-cells, in some alternatives, it was evaluated whether electroporation of adenoviral serotype 5 E4ORF6/E1B55K mRNAs could achieve a transient relief of post-entry restriction of AAV-based expression in primary T-cells (FIG. 2).

**[0286]** In some alternatives, for assessing AAV-mediated GFP expression following relief of post-entry AAV restriction by E4ORF6/E1B55K, primary CD4+ T-cells were electroporated with mRNA encoding adenoviral serotype 5 E4ORF6/E1B55K (0.33 µg each), rested for 2-4 hours, then transduced with AAV driving GFP expression. Cells were placed in culture for the indicated periods of time (FIG. 2A, left panel), following which the cells were collected and analyzed for GFP expression by flow cytometry. Expansion of cell populations following the indicated exposure to E4ORF6/E1B55K mRNA transfection and AAV transduction, following the same protocol as described in the left panel (FIG. 2A, right panel).

**[0287]** In some alternatives, following mRNA-based co-expression of E4ORF6/E1B55K in primary T-cells (but not either protein alone; data not shown), a 4 log increase in GFP

mean fluorescence intensity (MFI), and an 8 fold increase in GFP expression, driven from an AAV vector encoding a promoter/GFP cassette (FIG. 2A, left panel), without compromising the rate of cell expansion (FIG. 2A, right panel) was obtained.

**[0288]** In some alternatives, the increase in MFI of GFP (or one or more other reporters) can range from 2 log to 8 log. In some alternatives, the increase in MFI of GFP (or one or more other reporters) can be 2 log, 3 log, 4 log, 5 log, 6 log, 7 log or 8 log or within a range defined by any two of the aforementioned values.

**[0289]** In some alternative, the increased GFP (or one or more other reporters) expression can range from 2 fold to 16 fold. In some alternative, the increased GFP (or one or more other reporters) expression can be 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 11 fold, 12 fold, 13 fold, 14 fold, 15 fold or 16 fold or within a range defined by any two of the aforementioned values.

**[0290]** In some alternatives, comparison of effect of E4ORF6/E1B55K proteins on self-complementary and single-stranded AAV6-mediated gene expression was performed by electroporating primary CD4+ T-cells with mRNA encoding E4ORF6/E1B55K proteins (0.33 µg each), rested for 2-4 hours, and transduced with either single-stranded or self-complementary AAV6 driving GFP expression (MOI of both viruses:  $2 \times 10^4$ ) (FIG. 2B). Cells were placed in culture for the indicated periods of time, following which the cells were collected and analyzed for GFP expression by flow cytometry (FIG. 2B).

**[0291]** In some alternatives, the same enhancing effect was observed irrespective of whether a self-complementary or single stranded AAV was used (FIG. 2B), suggesting that E4ORF6/E1B55K complexes possess a robust capacity to relieve post-entry restrictions on AAV expression in primary human T-cells that is unrelated to initiation of second strand DNA synthesis. Thus, in some alternatives, the AAV vector can be single stranded. In some alternatives, the AAV vector can be self-complementary. In some alternatives, the AAV vector can be both single stranded and self-complementary.

Example 3: MRN Complex is a Dominant Post-Entry Restriction Mechanism on AAV Transduction of Primary Human T-Cells

**[0292]** In some alternatives, the effect of E4ORF6/E1B55K mutants on AAV-driven GFP expression was evaluated.

**[0293]** The ability of E4ORF6/E1B55K proteins to enhance AAV expression in cultured cell models has been reported to depend on their capacity to target the MreII/Rad51/NBS1 DNA repair complex (MRN) for degradation, thus allowing incoming AAV genomes to escape intranuclear detection and silencing.

**[0294]** In some alternatives, to determine if this same mechanism applied to primary human T-cells, a comparison of AAV-driven gene expression alone or following transient expression of wild type E4ORF6/E1B55K proteins or E4ORF6/E1B55K-H373A and E4ORF6/E1B55K-H354 mutants (FIG. 2C) was performed. Both of these mutants have largely lost the capacity for inducing degradation of MRN, whilst fully preserving other functions of wild type E4ORF6/E1B55K.

**[0295]** In some alternatives, primary CD4+ T-cells were electroporated with mRNA encoding Cas9-2A-mCherry (1 µg) along with E4ORF6/E1B55K (wild type) proteins or the

indicated E1B55K mutants at the indicated RNA doses, rested for 2-4 hours, and transduced with ssAAV driving both TCR $\alpha$  guide and GFP expression (FIG. 2C). E4ORF6 mRNA dose was the same as each E1B55K RNA dose for each indicated point (FIG. 2C). Cells were placed in culture for 2 days, following which the cells were collected and analyzed for GFP MFI by flow cytometry. See also FIG. 3 demonstrating a 2-3 fold increase in GFP expression catalyzed by the E4ORF6/E1B55K H373A mutant complex that is not visible on the same scale as GFP expression catalyzed by the wild type E4ORF6/E1B55K complex.

**[0296]** In some alternatives, as assessed by GFP MFI, E1B55K mutants were markedly less efficient at relieving post-entry restrictions on AAV expression than wild type E4ORF6/E1B55K, in a dose-dependent manner. Thus, in some alternatives, E1B55K MRN degradation mutants demonstrate requirement for MRN inactivation for complete relief of post-entry restriction on AAV-mediated expression (FIG. 2C).

**[0297]** In some alternatives, replicate experiments were performed in which primary CD4 $^{+}$  or CD3 $^{+}$  human T-cells were electroporated with mRNA encoding Cas9-2A-mCherry proteins (1  $\mu$ g) and either wild type or the indicated E4ORF6/E1B55K mutants (0.03  $\mu$ g each), rested for 2-4 hours, and transduced with AAV driving guide expression and GFP. Cells were placed in culture for the indicated periods of time, following which the cells were collected and analyzed for GFP expression and mean fluorescence intensity (MFI) by flow cytometry and quantified. FIG. 3A and FIG. 3B represent n=5-6 independent experiments.

**[0298]** In some alternatives, replicate experiments using the E1B55K-H373A mutant, analyzed at a smaller scale, demonstrated that E4ORF6/E1B55K-H373A expression was able to support a level of GFP expression significantly greater ( $1.58 \pm 0.09$ -fold at 96 hours) than that observed in the absence of E4ORF6/E1B55K expression, consistent with its possessing a residual capacity to relieve post-entry transduction or expression restrictions (FIG. 3A and FIG. 3B).

**[0299]** In some alternatives, the role of other known E4ORF6/E1B55K functional capabilities in relieving post-entry restriction of AAV transduction in T-cells was evaluated using two additional mutants—E1B55K R240A (SEQ ID NO: 22; FIG. 33), which disrupts the ability of E1B55K to catalyze degradation of p53, and E4ORF6 AXA (SEQ ID NO: 23; FIG. 34), which binds inefficiently to E1B55K and results in generally hypofunctional E4ORF6/E1B55K complexes. In some alternatives, the E4ORF6 AXA mutant has two polymorphisms—R243A and L245A (SEQ ID NO: 23; FIG. 34).

**[0300]** These mutants exhibit full (R240A) or partial (AXA) capacities to degrade the MRN complex, and consistent with a key role for MRN in post-entry restriction of AAV expression in T-cells, these mutants retained full (R240A) or partial (AXA; data not shown) capacities to enhance GFP expression following AAV transduction of T-cells (FIG. 3C and FIG. 3D). In some alternatives, expression of AXA/E1B55K was only able to enhance GFP expression from AAV vectors at high doses of mRNA electroporation (0.33  $\mu$ g), and not 10-fold lower, as shown in FIG. 3.

**[0301]** Thus, in some alternatives, the use of various combinations of wild type and mutant forms of E4ORF6 and E1B55K proteins are contemplated. For example, in some

alternatives, any one of the different forms of the E4ORF6 protein (e.g., wild type or AXA mutant) can be used in combination with any one of the different forms of E1B55K protein (e.g., wild type, H373A mutant, H354 mutant, R240A mutant). In some alternatives, the various combinations of wild type and mutant forms of E4ORF6 and E1B55K can be delivered as separate mRNAs. In some alternatives, the various combinations of wild type and mutant forms of E4ORF6 and E1B55K can be delivered as a single mRNAs.

#### Example 4: H373A and H354 Mutant E4ORF6/E1B55K Expression Enhance CRISPR-Mediated Knockout in Primary Human T-Cells

**[0302]** In some alternatives, enhancement of CRISPR-mediated gene knockout in primary human T-cells through use of adenoviral E4ORF6/E1B55K proteins was assessed.

**[0303]** Based on the capacity of E4ORF6/E1B55K proteins to enhance AAV-driven GFP expression in the analyses herein, it was hypothesized that their transient expression would similarly enhance the level and/or duration of guide RNA expression from a polIII-driven U6 promoter/guide RNA cassette incorporated into an AAV genome, and thus potentially enhance Cas9-mediated gene disruption efficiency by the mRNA/AAV system.

**[0304]** In some alternatives, this hypothesis was tested by expressing wild type E4ORF6/E1B55K proteins using the mRNA/AAV co-delivery protocol by including their respective mRNAs with Cas9 in the electroporation step, followed by transduction of the cells with an AAV vector encoding both a TCR $\alpha$  guide RNA and a promoter/GFP expression cassette. Thus, the effect of E4ORF6/E1B55K mutants on AAV-driven GFP expression was assessed.

**[0305]** In some alternatives, the expression of wild type E4ORF6/E1B55K proteins markedly increased GFP expression from the TCR $\alpha$  guide/GFP AAV, as expected from the analyses in FIG. 2.

**[0306]** In some alternatives, despite the marked increase in AAV-based expression, only a moderately increased level of TCR $\alpha$  knock-out (FIG. 4A) was observed, and only at lower AAV vector doses (FIG. 4B, top panel).

**[0307]** In some alternatives, an apparent toxicity was observed that had not been observed in the absence of Cas9 expression (manifesting as a loss, rather than stable level, of CD3 $^{+}$  cells over time. In some alternatives, primary CD4 $^{+}$  or CD3 $^{+}$  human T-cells were electroporated with mRNA encoding Cas9-T2A-mCherry proteins (1  $\mu$ g) and E4ORF6/E1B55K wildtype proteins or the indicated mutants, at high or low doses, as indicated (0.33  $\mu$ g or 0.03  $\mu$ g), rested for 2-4 hours, and transduced with AAV driving TCR $\alpha$  guide expression. Cells were placed in culture, and analyzed for TCR $\alpha$ /CD3 expression by flow cytometry at the indicated time-points (FIG. 5A).

**[0308]** In some alternatives, in order to gain information on the influence of specific biochemical activities attributed to E4ORF6/E1B55K complexes on gene editing outcome, H373A, H354, R240A, and AXA mutants were also expressed, and TCR $\alpha$  knockout efficiency among the various contexts was compared (FIG. 4).

**[0309]** In some alternatives, data related to a representative experiment indicating primary CD4 $^{+}$  T-cells electroporated with mRNA encoding Cas9-T2A-mCherry, (1  $\mu$ g), E4ORF6/E1B55K (wild type), or the indicated mutants (at

0.33  $\mu$ g or 0.03  $\mu$ g each), rested for 2-4 hours, and transduced with AAV driving TCR $\alpha$  guide expression are shown (FIG. 4A). Cells were placed in culture, following which the cells were collected and analyzed for CD3 expression by flow cytometry at the indicated time-points following EP/transduction. FIG. 4A, top panel, shows quantification of CD3 knockout. FIG. 4A, bottom panel, shows representative flow plots from a subset of the experiment at seven days post EP/transduction.

**[0310]** In some alternatives, E1B55K mutants enhance gene knockout achieved using mRNA/AAV delivery of CRISPR components. While expression of E4ORF6 with E1B55K-H373A and H354 mutants produced the expected much smaller effects on GFP expression (i.e., FIG. 2C), unexpectedly, substantial increases in TCR $\alpha$  knockout efficiency were also observed that were not accompanied by toxicity or loss of CD3<sup>+</sup> cells (FIG. 4A and FIG. 5A).

**[0311]** In some alternatives, despite their inability to fully relieve post-transduction restrictions on AAV gene expression, these E1B55K mutants retained residual activities that were sufficient to markedly enhance the overall efficiency of gene knockout achievable with the mRNA/AAV delivery approach. In some alternatives, this is supported by the results obtained when the E4ORF6/E1B55K R240A mutant was expressed. In some alternatives, potentiated toxicity was obtained relative to what was obtained with the wild type E4ORF6/E1B55K, along with marked reductions in efficiency of CD3 knockout (FIG. 4A and FIG. 4C). In some alternatives, p53 inactivation, for which R240A is deficient but which is preserved in the H373A and H354 mutants, contributed to the knockout potentiating properties of H373A and H354.

**[0312]** In some alternatives, T-cells edited using mRNA/AAV delivery exhibit normal expansion kinetics as determined by electroporating primary CD4<sup>+</sup> T- with mRNA encoding Cas9-T2A-mCherry (1  $\mu$ g) proteins along with wild type E4ORF6/E1B55K proteins or the indicated E1B55K mutants, resting for 2-4 hours, and transducing with AAV driving TCR $\alpha$  guide expression. Cells were placed in culture for the indicated periods of time, during which aliquots of the cells were collected and counted for quantification of cell expansion. FIG. 4C, left panel, shows low dose (0.03  $\mu$ g) of E4ORF6/E1B55K mutants electroporated with high dose of AAV (MOI=6000). FIG. 4C, right panel shows electroporation and transduction of both low and high dose (0.33  $\mu$ g) E4ORF6/E1B55K-R240A RNA, and low and high dose AAV.

**[0313]** In some alternatives, the H373A and H354 mutants exhibited considerable potency in their effects on Cas9-mediated gene disruption, with dose/response testing of the H373A mutant demonstrating that it maintained a nearly full effect at enhancing TCR $\alpha$  knockout at mRNA doses down to <0.04  $\mu$ g (FIG. 5B). In some alternatives, the mRNA dose can be 0.01  $\mu$ g to 1  $\mu$ g. In some alternatives, the mRNA dose can be 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1  $\mu$ g or within a range defined by any two of the aforementioned doses.

**[0314]** In some alternatives, representative flow plots of primary CD4<sup>+</sup> human T-cells that were electroporated with mRNA encoding Cas9-T2A-mCherry proteins (1  $\mu$ g) and E4ORF6/E1B55K H373A, at the indicated doses, rested for 2-4 hours, and transduced with AAV driving TCR $\alpha$  guide expression are shown in FIG. 5B. Cells were placed in

culture for one week, following which the cells were collected and analyzed for TCR $\alpha$ /CD3 expression by flow cytometry (FIG. 5B).

**[0315]** In some alternatives, the effect of E4ORF6/E1B55K MRN-inactivation deficient mutants on CRISPR-mediated knockout was assessed (FIG. 4B). In some alternatives, quantification of n=3-4 independent experiments at two different AAV MOIs was performed. In some alternatives, data using primary human CD4<sup>+</sup> or CD3<sup>+</sup> T-cells indicating that both E1B55K H373A and H354 mutants significantly increase CRISPR-mediated TCR $\alpha$  knockout, quantified by CD3 staining at seven days post EP/transduction (FIG. 4B). Thus, in some alternatives, E4ORF6/E1B55K mutants enhance TCR knockout.

**[0316]** In some alternatives, the effect of E4ORF6/E1B55K MRN mutants on indel spectra was assessed. Primary CD4<sup>+</sup> human T-cells were electroporated with mRNA encoding Cas9-T2A-mCherry proteins (1  $\mu$ g) and E4ORF6/E1B55K H373A or H354 (0.03  $\mu$ g), rested for 2-4 hours, and transduced with AAV driving TCR $\alpha$  guide expression. Cells were placed in culture for one week, following which cells were collected, genomic DNA was isolated, the region surrounding TCR $\alpha$  was amplified using PCR, cloned into a vector, and analyzed using Sanger sequencing (FIG. 5C).

**[0317]** In some alternatives, amplicon sequencing of the indel spectra generated by Cas9-mediated gene disruption in the context of both H373A and H354 mutant E4ORF6/E1B55K complexes demonstrated the expected higher rate of mutations as well as an increased proportion of larger deletions, up to 150 bp, spanning the predicted Cas9 cleavage site (FIG. 5C). In some alternatives, the rate of mutations increased 1.5 fold to 10 fold. In some alternatives, the rate of mutations increased 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 fold or within a range defined by any two of the aforementioned values.

#### Example 5: E4ORF6/E1B55K H373A and H354 Mutants Enhance CRISPR/Cas9-Mediated Homologous Recombination in Primary Human T-Cells

**[0318]** Given their biochemical activities and capacity to enhance gene disruption efficiency achievable with the mRNA/AAV co-delivery method, it was hypothesized that the E4ORF6/E1B55K H373A and H354 mutants would have similarly enhancing effects on homology-directed gene targeting rates. To test this hypothesis, Cas9 mRNA was electroporated along with E4ORF6 and wild type E1B55K, H373A or H354 mutant mRNAs into primary human T-cells, followed by transduction of the cells with separate AAV vectors to provide guide RNA expression and recombination template delivery, respectively (FIG. 10).

**[0319]** In some alternatives, one or more guide RNAs can be provided in separate AAV vectors. In some alternatives, one or more templates for homologous recombination can be provided in separate AAV vectors. In some alternatives, one or more guide RNAs and one or more templates for homologous recombination can be provided in the same AAV vector. In some alternatives, one or more guide RNAs and template for homologous recombination for a particular target gene can be provided in separate AAV vectors. In some alternatives, one or more guide RNAs and template for homologous recombination for a particular target gene can be provided in the same AAV vector.

**[0320]** Primary CD4+ or CD3+ T-cells were electroporated using the MaxCyte GT or the Neon systems with mRNA encoding Cas9-2A-mCherry proteins (1  $\mu$ g) along with wild type E4ORF6/E1B55K proteins or the indicated E1B55K mutants (0.03  $\mu$ g each), rested for 2-4 hours, and transduced with separate AAVs driving CCR5 guide expression and a targeting template for the CCR5 locus (FIG. 15). Cells were placed in culture, following which the cells were collected and analyzed for BFP expression by flow cytometry. Shown are representative flow plots from the indicated manipulations at three weeks post EP/transduction, from n=5-6 independent experiments (FIG. 10A).

**[0321]** In some alternatives, quantification of n=5-6 independent experiments of the fold change in knock-in frequency (BFP+ cells) over baseline (Cas9+guide+donor) at three weeks post EP/transduction were performed (FIG. 10B).

**[0322]** In these experiments, Cas9 alone plus the two AAVs allowed for integration of a promoter-BFP cassette into the CCR5 locus at an efficiency of  $17.6 \pm 4.0\%$ . In some alternatives, consistent with the results observed herein with the various E4ORF6/E1B55K complexes, substantial potentiation of early BFP expression by the wild type E4ORF6/E1B55K complexes relative to either the H373A or H354 mutants or without any Ad5 protein was observed (FIG. 6, top panel).

**[0323]** In some alternatives, the fold change in HDR was significantly increased using either E4ORF6/E1B55K-H354 or H373A with CRISPR/Cas9 (FIG. 10B). In some alternatives, similar to the effects of each of these mutant complexes on gene knockout, expression of either mutant complex generated significantly higher efficiency of recombination-based genome editing (FIG. 10A and FIG. 10B), increasing HDR by 1.8-fold ( $31.2 \pm 5.7\%$  BFP+ with H373A, and  $30.8 \pm 1.8$  with H354).

**[0324]** In some alternatives, the rate of HDR can be increased using either E4ORF6/E1B55K-H354 or H373A with CRISPR/Cas9 by 1.5 to 3.5 fold as compared to when using wild type E4ORF6/E1B55K proteins. In some alternatives, the rate of HDR can be increased by 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25 or 3.5 fold or within a range defined by any two of the aforementioned values.

**[0325]** Thus, in some alternatives, enhanced targeted knock-in can be achieved using E1B55K mutant proteins. In some alternatives, E4ORF6/E1B55K mutants can enhance targeted CRISPR knock-in. In some alternatives, E4ORF6/E1B55K H373A and H354 mutants enhance CRISPR-mediated recombination achieved with mRNA/AAV co-delivery

**[0326]** In order to determine whether T-cells edited via mRNA/AAV CRISPR-mediated recombination exhibited normal expansion kinetics, primary T-cells were electroporated with mRNA encoding control or Cas9-2A-mCherry proteins (1  $\mu$ g) along with wild type E4ORF6/E1B55K and the E1B55K mutants (0.03  $\mu$ g each), rested for 2-4 hours, and transduced with AAV driving CCR5 guide expression as well as AAV CCR5 BFP template. Cells were placed in culture for the indicated periods of time, following which the cells were collected and counted for quantification of cell expansion (FIG. 10C)

**[0327]** Importantly, expression of E4ORF6/E1B55K complexes (whether wild type or mutant) did not affect the rates of expansion of T-cells that had undergone homology-directed gene targeting (FIG. 10C).

Example 6: E4ORF6/E1B55K Mutant Proteins do not Enhance Non-Homologous AAV Insertion

**[0328]** In some alternatives, primary CD3+ or CD4+ T-cells were electroporated with mRNA encoding Cas9-2A-mCherry proteins (1  $\mu$ g) along with wild type E4ORF6/E1B55K proteins or the indicated E1B55K mutants (0.03  $\mu$ g each), rested for 2-4 hours, and transduced with AAV driving CCR5 guide expression and AAV containing a promoter-GFP cassette without flanking homology arms. Cells were placed in culture for the indicated periods of time, following which the cells were collected and analyzed for GFP expression by flow cytometry. GFP fluorescence detected at 96 hours reflects expression primarily from episomal AAV genomes. GFP fluorescence detected at three weeks represents expression from both residual episomal or integrated AAV genomes. n=5-6 independent experiments (FIG. 6).

**[0329]** In some alternatives, representative flow plots of primary T-cells demonstrating low rate of insertion events at Cas9-induced double strand break by AAV lacking homology arms are shown in FIG. 6.

**[0330]** Importantly, expression of E4ORF6/E1B55K complexes (whether wild type or mutant) did not affect the rates of non-homologous AAV integration, as assessed by the rate of long term fluorophore expression following co-delivery of Cas9 with AAVs expressing the same guide and a promoter/fluorophore cassette lacking CCR5 homology arms (FIG. 6, top panel).

**[0331]** Thus, in some alternatives, E4ORF6/E1B55K wild type proteins mildly increase non-specific AAV integration at target site for CRISPR knockout whereas mutant proteins do not.

Example 7: E4ORF6/E1B55K Mutants Enhance CRISPR Single Knockouts for Other Loci than TCR

**[0332]** In some alternatives, the influence of E4ORF6/E1B55K H373A and H354 mutant complexes on the efficiency of CRISPR/Cas9 gene disruption at other genomic targets was evaluated. In some alternatives, guide RNAs were generated and validated targeting four translationally relevant human surface protein targets: the T-cell inhibitory checkpoint proteins PD-1, TIGIT, LAG-3, and Tim3. The guide RNAs targeting these proteins are represented by SEQ ID NO: 18 (FIG. 31) for PD1, SEQ ID NO: 19 (FIG. 31) for TIGIT, SEQ ID NO: 20 (FIG. 31) for LAG-3, and SEQ ID NO: 21 (FIG. 31) for Tim3. In some alternatives, one or more of these guide RNAs were incorporated into U6-guide expression cassettes in AAV vector backbones upstream of the MND-GFP cassette to provide for tracking of transduction/expression, and packaged into AAV vectors.

**[0333]** Primary human CD3+ T-cells were electroporated using the MaxCyte GT system with mRNA encoding Cas9-2A-mCherry proteins (1  $\mu$ g) along with E4ORF6/E1B55K-H373A proteins (0.03  $\mu$ g each), rested for 2-4 hours, and transduced with AAV driving guide expression against the indicated surface proteins. Cells were placed in culture and allowed to expand; 9-12 days following initial stimulation, cells were re-stimulated using Dynal CD3/CD28 beads for 48 hours, following which the cells were collected and analyzed for expression of the indicated surface proteins by flow cytometry and assessed for knockout by amplicon sequencing. Representative flow cytometry plots indicating that T-cells edited using mRNA/AAV co-delivery exhibit loss of targeted surface checkpoint proteins. Data represent

n=3-5 independent editing experiments. The representative flow cytometry data are presented in FIG. 7A.

**[0334]** In some alternatives, analysis of knockout by flow cytometry is assessed by percent loss of induction of surface protein expression. Data represent n=3-5 independent editing experiments (FIG. 7B). Quantification and summary data from flow cytometry analysis of gene knockout and sequencing analysis of amplicons from genomic target sites are shown in FIG. 7B.

**[0335]** Thus, in some alternatives, knockout efficiency can be assessed by sequencing analysis of amplicons from genomic target sites. In some alternatives, knockout efficiency can be assessed by flow cytometry (if the protein encoded by the targeted gene is expressed on the surface). Thus, in some alternatives, knockout efficiency can be assessed by sequencing analysis of amplicons from genomic target sites as well as surface expression by flow cytometry (if the protein encoded by the targeted gene is expressed on the surface).

**[0336]** In some alternatives, the use of these AAV vectors with the E4ORF6/E1B55K H373A mutant in a scaled up expansion/manufacturing protocol based on the MaxCyte GT electroporation system resulted in generation of human T-cell populations with approximate respective targeted gene disruption efficiencies of  $71.6 \pm 2.7\%$ ,  $59.1 \pm 14.8\%$ ,  $59.2 \pm 8.5\%$ , and  $66.1 \pm 14.3\%$  of indels at the intended cleavage site of PD-1, TIGIT, LAG-3, and Tim3, respectively, as derived from sequence analysis (PD-1, TIGIT, Tim3) or flow cytometry (LAG-3).

**[0337]** Thus, in some alternatives, implementation of CRISPR/Cas9 with mRNA/AAV delivery is able to achieve efficient knockout at multiple genomic sites.

**[0338]** An important secondary observation that emerged from these experiments was that the influence of E4ORF6/E1B55K H373A mutant complexes on gene disruption efficiency was particularly prominent when the activity of a particular guide RNA was relatively low. For example, the knockout rates at the PD-1 and TIGIT loci doubled with the chosen guide RNAs in the presence of E4ORF6/E1B55K H373A as compared to the knockout rates in the absence of E4ORF6/E1B55K expression, which were only  $36.4 \pm 10.9\%$  and  $40.4 \pm 3.6\%$ , respectively. In some alternatives, the rates were assessed by sequencing.

**[0339]** Thus, in some alternatives a particularly salient feature of E4ORF6/E1B55K H373A expression is that it can 'rescue' poor guide RNA activity. In other words, in some alternatives, E4ORF6/E1B55K H373A expression can potentiate the activity of poor guide RNAs. In some alternatives, the effect of highly active guide RNAs is not as effectively potentiated by E4ORF6/E1B55K protein expression.

**[0340]** In some alternatives, a poor guide RNA is only 5% to 30% efficient. In some alternatives, a poor guide RNA is only 5, 10, 15, 20, 25 or 30% efficient or within a range defined by any two of the aforementioned values. In some alternatives, E4ORF6/E1B55K H373A expression potentiates the activity of a poor guide RNA by 5% to 150%. In some alternatives, E4ORF6/E1B55K H373A expression potentiates the activity of a poor guide RNA by 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150% or within a range defined by any two of the aforementioned values.

#### Example 8: H373A Mutant E4ORF6/E1B55K Expression Enhance CRISPR-Mediated Multiplex Knockout of Two Genes in Primary Human T-Cells

**[0341]** Based on our analyses herein, it was hypothesized that efficient levels of multiplex knockout could be successfully achieved, using a single AAV vector to deliver multiple guides. In some alternatives, a single AAV vector can be used to deliver one or more guides. In some alternatives, a single AAV vector can be used to deliver 1 to 5 guides. In some alternatives, a single AAV vector can be used to deliver 1, 2, 3, 4 or 5 guides. In some alternatives, one AAV vector is used to deliver a single guide. In some alternatives, separate AAV vectors are used to deliver separate guides.

**[0342]** In some alternatives, primary human CD3+ T-cells were electroporated using the MaxCyte GT system with mRNA encoding Cas9-2A-mCherry proteins (1  $\mu$ g) along with E4ORF6/E1B55K-H373A proteins (0.03  $\mu$ g each), rested for 2-4 hours, and transduced with AAVs driving guide expression against Tim3 and TCR $\alpha$ , as well as GFP expression to track transduction efficiency. Cells were placed in culture and allowed to expand; 7 days following EP/transduction, cells were assessed for TCR $\alpha$  knockout by CD3 stain. Three weeks following initial stimulation, cells were re-stimulated using PMA/ionomycin for 3-4 hours and allowed to recover for 48 hours, following which the cells were collected and analyzed for expression of Tim3 by flow cytometry (FIG. 8).

**[0343]** In some alternatives, using the same architecture as the single AAV guide vectors, a dual-guide Tim3/TCR $\alpha$  vector was constructed, with both guides driven by individual U6 promoters. A schematic of the multiplex AAV vector expressing guide RNAs against Tim3 and TCR $\alpha$ , with individual U6 promoters is shown in FIG. 8A. In some alternatives, TCR $\alpha$  and Tim3 knockout was analyzed following MaxCyte electroporation with Cas9 or E4ORF6/E1B55K-H373A and AAV transduction with either the single Tim3 guide AAV or the AAV containing dual Tim3/TCR $\alpha$  guides.

**[0344]** A representative flow cytometry analysis of TCR $\alpha$  knockout by CD3 staining, seven days after EP/transduction, is shown in FIG. 8B. A representative flow cytometry analysis of TCR $\alpha$  knockout and Tim3 knockout, three weeks after initial stimulation, is shown in FIG. 8C. In some alternatives, to upregulate Tim3 surface expression independently of TCR, cells were stimulated using PMA/ionomycin (10 ng/mL and 1  $\mu$ g/mL, respectively), for 3-4 hours and rested for 48 hours.

**[0345]** In some alternatives, upregulation of Tim3 with and without PMA/ionomycin stimulation was assessed by comparing control cells (AAV treatment only) with and without PMA/ionomycin treatment, and stimulated cells with Tim3 knockout compared to stimulated cells missing both Tim3 and TCR $\alpha$ . There were no differences between cells proficient and deficient in TCR $\alpha$  signaling, suggesting that PMA/ionomycin stimulation is independent of this pathway. In shaded grey are unstained cells is shown in FIG. 8D.

**[0346]** In some alternatives, successful knockout of both targeted genes using a single AAV, along with an increased efficiency of knockout when E4ORF6/E1B55K-H373A were co-transfected with Cas9 was obtained.

**[0347]** In some alternatives, on significant differences in knockout efficiency between the single Tim3 guide AAV and the dual Tim3 guide/TCR $\alpha$  guide AAV were observed. In

addition, in some alternatives, the majority of Tim3<sup>+</sup> cells were also CD3<sup>+</sup> cells (thus TCRα<sup>+</sup>), consistent with the expected outcome that any cell sufficiently well-transduced to drive guide expression to cleave one target gene also experienced a high level of guide expression for the other target gene.

**[0348]** Thus, in some alternatives, Cas9 mRNA/AAV guide delivery is able to achieve efficient CRISPR-mediated multiplex knockout in primary human T-cells with E4ORF6/E1B55K H373A expression. In some alternatives, E4ORF6/E1B55K mutants enhance CRISPR-mediated multiplex knockout of more than one gene. In some alternatives, E4ORF6/E1B55K mutants enhance CRISPR-mediated multiplex knockout of two genes.

Example 9: H373A Mutant E4ORF6/E1B55K  
Expression Enhance CRISPR-Mediated Multiplex  
Knockout of Five Genes in Primary Human T-Cells

**[0349]** In some alternatives, a multiplex knockout of five genes was performed. In some alternatives, cells were cultured for 3 weeks and allowed to expand prior to analysis. Unstimulated cells did not have significant expression of cell surface proteins. One million cells per condition were stimulated with PMA (10 ng/mL) and ionomycin (1 μg/mL) to up-regulate surface checkpoint protein expression. PMA/ionomycin was left in the media for three hours, following which the cells were washed 4 times with PBS, and left to recover in full media for 48 hours and stained, for the indicated cell surface proteins (CD3, PD1, Tim3, Lag3, and TIGIT) as a measure of gene knockout.

**[0350]** Data are presented in FIG. 9. Top panel shows data for cells that received Cas9 RNA and AAV guide construct only. Bottom panel shows data for cells that received Cas9 RNA, AAV guide construct, and E4ORF6/E1B55K-H373A RNA during the electroporation.

**[0351]** In some alternatives, simultaneous multiplex deletion of five genes was achieved. Thus, in some alternatives, the method of the present disclosure can be used to delete at least two genes. In some alternatives, the method of the present disclosure can be used to delete at least five genes. In some alternatives, the method of the present disclosure can be used to delete 1 to 10 genes. In some alternatives, the method of the present disclosure can be used to delete 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 genes. In some alternatives, the method of the present disclosure can be used to delete at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten genes.

**[0352]** In some alternatives, one or more guide RNAs targeting one or more genes can be delivered using AAV transduction. In some alternatives, 1 to 5 guide RNAs targeting 1 to 10 genes can be delivered using AAV transduction. In some alternatives, 1, 2, 3, 4 or 5 guide RNAs can be delivered targeting 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 genes using AAV transduction.

Example 10: Addition of E4ORF6/E1B55K H373A  
Rescues HDR when Shorter Homology Arms are  
Used for Gene Knock-in with CRISPR-Cas9 at the  
CCR5 Locus

**[0353]** In some alternatives, the effect of addition of the Ad5 proteins (the two E1B55K mutants, H373A or H354, both with E4ORF6) on the lower levels of HDR knock-in

that are caused by using templates with shorter homology arms with CRISPR/Cas9 was evaluated.

**[0354]** In some alternatives, quantification of n=2-5 experiments of primary human T-cells treated with Cas9 RNA, AAV expressing a guide against the CCR5 gene, AAV donors containing a GFP knock-in construct with different homology arm lengths (0.8 kb, 0.5 kb, and 0.25 kb), and RNA expressing the E4ORF6/E1B55K H354 or H373A mutant proteins are shown in FIG. 11. Fold change in HR is calculated based on change from baseline, defined here as CRISPR-Cas9 with AAV donor containing the 0.8 kb homology arm, at three weeks following electroporation and transduction.

**[0355]** In some alternatives, the length of the homology arm can range from 0.05 kb to 1 kb. In some alternatives, the length of the homology arm can be 0.05, 0.075, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95 or 1 kb or within a range defined by any two of the aforementioned lengths.

**[0356]** In some alternatives, as shown in FIG. 11, the addition of E4ORF6/E1B55K H373A proteins significantly rescues the low rate of HDR due to the use of shorter homology arms. Data are presented for the CCR5 locus.

**[0357]** In some alternatives, the addition of the Ad5 proteins (the two E1B55K mutants, H373A or H354, both with E4ORF6), can rescue lower levels of HDR knock-in that are caused by using templates with shorter homology arms with CRISPR/Cas9. In some alternatives, the fold change in HDR can range from 50% to 150%. In some alternatives, the fold change in HDR can be 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145 or 150% or within a range defined by any two of the aforementioned values.

Example 11: Addition of E4ORF6/E1B55K H373A  
Rescues HDR when Shorter Homology Arms are  
Used for Gene Knock-in with CRISPR-Cas9 at the  
TCR Locus

**[0358]** In some alternatives, effect of addition of E4ORF6/E1B55K H354 on homology directed repair (HDR) when using shorter homology arms for gene knock-in with CRISPR-Cas9 was assessed for the TCR locus.

**[0359]** In some alternatives, 1×10<sup>6</sup> T-cells were stimulated with CD3/CD28 beads for 48 hours, and electroporated with the combinations of RNAs encoding the proteins indicated on the legend to the graph (FIG. 12A). Cas9 mRNA was 1.0 μg. Ad5 proteins were 0.1 μg each (0.1 μg of E4ORF6, and 0.1 μg of E1B55K H354 mutant). AAV's encoding the repair templates and guides were iodixanol concentrated viral preps, used at 10% of culture volume.

**[0360]** In some alternatives, H354 mutant increased knock-in at the TCR locus (FIG. 12A). In the bar graph of FIG. 12B, NHEJ rates are shown in red, HR rates are shown in blue. In some alternatives, the use of the H354 mutant substantially increased the percentage of breaks resolved through a homology-directed repair assay.

**[0361]** In some alternatives, the observed HDR observed had occurred as early by day 4 post-electroporation (FIG. 12C). In some alternatives, the H354 mutant biases toward increased HDR without significantly increasing NHEJ. In some alternatives, the H354 mutant biases toward increased HDR without significantly increasing NHEJ when a template is present.



Example 12: Edited Primary T-Cells with E4ORF6/E1B55K H373A Exhibit Normal Surface Marker Phenotype

[0362] In some alternatives, whether expression of the E4ORF6/E1B55K H373A mutant was detrimentally influencing T-cell phenotype or signaling properties over the course of the editing process was assessed for which expression of a panel of surface markers and measured PHA-induced calcium signaling at two weeks post-editing was evaluated.

[0363] In some alternatives, representative flow plots (FIG. 13A) of primary CD4+ T-cells that were electroporated with mRNA encoding Cas9-2A-mCherry proteins (1 µg) along with E4ORF6/E1B55K H373A proteins (0.03 µg each) and transduced with AAV driving TCRα guide expression as shown (FIG. 13A). Cells were placed in culture and assessed for surface protein markers 16-20 days following EP/transduction by flow cytometry. n=2 independent experiments (FIG. 13A).

[0364] Flow cytometric assessment of cell surface markers that define naïve and memory T-cell populations in T-cells edited using mRNA/AAV co-delivery exhibited normal surface marker phenotype and no differences were between edited versus unedited populations (FIG. 13A).

Example 13: T-Cells Rendered TCR-Deficient Via mRNA/AAV Co-Delivery Deficient in TCR Signaling

[0365] In some alternatives, primary CD4+ T-cells were electroporated with mRNA encoding Cas9-T2A-mCherry proteins (1 µg) along with E4ORF6/E1B55K H373A (0.03 µg each), rested for 2 hours, and transduced with AAV driving TCRα guide expression. Nine days following EP/transduction, CD3+ cells were purified using CD3 microbeads (Miltenyi Biotech) and placed back in culture. Cells were allowed to expand for ten days, following which they were collected, re-suspended in Hanks calcium signaling buffer, incubated with 100 µM Indo calcium dye for 30 min, and analyzed for anti-CD3-stimulated calcium signaling by flow cytometry. 200 µg/mL PHA was used to stimulate the cells. Five million cells per condition were used (FIG. 13B).

[0366] In some alternatives, edited T-cells exhibited a loss of surface TCR following TCRα gene editing showing a loss of capacity to mobilize Ca<sup>2+</sup> in response to stimulation with PHA relative to cells retaining surface TCR (FIG. 13B). Thus, in some alternatives, TCR knockout T-cells using E4ORF6/E1B55K mutants were deficient in Ca<sup>2+</sup> signaling.

Example 14: Cells Exhibit Normal Karyotype Following Multiplex CRISPR Editing

[0367] As translocations are a potential consequence of simultaneous induction of multiple double strand breaks, in some alternatives, karyotyping was performed as an unbiased approach to detecting cell engineering-associated translocations, and did not observe any gross abnormalities in any of twenty metaphase spreads from each condition (FIG. 14).

[0368] In some alternatives, G-banding analysis following GTW staining indicated normal phenotype in cells that have undergone CRISPR/Cas9 editing with E4ORF6/E1B55K-H373A (FIG. 14). Cells were stimulated using PMA/ionomycin for 3-4 hours, and left to recover for 72 hours. All samples achieved metaphase spreads. Twenty metaphase spreads were created and analyzed using G-banding karyo-

type analysis per sample. In some alternatives, no abnormalities were detected in any sample (FIG. 14).

[0369] In some alternatives, representative image (FIG. 14A) shows normal karyotype in cells treated with Cas9 (1 µg) with AAV expressing guides against Tim3 and TCRα. Knockout frequencies can be seen in FIG. 8B and FIG. 8C.

[0370] Representative image (FIG. 14A) shows normal karyotype in cells treated with Cas9 (1 µg) with AAV expressing guides against Tim3 and TCRα, and E4ORF6/E1B55K-H373A (0.03 µg) RNAs. Knockout frequencies can be seen in FIG. 8B and FIG. 8C.

[0371] For karyotype analysis, in some alternatives, ~20×10<sup>6</sup> cells per sample were submitted for analysis following PMA/ionomycin stimulation, and metaphase spreads were successfully obtained from each sample. Data from karyotyping results are shown in TABLE 1.

TABLE 1

Sample	Band Level	Metaphase Cells Analyzed	Abnormalities Detected (Y/N)?
Untreated	400-450	20	N
AAV.sgTim3.GFP	300-450	20	N
AAV.sgTim3.sg.TCRα.GFP	300-400	20	N
Cas9 alone	300-550	20	N
Cas9 + AAV.sgTim3.GFP	300-450	20	N
Cas9 + AAV.sgTim3.sg.TCRα.GFP	450-650	20	N
Cas9 + E4ORF6/E1B55K-H373A + AAV.sgTim3.GFP	300-400	20	N
Cas9 + E4ORF6/E1B55K-H373A + AAV.sgTim3.sg.TCRα.GFP	300-450	20	N

[0372] In some alternatives, no discernable abnormalities were detected in any of the twenty spreads analyzed, at the band resolutions indicated, suggesting a translocation rate of less than 5% indicating that cells with double gene knockout do not commonly have gross rearrangements/karyotypic abnormalities.

Example 15: Molecular Confirmation of Precise HDR Events Following CRISPR-Cas9 Breaks with E4ORF6/E1B55K H373A or H354

[0373] The molecular nature of the HDR events was assessed by sequencing through the junctions to confirm seamless HDR (FIG. 15). A schematic of donor template, with homology arms and BFP insert. Primer binding sites are indicated, and resulting amplicon (1.3 kb) is shown in FIG. 15A. A representative agarose gel indicating results of PCR from primers is shown in FIG. 15A. Results are from n=3 independent PCR experiments, from cells obtained from data shown in FIG. 10. PCR products from FIG. 15B were purified, cloned into vectors, and sequenced. Representative amplicons are shown indicating precise junctions at both the upstream (1) and downstream (2) regions of the 3' homology arm, as indicated in FIG. 15A. No clones were obtained that had non-precise junctions, nor were any clones obtained that included AAV-based ITR sequence

[0374] Thus, in some alternatives, targeted integrations are indeed seamless integrations as determined by the precise HDR events following CRISPR-Cas9 breaks with E4ORF6/E1B55K H373A or H354.

Example 16: Comparison of Different Guide RNA Alternatives for Generating TCR Knockout

**[0375]** In some alternatives, the CRISPR-Cas9 system was used for generating TCR knockout. Human TCR  $\alpha$  6 locus corresponds to chr14 NG\_001332.2. Location within the TCR $\alpha$  gene corresponds to 1,071,537-1,071,809.

**[0376]** In some alternatives, guide RNAs guide1 (SEQ ID NO: 15; FIG. 16A), guide2 (SEQ ID NO: 16; FIG. 16A), guide3 (SEQ ID NO: 17; FIG. 16A), and guide4 (SEQ ID NO: 5; FIG. 16A) were used.

**[0377]** In some alternatives, primary T-cells were transfected with Cas9-mCherry mRNA followed by transduction with AAV guides. Data from four different experiments are shown in FIG. 16B-FIG. 16I.

**[0378]** In some alternatives, comparison of the efficiency of generation of TCR knockout in primary T-cells from donor 1 when using guide RNAs guide1-guide4. Cas9-mCherry expression at 24 hrs was comparable in primary T-cells from donor 1 irrespective of the guide RNA sequence alternative used (FIG. 16B). Same MOI was used for all AAV guide RNAs. Controls are shown in FIG. 16B, top panel.

**[0379]** In some alternatives, comparison of the efficiency of generation of TCR knockout in primary T-cells from donor 1 when using guide RNAs guide1-guide4 showed that guide4 (FIG. 16A) yielded the highest knockout efficiency (90%) (FIG. 16C). Flow cytometry analysis was performed using anti-CD3-Alexa488 antibody at 168 hrs. Controls are shown in FIG. 16C, top panel. FIG. 21 also shows data that guide4 generated the highest TCR $\alpha$  knockout.

**[0380]** In some alternatives, comparison of Cas9-mCherry expression levels at 24 hrs in primary T-cells from donor 1 when using different volumes of Cas9/guide sample showed a slightly higher percentage of cells expressing Cas9-mCherry at 20  $\mu$ L volume (96.4%) as compared to 10  $\mu$ L (87.2%) or 15  $\mu$ L (85.1%) (FIG. 16D). Controls are shown in FIG. 16D, top panel.

**[0381]** In some alternatives, comparison of efficiency of generation of TCR knockout in primary T-cells from donor 1 when using different volumes of sample containing guide4 yielded highest efficiency at 20  $\mu$ L volume (91.9%). The efficiency was 73.2% at 10  $\mu$ L and 78.2% at 15  $\mu$ L (FIG. 16E). Flow cytometry analysis was performed using anti-CD3-Alexa488 antibody at 168 hrs. Controls are shown in FIG. 16E, top panel.

**[0382]** In some alternatives, comparison of Cas9-mCherry expression levels at 24 hrs in primary T-cells from donor 2 when using different volumes of Cas9/guide sample showed a similar percentage of cells expressing Cas9-mCherry at 5  $\mu$ L (91%), 10  $\mu$ L (90.2%) and 20  $\mu$ L (90.8%) of sample volume (FIG. 16F).

**[0383]** In some alternatives, comparison of efficiency of generation of TCR knockout in primary T-cells from donor 2 when using different volumes of sample containing guide RNA guide4 yielded highest efficiency at 20  $\mu$ L volume (68.4%). The efficiency was 30.7% at 5  $\mu$ L and 38.4% at 10  $\mu$ L (FIG. 16G). Flow cytometry analysis was performed using anti-CD3-Alexa488 antibody at 168 hrs. Controls are shown in FIG. 16G, top panel.

**[0384]** In some alternatives, Cas9-mCherry expression at 24 hrs was comparable in Jurkat T-cells irrespective of the guide RNA sequence alternative used (FIG. 16H, bottom panel). Cas9-mCherry expression was lowest for guide1.

Same MOI was used for all AAV guide RNAs. Controls are shown in FIG. 16H, top panel.

**[0385]** In some alternatives, comparison of the efficiency of generation of TCR knockout in Jurkat T-cells when using guide RNAs guide 1-guide4 showed that guide4 (FIG. 16A) yielded the highest knockout efficiency (83.3%) (FIG. 16I, bottom panel). Flow cytometry analysis was performed using anti-CD3-Alexa488 antibody at 168 hrs. Controls are shown in FIG. 16I, top panel.

Example 17: CRISPR/Cas9 System Using the TCR $\alpha$  CRISPR Guide RNA Guide4

**[0386]** In some alternatives, primary human CD4+ T-cells were thawed from a frozen isolate, stimulated with CD3/CD28 Dynabeads (Life Technologies) in the presence of cytokines (IL-2, IL-7 and IL-15) for 60 hours in antibiotic free media. Next, beads were removed and  $4.5 \times 10^5$  cells per condition were electroporated using a 10  $\mu$ L Neon tip ( $3 \times 10^5$  cells post electroporation) and AAV was added 3 hours post electroporation. Cas9 RNA was used at 1.5  $\mu$ g/sample (1  $\mu$ g post electroporation) and guide-specific AAV's were added at an MOI of  $1.33 \times 10^7$ /sample. Post electroporation, cells were plated in a 96 well plate in 200  $\mu$ L media with cytokines and left in a 30° C. CO<sub>2</sub> incubator for 24 hours, after which cells were moved to a 37° C. CO<sub>2</sub> incubator.

**[0387]** At 24 hours post electroporation, cells were checked for Cas9-mCherry expression and subsequently at 72, 96 and 168 hours for both mCherry and TCR-knockout with CD3-Alexa488 antibody (Biolegend) using BD LSR II. Voltages were kept same throughout the duration of the experiment.

**[0388]** In some alternatives, data showed that TCR $\alpha$  CRISPR guide RNA guide4 generated the highest TCR $\alpha$  knockout (FIG. 16B-FIG. 16I).

Example 18: Enhanced Efficiency of CRISPR-Mediated Gene Knockout in Primary Human T-Cells

**[0389]** Translational application of the CRISPR/Cas9 programmable endonuclease system has been hindered by the need to transiently and simultaneously express Cas9 protein and guide RNA at sufficient levels to achieve high on-target nuclease activity in primary cells. In some alternatives, an mRNA/AAV split vector system that allows for highly efficient CRISPR-mediated gene editing in primary human T-cells is provided. This approach utilizes mRNA to express Cas9 in conjunction with adenoviral serotype 5 E4ORF6 and E1B55K proteins, the latter serving to render the T-cell permissive to AAV transduction for the purpose of guide RNA expression. In some alternatives, this approach is applied to disrupt the T-cell receptor  $\alpha$  subunit gene, a translationally relevant target, at efficiencies up to 60%, and demonstrate that the resulting edited T-cell population is otherwise phenotypically indistinguishable from the parental population. In some alternatives, this approach can be coupled to mRNA-based TREX2 exonuclease expression to achieve even higher editing efficiencies, illustrating the flexibility and potency of a split-vector approach. Transient expression of Ad5<sup>wt</sup> proteins increases AAV transduction in human T-cells. Transient expression of Ad5<sup>wt</sup> proteins increases AAV transduction for both ssAAV6 and scAAV6. Transient expression of Ad5<sup>MREN</sup> proteins increases CRISPR knockout efficiency in primary human T-cells.

## Example 19: Increased Rate of HDR with TALENs

**[0390]** In some alternatives, primary human CD4+ T-cells were electroporated with 0.5 µg of each half of CCR5 TALEN mRNA (FIG. 32A) or CD40L TALEN mRNA (FIG. 32B), without or with E4ORF6/E1B55K-H373A or without or with E1B55K-H354 mRNA (0.03 µg each) on a Neon Transfection System (Life Technologies). Immediately following electroporation, cells were placed at 30° C. for 24 hours and returned to 37° C. for the duration of culture. Two hours following electroporation, cells were transduced with AAV6 containing donor template at 10% culture volume. Cells were analyzed for knock-in of the donor template (GFP+) at three weeks following electroporation/transduction on an LSRII flow cytometer (BD Biosciences).

**[0391]** In some alternatives, TALENs used in combination with the Ad5 mutants, increased gene targeting at two different loci. Thus, in some alternatives, TALENs used in combination with the Ad5 mutants, increased gene targeting at the CCR5 locus (FIG. 32A) and at the CD40L (FIG. 32B).

**[0392]** In some alternatives, the number of genes that can be targeted using TALENs ranges from 1-10. In some alternatives, the number of genes that can be targeted using TALENs is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or within a range defined by any two of the aforementioned numbers.

## Example 20: Endonuclease-Based Genome Editing

**[0393]** A system for editing at least one target gene in a cell and a method of using the system for genome editing are contemplated. The target gene is a gene of interest, which is edited by can be either gene disruption. The cell is a primary T-cell.

**[0394]** The system comprises a first nucleic acid sequence encoding one or more guide RNA and a second nucleic acid sequence encoding an endonuclease protein. The endonuclease can be any of the endonucleases disclosed herein and/or alternative variants and modifications of that are within the scope of the current disclosure. The second nucleic acid is an mRNA and encodes any of the endonuclease protein. The second nucleic acid sequence encoding the endonuclease protein is codon optimized for expression in a eukaryotic cell. The one or more guide RNA is complementary to the at least one target gene in a cell. The one or more guide RNA is provided in a vector. The vector can be a viral vector. The viral vector is an Adeno-associated virus (AAV) vector. The AAV vector can be a self-complementary vector, or a single stranded vector, or a combination of a self-complementary vector and a single stranded vector.

**[0395]** As many cell types possess a post-entry restriction on AAV vectors that renders AAV-mediated expression of transgenes, including guide RNAs, very inefficient, proteins that suppress the post-entry restriction on AAV vectors are provided on additional nucleic acid sequences. Thus, the system comprises a third nucleic acid sequence encoding a first adenoviral protein and a fourth nucleic acid sequence encoding a second adenoviral protein. The third nucleic acid and the fourth nucleic acid are mRNAs, which are codon optimized for expression in a eukaryotic cell. The nucleic acid sequences can either be introduced into the cell sequentially and in any order or be introduced into the cell simultaneously.

**[0396]** The first and second adenoviral proteins are from an AAV of serotype 5. The first adenoviral protein is a wild type E4ORF6, or an AXA mutant of E4ORF6. The second

adenoviral protein is a wild type E1B55K, or an H373A mutant of E1B55K, or an H354 mutant of E1B55K, or an R240A mutant of E1B55K. While the mutant proteins are not as efficient as wild type proteins at suppressing at post-entry restriction on AAV vectors, they are relatively more efficient at enhancing gene targeting.

**[0397]** The first, second, third and fourth nucleic acid sequences are operably linked to regulatory elements that are operable in a eukaryotic cell. The first nucleic acid sequence can encode one or more guide RNA and each guide RNA is operably linked to a separate regulatory element. The first nucleic acid sequence encoding the guide RNA is transiently expressed in the cell. The one or more guide RNA sequences are complementary to the TCRα gene, the PD1 gene, the TIGIT gene, the Lag3 gene, and/or the Tim3 gene. The system also comprises nucleic acid sequences regions that bear homology to the gene of interest.

**[0398]** The system comprising the above-mentioned components is introduced into the primary T cell. These nucleic acid sequence regions that bear homology to the gene of interest direct the endonuclease-based system to be targeted to a specific gene. Targeting to the specific gene can result in a gene knockout, a gene knock-in, or both.

**[0399]** Depending on the nature of gene targeting approach (knockout or knock-in) the result can be determined by flow cytometry, or sequencing or both. For example, if the system is used for knocking out a gene of interest that encodes a cell surface-expressed protein, flow cytometry can be used to check for suppressed and/or lack of cell surface expression of the protein. Or, if the system is used for knocking out a gene of interest that encodes an intracellularly-expressed protein, flow cytometry can be used to check for suppressed and/or lack of intracellular expression of the protein. Or, if the system is used for knock-in, for example, knock-in of a dominant epitope of an antigen into a gene of interest that encodes a cell surface-expressed protein, flow cytometry can be used to check for cell surface expression of the dominant epitope. Or, if the system is used for knock-in, for example, knock-in of a dominant epitope of an antigen into a gene of interest that encodes an intracellularly-expressed protein, flow cytometry can be used to check for intracellular expression of the dominant epitope. In any of the above cases, the DNA sequencing of genomic DNA can also be used to confirm the desired gene targeting event. The number of genes that can be simultaneously targeted for knockout, knock-in or both can be 2-5.

**[0400]** The T-cells in which the gene of interest has been targeted are enriched by cell sorting or other cell enrichment methods. If the enriched cells are intended to be used for treating, ameliorating, and/or inhibiting a disease and/or a condition in a subject, the enriched cells are administered to the subject. For example, the subject may have a disease and/or a condition because the T-cells in the subject are "exhausted," and therefore, are not effective at clearing one or more antigens from the disease and/or condition.

**[0401]** By targeting one or more "exhaustion" markers (e.g., PD1, TIGIT, Lag3 and Tim3), the "exhausted" condition of T-cells can be reversed. The targeted T-cells are administered to the subject (e.g., via the intravenous route). Follow-up testing is performed on the subject to assess the status of the targeted T-cells and their effect on the disease and/or condition. For example, blood is drawn from the subject at various intervals following administration of the

targeted T-cells. Testing is performed to determine whether the administered T-cells are activated, for example, by assessing their secretion of the cytokine (e.g., IL-2, TNF $\alpha$ ). Testing is also performed to determine the effect of administration of the targeted T-cells on the disease and/or condition.

#### Example 21: Materials and Methods

##### [0402] DNA Constructs—

[0403] Cas9 was obtained from Addgene (plasmid #41815), PCR amplified and cloned into pWNY backbone (an in-house modified pUC57), pEVL200 and pEVL300 (linear mRNA vector with a 200 or 300 encoded polyA tail) with a T7 promoter and two Nuclear Localization Signals (NLS)—one each at the N-terminus and C-terminus, respectively. Cas9 was modified to remove BsaI sites to clone into the pEVL vector, without changing amino acid sequence. mCherry was linked to Cas9 with a T2A peptide at 3' end of Cas9. An mCherry only control containing a T7 promoter and a single NLS at the 5' end of mCherry was also generated in pWNY and pEVL200. E4ORF6 and E1B55K genes were gene synthesized (Integrated DNA Technologies, IDT) and cloned into pWNY downstream of a T7 promoter. E1B55K mutants were generated using site-directed mutagenesis (QuikChange II XL Site-Directed Mutagenesis Kit, Agilent).

##### [0404] AAV Constructs for Single Guide RNA (sgRNA) Design, Cloning and Expression—

[0405] Guides targeting the constant region of TCR $\alpha$ , PD-1, TIGIT, Lag3, Tim3, and CCR5 were designed using online CRISPR design tools (<http://crispr.mit.edu> and the Broad Institute's sgRNA designer—<http://www.broadinstitute.org/rnai/public/analysis-tools/sgRNA-design>). Guides were then generated as gblocks by commercial DNA synthesis (Integrated DNA Technologies). The gblocks were cloned into scAAV6 or ssAAV6-GFP constructs using standard cloning techniques.

[0406] The gblocks were cloned into scAAV or ssAAV-GFP constructs with either a “GG” (T7 promoter requirement) or a “G” (U6 promoter) at the beginning of the guide, if a “G” was not already present at the start of the guide. Some guides with a U6 promoter had “GG” but the editing efficiency of the ones with “GG” or “G” was similar. Post ITR check, the constructs were used to generate AAV6.

[0407] In some alternatives, the guide targets used correspond to the following guide sequences: TCR $\alpha$  guide target: ACAAACTGTGCTAGACATG (SEQ ID NO: 16); PD1 guide target: GCCACGACACCAACCACCA (SEQ ID NO: 18); TIGIT guide target: TCTTCCCTAGGAATGATGAC (SEQ ID NO: 19); Lag3 guide target: GCGGTCCCTGAGGTGCACCG (SEQ ID NO: 20); Tim3 guide target: AGAAGTGAATACAGAGCGG (SEQ ID NO: 21).

##### [0408] Production of Recombinant AAV6 Vectors—

[0409] AAV stocks were produced by triple transfection of AAV vector, serotype helper and Adenoviral helper (HGT1-Adeno) plasmids in HEK293T cells. Transfected cells were collected 48 hrs later, lysed by freeze-thaw, benzonase treated and purified over iodixanol density gradient. Titers of the viral stocks were determined by qPCR of AAV genomes and ranged from  $10^{10}$ - $10^{12}$ /ml.

##### [0410] mRNA Production—

[0411] DNA template was linearized with unique restriction enzymes and linearized plasmids were purified using the QiaQuick PCR purification kit (Qiagen). mRNA was

transcribed in-vitro using commercial kits (mMessage mMachine T7 Ultra; Ambion or T7 mScript Standard RNA production system; CellScript) with slight modifications from the manufacturer's protocol. Briefly, the IVT reaction incubated for 2.5-3 hours, followed by DNase treatment for 1 hour. Poly(A) tailing, if required, was done for 1 hour and mRNA was purified using RNeasy (Qiagen).

##### [0412] Primary Human T Cell Transfection by Electroporation and Transduction—

[0413] T-cells were obtained from frozen PBMCs, using CD4+ or CD3+ isolation kits (Miltenyi Biotec). Briefly, PBMCs were thawed using drop-wise addition of cold DNase I Buffer: PBS, 5 mM MgCl<sub>2</sub>, 20 Kunitz Units/ml DNase I (EMD-Millipore), followed by centrifugation, and left to rest overnight in T cell media (RPMI, 20% FBS, 1% HEPES, 1% L-glutamine) supplemented with low-dose IL-15 (0.1 ng/mL). T-cells were isolated the following day, according to the manufacturer's instructions, and purified T-cells were resuspended at  $1 \times 10^6$  live cells/ml in T cell growth media (culture media supplemented with IL-2 and IL-15; 5 and 1 ng/ml, respectively), and stimulated by using CD3/CD28 beads (Dynal Beads, Life Technologies) for 72 hrs at a 1:1 cell-bead ratio. Beads were then removed and cells were allowed to rest in T cell growth media for 0.5-2 hrs. Next, cells were electroporated with mRNA using either a Neon Transfection System (FIGS. 1, 2, 4) or MaxCyte GT (FIG. 3) as follows: Cells were washed twice with PBS, resuspended in Neon Buffer T or MaxCyte Buffer at a density of  $4.5 \times 10^7$  cells/ml (Neon) or  $1.25 \times 10^8$  cells/ml (MaxCyte). After mixing, cells were electroporated (Neon conditions: 1400 V, 10 ms, 3 pulses, 10  $\mu$ l tip; MaxCyte conditions determined by the manufacturer for primary T-cells) and immediately dispensed into 200  $\mu$ L of pre-warmed T cell growth media in a 96-well plate. Cells were immediately incubated at 30° C., and AAV was added to the culture 2-4 hrs post electroporation, followed by continued 30° C. incubation for 20 additional hrs. AAV donor was added as 10% of the final culture volume regardless of titer ( $\sim 1 \times 10^{4-5}$  MOI), unless specified otherwise. Subsequently, edited cells were cultured using standard conditions: 37° C. and expanded in T cell growth media, replenished as needed to maintain a density of  $\sim 1 \times 10^6$  cells/ml every 2-3 days.

##### [0414] Flow Cytometry and Antibodies—

[0415] Analysis of knock-out (TCR $\alpha$ , PD-1, TIGIT, Lag3, and Tim3) and HDR (BFP) was performed using the LSRII flow cytometer (BD Biosciences) and data was analyzed using FlowJo software (Treestar). All antibodies were from Biolegend, unless otherwise indicated. To assess knockout of surface markers, cells were labeled with fluorophore-conjugated antibodies, as follows: CD3-Alexa 488, CD3-PerCPy5.5, or CD3-APC clone HIT3a; PD1-APC clone eh12.2H7; TIGIT-Alexa 700 clone 741182 (Novus Biologicals); Tim3-APC-Cy7 clone F38-2E2; and Lag3-FITC clone 3DS223H (eBioscience). CD4 or CD8 staining was done using CD4-BFP (clone OKT4) or CD8-BFP (RPA-T8). To upregulate surface expression of T cell exhaustion markers, T-cells were stimulated using CD3/CD28 beads for 48 hrs, 9-12 days following initial stimulation, except in the absence of TCR $\alpha$ , in which case PMA/ionomycin stimulation was used (see below). Cells were washed and acquired on LSRII by gating on live cells based on the forward and side scatter for downstream analysis.

**[0416]** Stimulation with PMA/Ionomycin—

**[0417]** Cells were plated at a density of  $1 \times 10^6$  in a 48 or 24 well plate. 10 ng/mL PMA (Sigma) and 1  $\mu$ g/mL of ionomycin (Sigma) was added to the media for 3-4 hours, cells were washed 3-4 times with PBS with 2% FBS, and then re-plated with fresh media. Cells were allowed to recover for 48 hours before flow cytometry, or for 72 hours for karyotype analysis.

**[0418]** Karyotype Analysis—

**[0419]** Cells were grown in T-25 flasks at a density of  $1 \times 10^6$ - $1.5 \times 10^6$  per sample. Each sample was stimulated with PMA/ionomycin for 3-4 hrs, and then allowed to rest for 72 hrs in full media and cytokines. Karyotype analysis was done by the University of Washington Cytogenetics and Genomics Laboratory as Research Testing. Standard G-banding (GTW stain) chromosome analysis was performed, on 20 cells per sample.

**[0420]** T7 Endonuclease I (T7EI) Assay—

**[0421]** The cleavage efficiency of Cas9 and sgRNA was estimated using the T7EI assay for both TCR $\alpha$  and CCR5 loci. Targeted genomic loci were amplified using either Accuprime Pfx or Hifi Platinum Taq DNA polymerase (Life Technologies), using the manufacturer's instructions. 400 ng of the purified product (Qiaquick PCR clean-up kit, Qiagen) was denatured, subjected to T7EI (New England Biolabs) digestion for 30 mins at 37° C. and analyzed on a 1-2% agarose gel (FIG. 2B).

**[0422]** Analysis of Calcium Signaling—

**[0423]**  $5 \times 10^6$  cells were used per sample. Cells were washed in HBSS (with Ca $^{2+}$  and Mg $^{2+}$ ) (ThermoFisher), loaded with 30  $\mu$ M Indo-1 AM (Molecular Probes, Life Technologies) in HBSS and incubated at 37° C. for 30 min, washed twice, and re-suspended in buffer. Baseline flow was obtained for 30 sec, after which cells were stimulated with 200  $\mu$ g/mL PHA to stimulate T-cells, and data was collected for 5 min.

**[0424]** Statistical Analysis—

**[0425]** Statistical analyses were performed with Prism 6 (GraphPad Software). Data is shown as mean $\pm$ -SEM unless otherwise noted. Tests of statistical significance were performed using an unpaired two-tailed Student's t-test with Welch's correction for unequal standard deviations when appropriate.

**[0426]** In some alternatives, implementation of CRISPR/Cas9 nuclease technology in primary human T-cells using an mRNA/AAV co-delivery method in which mRNA is used for Cas9 expression and an AAV vector is used for guide RNA expression and/or recombination template delivery is provided.

**[0427]** As AAV transduction manifested as an important limitation on efficacy during initial development of the mRNA/AAV co-delivery method, in some alternatives, mRNA-based co-expression of E4ORF6/E1B55K adenoviral helper proteins and a panel of mutants to determine whether a combination of biochemical activities could be identified that would disable post-entry restrictions on AAV-mediated gene expression while maintaining a cellular DNA repair environment conducive to efficient gene editing is evaluated.

**[0428]** In some alternatives, two of the mutants, E4ORF6/E1B55K H373A and H354, were identified as uniquely capable of supporting substantially enhanced efficiencies of both CRISPR-Cas9-mediated gene disruption and homology-directed gene targeting.

**[0429]** Adenoviral serotype 4 E4ORF6/E1B55K complexes enhance CRISPR-mediated gene targeting (but not gene disruption) in cultured cell models, an effect attributed to inhibition of DNA ligase IV activity and, as a consequence, reduced non-homologous end joining repair activity.

**[0430]** Thus, in some alternatives, the expression of adenoviral serotype 5 E4ORF6/E1B55K complexes with mRNA/AAV co-delivery might produce a synergistic effect on gene targeting efficiency through both inhibition of DNA ligase IV activity and relief of AAV post-entry transduction restrictions was contemplated.

**[0431]** In some alternatives, although transient expression of wild type E4ORF6/E1B55K complexes was highly efficacious at relieving restrictions on AAV-driven gene expression, it produced only modest increases in gene disruption or gene targeting efficiency in the primary human T-cell context. In contrast, in some alternatives, E4ORF6/E1B55K H373A or H354 mutants, which exhibited only a modest capacity to enhance AAV-driven gene expression, were observed to produce substantial enhancements in both gene disruption and gene targeting efficiency.

**[0432]** The H373A and H354 mutants' modest effect on AAV-driven gene expression (e.g. as in FIG. 3), which would be predicted to produce a correspondingly modest increase in both the level and duration of guide RNA expression, may in part explain their capacities to potentiate both gene disruption and gene targeting. Their collective residual biochemical activities may also allow an increased proportion of AAV genomes to remain available to participate in homology-directed repair, thus contributing to increased gene targeting efficiency.

**[0433]** However, two known biochemical activities are contemplated as central to these mutants' capacity to potentiate both gene disruption and gene targeting efficiency relative to the wild type E1B55K: 1) they preserve MRN-dependent DNA damage signaling (which promotes double strand break resolution by various forms of homology-directed DNA repair) while 2) limiting p53-dependent DNA damage signaling (which arrests cells in G1-phase in response to DNA double strand breaks). As a consequence, in some alternatives, T-cells expressing these complexes would be predicted to permit a high fraction of Cas9-induced double strand breaks to transition to S-phase where they would be repaired by mutagenic alternative end joining in the absence of a recombination template, or by homology-directed repair in the case that a recombination template is provided.

**[0434]** In some alternatives, adenoviral serotype 5 E4ORF6/E1B55K H373A and H354 mutant "helper" proteins were identified as possessing the capacity to enhance the efficiency of Cas9-mediated gene editing in primary human T-cells. Collectively, in some alternatives, our results suggest that E4ORF6/E1B55K-H373A might be the best choice for an investigator interested in a general tool to enhance CRISPR/Cas9 gene editing, as it exhibited the most consistent activity across multiple types of gene editing applications.

**[0435]** The biochemical activities of these proteins suggest that their effects on gene editing efficiency are likely attributable to their promotion of S-phase repair of DNA double strand breaks. Thus, in some alternatives, they are likely to be generally applicable approaches to enhance homology-directed genome modification in primary human

cells. In some alternatives, they are likely to be generally applicable as approaches to enhance homology-directed genome modification in primary human cells including with alternative nuclease platforms. In some alternatives, they are likely to be generally applicable approaches to enhance homology-directed genome modification in primary human cells including with alternative viral template delivery methods other than AAV.

**[0436]** Further, as accessory proteins from many human viruses can disable or modify various components of cellular DNA damage response and repair mechanisms, such proteins may represent a rich trove of biochemical activities for use as tools in human genome engineering.

**[0437]** Thus, in some alternatives, the use of accessory proteins from other human (and/or mammalian) viruses that disable and/or modify various components of cellular DNA damage response and/or repair mechanisms are contemplated in the CRISPR/Cas9 system provided herein. In some alternatives, such proteins are contemplated to represent a rich trove of biochemical activities for use as tools in human genome engineering.

**[0438]** The foregoing description and Examples detail certain alternatives of the invention. However, no matter how detailed the foregoing may appear in text, it will be

appreciated that the invention may be practiced in many ways and the invention should be construed in accordance with the appended claims and any equivalents thereof. While the present teachings have been described in terms of these exemplary alternatives, one of ordinary skill in the art will readily comprehend that numerous variations and modifications of these exemplary alternatives are possible without undue experimentation. All such variations and modifications are within the scope of the current teachings.

**[0439]** The foregoing examples are provided to better illustrate the disclosed teachings and are not intended to limit the scope of the teachings presented herein. All references cited herein, including patents, patent applications, papers, text books, and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated by reference in their entirety.

**[0440]** The foregoing is considered to be sufficient to enable one of ordinary skill in the art to practice the invention. The foregoing description and examples detail certain preferred alternatives of the invention and describe the best mode contemplated by the inventors. In the event that one or more of the incorporated literature and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.

---

SEQUENCE LISTING

---

<160> NUMBER OF SEQ ID NOS: 23

<210> SEQ ID NO 1

<211> LENGTH: 496

<212> TYPE: PRT

<213> ORGANISM: adeno-associated virus

<400> SEQUENCE: 1

```

Met Glu Arg Arg Asn Pro Ser Glu Arg Gly Val Pro Ala Gly Phe Ser
1           5           10          15

Gly His Ala Ser Val Glu Ser Gly Cys Glu Thr Gln Glu Ser Pro Ala
          20          25          30

Thr Val Val Phe Arg Pro Pro Gly Asp Asn Thr Asp Gly Gly Ala Ala
          35          40          45

Ala Ala Ala Gly Gly Ser Gln Ala Ala Ala Ala Gly Ala Glu Pro Met
          50          55          60

Glu Pro Glu Ser Arg Pro Gly Pro Ser Gly Met Asn Val Val Gln Val
          65          70          75          80

Ala Glu Leu Tyr Pro Glu Leu Arg Arg Ile Leu Thr Ile Thr Glu Asp
          85          90          95

Gly Gln Gly Leu Lys Gly Val Lys Arg Glu Arg Gly Ala Cys Glu Ala
          100         105         110

Thr Glu Glu Ala Arg Asn Leu Ala Phe Ser Leu Met Thr Arg His Arg
          115         120         125

Pro Glu Cys Ile Thr Phe Gln Gln Ile Lys Asp Asn Cys Ala Asn Glu
          130         135         140

Leu Asp Leu Leu Ala Gln Lys Tyr Ser Ile Glu Gln Leu Thr Thr Tyr
          145         150         155         160

Trp Leu Gln Pro Gly Asp Asp Phe Glu Glu Ala Ile Arg Val Tyr Ala
          165         170         175

Lys Val Ala Leu Arg Pro Asp Cys Lys Tyr Lys Ile Ser Lys Leu Val

```

-continued

180				185				190							
Asn	Ile	Arg	Asn	Cys	Cys	Tyr	Ile	Ser	Gly	Asn	Gly	Ala	Glu	Val	Glu
	195						200						205		
Ile	Asp	Thr	Glu	Asp	Arg	Val	Ala	Phe	Arg	Cys	Ser	Met	Ile	Asn	Met
	210					215					220				
Trp	Pro	Gly	Val	Leu	Gly	Met	Asp	Gly	Val	Val	Ile	Met	Asn	Val	Arg
	225				230					235					240
Phe	Thr	Gly	Pro	Asn	Phe	Ser	Gly	Thr	Val	Phe	Leu	Ala	Asn	Thr	Asn
				245					250					255	
Leu	Ile	Leu	His	Gly	Val	Ser	Phe	Tyr	Gly	Phe	Asn	Asn	Thr	Cys	Val
		260						265					270		
Glu	Ala	Trp	Thr	Asp	Val	Arg	Val	Arg	Gly	Cys	Ala	Phe	Tyr	Cys	Cys
		275					280						285		
Trp	Lys	Gly	Val	Val	Cys	Arg	Pro	Lys	Ser	Arg	Ala	Ser	Ile	Lys	Lys
	290					295					300				
Cys	Leu	Phe	Glu	Arg	Cys	Thr	Leu	Gly	Ile	Leu	Ser	Glu	Gly	Asn	Ser
	305				310					315					320
Arg	Val	Arg	His	Asn	Val	Ala	Ser	Asp	Cys	Gly	Cys	Phe	Met	Leu	Val
				325					330					335	
Lys	Ser	Val	Ala	Val	Ile	Lys	His	Asn	Met	Val	Cys	Gly	Asn	Cys	Glu
		340						345					350		
Asp	Arg	Ala	Ser	Gln	Met	Leu	Thr	Cys	Ser	Asp	Gly	Asn	Cys	His	Leu
		355					360					365			
Leu	Lys	Thr	Ile	His	Val	Ala	Ser	His	Ser	Arg	Lys	Ala	Trp	Pro	Val
	370					375					380				
Phe	Glu	His	Asn	Ile	Leu	Thr	Arg	Cys	Ser	Leu	His	Leu	Gly	Asn	Arg
	385				390					395					400
Arg	Gly	Val	Phe	Leu	Pro	Tyr	Gln	Cys	Asn	Leu	Ser	His	Thr	Lys	Ile
				405					410					415	
Leu	Leu	Glu	Pro	Glu	Ser	Met	Ser	Lys	Val	Asn	Leu	Asn	Gly	Val	Phe
		420						425					430		
Asp	Met	Thr	Met	Lys	Ile	Trp	Lys	Val	Leu	Arg	Tyr	Asp	Glu	Thr	Arg
	435						440					445			
Thr	Arg	Cys	Arg	Pro	Cys	Glu	Cys	Gly	Gly	Lys	His	Ile	Arg	Asn	Gln
	450				455					460					
Pro	Val	Met	Leu	Asp	Val	Thr	Glu	Glu	Leu	Arg	Pro	Asp	His	Leu	Val
	465				470					475					480
Leu	Ala	Cys	Thr	Arg	Ala	Glu	Phe	Gly	Ser	Ser	Asp	Glu	Asp	Thr	Asp
				485					490					495	

&lt;210&gt; SEQ ID NO 2

&lt;211&gt; LENGTH: 496

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: adeno-associated virus

&lt;400&gt; SEQUENCE: 2

Met	Glu	Arg	Arg	Asn	Pro	Ser	Glu	Arg	Gly	Val	Pro	Ala	Gly	Phe	Ser
1				5						10				15	

Gly	His	Ala	Ser	Val	Glu	Ser	Gly	Cys	Glu	Thr	Gln	Glu	Ser	Pro	Ala
		20						25					30		

Thr	Val	Val	Phe	Arg	Pro	Pro	Gly	Asp	Asn	Thr	Asp	Gly	Gly	Ala	Ala
	35						40					45			

-continued

Ala	Ala	Ala	Gly	Gly	Ser	Gln	Ala	Ala	Ala	Ala	Gly	Ala	Glu	Pro	Met
50						55					60				
Glu	Pro	Glu	Ser	Arg	Pro	Gly	Pro	Ser	Gly	Met	Asn	Val	Val	Gln	Val
65					70					75				80	
Ala	Glu	Leu	Tyr	Pro	Glu	Leu	Arg	Arg	Ile	Leu	Thr	Ile	Thr	Glu	Asp
			85						90					95	
Gly	Gln	Gly	Leu	Lys	Gly	Val	Lys	Arg	Glu	Arg	Gly	Ala	Cys	Glu	Ala
			100						105				110		
Thr	Glu	Glu	Ala	Arg	Asn	Leu	Ala	Phe	Ser	Leu	Met	Thr	Arg	His	Arg
			115					120					125		
Pro	Glu	Cys	Ile	Thr	Phe	Gln	Gln	Ile	Lys	Asp	Asn	Cys	Ala	Asn	Glu
	130					135					140				
Leu	Asp	Leu	Leu	Ala	Gln	Lys	Tyr	Ser	Ile	Glu	Gln	Leu	Thr	Thr	Tyr
145					150					155					160
Trp	Leu	Gln	Pro	Gly	Asp	Asp	Phe	Glu	Glu	Ala	Ile	Arg	Val	Tyr	Ala
				165					170					175	
Lys	Val	Ala	Leu	Arg	Pro	Asp	Cys	Lys	Tyr	Lys	Ile	Ser	Lys	Leu	Val
			180					185					190		
Asn	Ile	Arg	Asn	Cys	Cys	Tyr	Ile	Ser	Gly	Asn	Gly	Ala	Glu	Val	Glu
		195					200					205			
Ile	Asp	Thr	Glu	Asp	Arg	Val	Ala	Phe	Arg	Cys	Ser	Met	Ile	Asn	Met
	210					215					220				
Trp	Pro	Gly	Val	Leu	Gly	Met	Asp	Gly	Val	Val	Ile	Met	Asn	Val	Arg
225					230					235					240
Phe	Thr	Gly	Pro	Asn	Phe	Ser	Gly	Thr	Val	Phe	Leu	Ala	Asn	Thr	Asn
				245					250					255	
Leu	Ile	Leu	His	Gly	Val	Ser	Phe	Tyr	Gly	Phe	Asn	Asn	Thr	Cys	Val
			260					265					270		
Glu	Ala	Trp	Thr	Asp	Val	Arg	Val	Arg	Gly	Cys	Ala	Phe	Tyr	Cys	Cys
		275						280				285			
Trp	Lys	Gly	Val	Val	Cys	Arg	Pro	Lys	Ser	Arg	Ala	Ser	Ile	Lys	Lys
	290					295					300				
Cys	Leu	Phe	Glu	Arg	Cys	Thr	Leu	Gly	Ile	Leu	Ser	Glu	Gly	Asn	Ser
305					310					315					320
Arg	Val	Arg	His	Asn	Val	Ala	Ser	Asp	Cys	Gly	Cys	Phe	Met	Leu	Val
				325					330					335	
Lys	Ser	Val	Ala	Val	Ile	Lys	His	Asn	Met	Val	Cys	Gly	Asn	Cys	Glu
			340					345					350		
Asp	Arg	Ala	Ser	Gln	Met	Leu	Thr	Cys	Ser	Asp	Gly	Asn	Cys	His	Leu
		355					360					365			
Leu	Lys	Thr	Ile	Ala	Val	Ala	Ser	His	Ser	Arg	Lys	Ala	Trp	Pro	Val
	370					375					380				
Phe	Glu	His	Asn	Ile	Leu	Thr	Arg	Cys	Ser	Leu	His	Leu	Gly	Asn	Arg
385					390					395					400
Arg	Gly	Val	Phe	Leu	Pro	Tyr	Gln	Cys	Asn	Leu	Ser	His	Thr	Lys	Ile
				405					410					415	
Leu	Leu	Glu	Pro	Glu	Ser	Met	Ser	Lys	Val	Asn	Leu	Asn	Gly	Val	Phe
			420					425					430		
Asp	Met	Thr	Met	Lys	Ile	Trp	Lys	Val	Leu	Arg	Tyr	Asp	Glu	Thr	Arg
	435						440					445			
Thr	Arg	Cys	Arg	Pro	Cys	Glu	Cys	Gly	Gly	Lys	His	Ile	Arg	Asn	Gln



-continued

---

450	455	460
Pro Val Met Leu Asp Val Thr Glu Glu Leu Arg Pro Asp His Leu Val		
465	470	475 480
Leu Ala Cys Thr Arg Ala Glu Phe Gly Ser Ser Asp Glu Asp Thr Asp		
	485	490 495

<210> SEQ ID NO 3  
 <211> LENGTH: 294  
 <212> TYPE: PRT  
 <213> ORGANISM: adeno-associated virus

<400> SEQUENCE: 3

Met Thr Thr Ser Gly Val Pro Phe Gly Met Thr Leu Arg Pro Thr Arg		
1	5	10 15
Ser Arg Leu Ser Arg Arg Thr Pro Tyr Ser Arg Asp Arg Leu Pro Pro		
	20	25 30
Phe Glu Thr Glu Thr Arg Ala Thr Ile Leu Glu Asp His Pro Leu Leu		
	35	40 45
Pro Glu Cys Asn Thr Leu Thr Met His Asn Val Ser Tyr Val Arg Gly		
	50	55 60
Leu Pro Cys Ser Val Gly Phe Thr Leu Ile Gln Glu Trp Val Val Pro		
	65	70 75 80
Trp Asp Met Val Leu Thr Arg Glu Glu Leu Val Ile Leu Arg Lys Cys		
	85	90 95
Met His Val Cys Leu Cys Cys Ala Asn Ile Asp Ile Met Thr Ser Met		
	100	105 110
Met Ile His Gly Tyr Glu Ser Trp Ala Leu His Cys His Cys Ser Ser		
	115	120 125
Pro Gly Ser Leu Gln Cys Ile Ala Gly Gly Gln Val Leu Ala Ser Trp		
	130	135 140
Phe Arg Met Val Val Asp Gly Ala Met Phe Asn Gln Arg Phe Ile Trp		
	145	150 155 160
Tyr Arg Glu Val Val Asn Tyr Asn Met Pro Lys Glu Val Met Phe Met		
	165	170 175
Ser Ser Val Phe Met Arg Gly Arg His Leu Ile Tyr Leu Arg Leu Trp		
	180	185 190
Tyr Asp Gly His Val Gly Ser Val Val Pro Ala Met Ser Phe Gly Tyr		
	195	200 205
Ser Ala Leu His Cys Gly Ile Leu Asn Asn Ile Val Val Leu Cys Cys		
	210	215 220
Ser Tyr Cys Ala Asp Leu Ser Glu Ile Arg Val Arg Cys Cys Ala Arg		
	225	230 235 240
Arg Thr Arg Arg Leu Met Leu Arg Ala Val Arg Ile Ile Ala Glu Glu		
	245	250 255
Thr Thr Ala Met Leu Tyr Ser Cys Arg Thr Glu Arg Arg Arg Gln Gln		
	260	265 270
Phe Ile Arg Ala Leu Leu Gln His His Arg Pro Ile Leu Met His Asp		
	275	280 285
Tyr Asp Ser Thr Pro Met		
	290	

<210> SEQ ID NO 4  
 <211> LENGTH: 500

-continued

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: adeno-associated virus

&lt;400&gt; SEQUENCE: 4

```

Met Glu Arg Arg Asn Pro Ser Glu Arg Gly Val Pro Ala Gly Phe Ser
1      5      10      15
Gly His Ala Ser Val Glu Ser Gly Cys Glu Thr Gln Glu Ser Pro Ala
20      25      30
Thr Val Val Phe Arg Pro Pro Gly Asp Asn Thr Asp Gly Gly Ala Ala
35      40      45
Ala Ala Ala Gly Gly Ser Gln Ala Ala Ala Ala Gly Ala Glu Pro Met
50      55      60
Glu Pro Glu Ser Arg Pro Gly Pro Ser Gly Met Asn Val Val Gln Val
65      70      75      80
Ala Glu Leu Tyr Pro Glu Leu Arg Arg Ile Leu Thr Ile Thr Glu Asp
85      90      95
Gly Gln Gly Leu Lys Gly Val Lys Arg Glu Arg Gly Ala Cys Glu Ala
100     105     110
Thr Glu Glu Ala Arg Asn Leu Ala Phe Ser Leu Met Thr Arg His Arg
115     120     125
Pro Glu Cys Ile Thr Phe Gln Gln Ile Lys Asp Asn Cys Ala Asn Glu
130     135     140
Leu Asp Leu Leu Ala Gln Lys Tyr Ser Ile Glu Gln Leu Thr Thr Tyr
145     150     155     160
Trp Leu Gln Pro Gly Asp Asp Phe Glu Glu Ala Ile Arg Val Tyr Ala
165     170     175
Lys Val Ala Leu Arg Pro Asp Cys Lys Tyr Lys Ile Ser Lys Leu Val
180     185     190
Asn Ile Arg Asn Cys Cys Tyr Ile Ser Gly Asn Gly Ala Glu Val Glu
195     200     205
Ile Asp Thr Glu Asp Arg Val Ala Phe Arg Cys Ser Met Ile Asn Met
210     215     220
Trp Pro Gly Val Leu Gly Met Asp Gly Val Val Ile Met Asn Val Arg
225     230     235     240
Phe Thr Gly Pro Asn Phe Ser Gly Thr Val Phe Leu Ala Asn Thr Asn
245     250     255
Leu Ile Leu His Gly Val Ser Phe Tyr Gly Phe Asn Asn Thr Cys Val
260     265     270
Glu Ala Trp Thr Asp Val Arg Val Arg Gly Cys Ala Phe Tyr Cys Cys
275     280     285
Trp Lys Gly Val Val Cys Arg Pro Lys Ser Arg Ala Ser Ile Lys Lys
290     295     300
Cys Leu Phe Glu Arg Cys Thr Leu Gly Ile Leu Ser Glu Gly Asn Ser
305     310     315     320
Arg Val Arg His Asn Val Ala Ser Asp Cys Gly Cys Phe Met Leu Val
325     330     335
Lys Ser Val Ala Val Ile Lys His Asn Met Val Cys Gly Asn Cys Glu
340     345     350
Asp Arg Ala Gly Ile Pro Ala Ser Gln Met Leu Thr Cys Ser Asp Gly
355     360     365
Asn Cys His Leu Leu Lys Thr Ile His Val Ala Ser His Ser Arg Lys
370     375     380

```

-continued

---

Ala Trp Pro Val Phe Glu His Asn Ile Leu Thr Arg Cys Ser Leu His  
 385 390 395 400

Leu Gly Asn Arg Arg Gly Val Phe Leu Pro Tyr Gln Cys Asn Leu Ser  
 405 410 415

His Thr Lys Ile Leu Leu Glu Pro Glu Ser Met Ser Lys Val Asn Leu  
 420 425 430

Asn Gly Val Phe Asp Met Thr Met Lys Ile Trp Lys Val Leu Arg Tyr  
 435 440 445

Asp Glu Thr Arg Thr Arg Cys Arg Pro Cys Glu Cys Gly Gly Lys His  
 450 455 460

Ile Arg Asn Gln Pro Val Met Leu Asp Val Thr Glu Glu Leu Arg Pro  
 465 470 475 480

Asp His Leu Val Leu Ala Cys Thr Arg Ala Glu Phe Gly Ser Ser Asp  
 485 490 495

Glu Asp Thr Asp  
 500

<210> SEQ ID NO 5  
 <211> LENGTH: 18  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 5

tcaagagcaa cagtgtgtg

18

<210> SEQ ID NO 6  
 <211> LENGTH: 1368  
 <212> TYPE: PRT  
 <213> ORGANISM: Streptococcus pyogenes

<400> SEQUENCE: 6

Met Asp Lys Lys Tyr Ser Ile Gly Leu Ala Ile Gly Thr Asn Ser Val  
 1 5 10 15

Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe  
 20 25 30

Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile  
 35 40 45

Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu  
 50 55 60

Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys  
 65 70 75 80

Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser  
 85 90 95

Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys  
 100 105 110

His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr  
 115 120 125

His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp  
 130 135 140

Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His  
 145 150 155 160

Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro

-continued

165								170								175							
Asp	Asn	Ser	Asp Val 180			Asp	Lys	Leu	Phe 185	Ile	Gln	Leu	Val	Gln 190	Thr	Tyr							
Asn	Gln	Leu	Phe 195	Glu	Glu	Asn	Pro 200	Ile	Asn	Ala	Ser	Gly 205	Val	Asp	Ala								
Lys	Ala 210	Ile	Leu	Ser	Ala	Arg 215	Leu	Ser	Lys	Ser	Arg 220	Arg	Leu	Glu	Asn								
Leu 225	Ile	Ala	Gln	Leu	Pro 230	Gly	Glu	Lys	Lys	Asn 235	Gly	Leu	Phe	Gly 240	Asn								
Leu	Ile	Ala	Leu	Ser 245	Leu	Gly	Leu	Thr	Pro 250	Asn	Phe	Lys	Ser	Asn 255	Phe								
Asp	Leu	Ala	Glu 260	Asp	Ala	Lys	Leu	Gln 265	Leu	Ser	Lys	Asp 270	Thr	Tyr	Asp								
Asp	Asp 275	Leu	Asp	Asn	Leu	Leu	Ala 280	Gln	Ile	Gly	Asp 285	Gln	Tyr	Ala	Asp								
Leu	Phe 290	Leu	Ala	Ala	Lys	Asn 295	Leu	Ser	Asp	Ala	Ile 300	Leu	Leu	Ser	Asp								
Ile 305	Leu	Arg	Val	Asn	Thr 310	Glu	Ile	Thr	Lys	Ala 315	Pro	Leu	Ser	Ala	Ser 320								
Met	Ile	Lys	Arg	Tyr 325	Asp	Glu	His	His	Gln 330	Asp	Leu	Thr	Leu	Leu 335	Lys								
Ala	Leu	Val	Arg 340	Gln	Gln	Leu	Pro	Glu 345	Lys	Tyr	Lys	Glu	Ile 350	Phe	Phe								
Asp	Gln	Ser 355	Lys	Asn	Gly	Tyr	Ala 360	Gly	Tyr	Ile	Asp 365	Gly	Gly	Ala	Ser								
Gln	Glu 370	Glu	Phe	Tyr	Lys	Phe 375	Ile	Lys	Pro	Ile	Leu 380	Glu	Lys	Met	Asp								
Gly 385	Thr	Glu	Glu	Leu	Leu 390	Val	Lys	Leu	Asn	Arg 395	Glu	Asp	Leu	Leu	Arg 400								
Lys	Gln	Arg	Thr	Phe 405	Asp	Asn	Gly	Ser	Ile 410	Pro	His	Gln	Ile 415	His	Leu								
Gly	Glu	Leu	His 420	Ala	Ile	Leu	Arg	Arg 425	Gln	Glu	Asp	Phe 430	Tyr	Pro	Phe								
Leu	Lys 435	Asp	Asn	Arg	Glu	Lys	Ile 440	Glu	Lys	Ile	Leu 445	Thr	Phe	Arg	Ile								
Pro	Tyr 450	Tyr	Val	Gly	Pro	Leu 455	Ala	Arg	Gly	Asn	Ser 460	Arg	Phe	Ala	Trp								
Met 465	Thr	Arg	Lys	Ser	Glu 470	Glu	Thr	Ile	Thr	Pro 475	Trp	Asn	Phe	Glu	Glu 480								
Val	Val	Asp	Lys 485	Gly	Ala	Ser	Ala	Gln	Ser	Phe 490	Ile	Glu	Arg	Met	Thr 495								
Asn	Phe	Asp	Lys 500	Asn	Leu	Pro	Asn	Glu 505	Lys	Val	Leu	Pro	Lys 510	His	Ser								
Leu	Leu	Tyr	Glu 515	Tyr	Phe	Thr	Val 520	Tyr	Asn	Glu	Leu	Thr 525	Lys	Val	Lys								
Tyr	Val 530	Thr	Glu	Gly	Met	Arg 535	Lys	Pro	Ala	Phe	Leu 540	Ser	Gly	Glu	Gln								
Lys 545	Lys	Ala	Ile	Val	Asp 550	Leu	Leu	Phe	Lys	Thr 555	Asn	Arg	Lys	Val	Thr 560								
Val	Lys	Gln	Leu	Lys 565	Glu	Asp	Tyr	Phe	Lys 570	Lys	Ile	Glu	Cys	Phe 575	Asp								

-continued

---

Ser	Val	Glu	Ile	Ser	Gly	Val	Glu	Asp	Arg	Phe	Asn	Ala	Ser	Leu	Gly
		580						585					590		
Thr	Tyr	His	Asp	Leu	Leu	Lys	Ile	Ile	Lys	Asp	Lys	Asp	Phe	Leu	Asp
		595				600						605			
Asn	Glu	Glu	Asn	Glu	Asp	Ile	Leu	Glu	Asp	Ile	Val	Leu	Thr	Leu	Thr
	610					615					620				
Leu	Phe	Glu	Asp	Arg	Glu	Met	Ile	Glu	Glu	Arg	Leu	Lys	Thr	Tyr	Ala
	625				630					635					640
His	Leu	Phe	Asp	Asp	Lys	Val	Met	Lys	Gln	Leu	Lys	Arg	Arg	Arg	Tyr
			645						650					655	
Thr	Gly	Trp	Gly	Arg	Leu	Ser	Arg	Lys	Leu	Ile	Asn	Gly	Ile	Arg	Asp
		660						665					670		
Lys	Gln	Ser	Gly	Lys	Thr	Ile	Leu	Asp	Phe	Leu	Lys	Ser	Asp	Gly	Phe
		675					680					685			
Ala	Asn	Arg	Asn	Phe	Met	Gln	Leu	Ile	His	Asp	Asp	Ser	Leu	Thr	Phe
	690					695					700				
Lys	Glu	Asp	Ile	Gln	Lys	Ala	Gln	Val	Ser	Gly	Gln	Gly	Asp	Ser	Leu
	705				710					715					720
His	Glu	His	Ile	Ala	Asn	Leu	Ala	Gly	Ser	Pro	Ala	Ile	Lys	Lys	Gly
			725						730				735		
Ile	Leu	Gln	Thr	Val	Lys	Val	Val	Asp	Glu	Leu	Val	Lys	Val	Met	Gly
		740						745					750		
Arg	His	Lys	Pro	Glu	Asn	Ile	Val	Ile	Glu	Met	Ala	Arg	Glu	Asn	Gln
		755				760					765				
Thr	Thr	Gln	Lys	Gly	Gln	Lys	Asn	Ser	Arg	Glu	Arg	Met	Lys	Arg	Ile
	770					775					780				
Glu	Glu	Gly	Ile	Lys	Glu	Leu	Gly	Ser	Gln	Ile	Leu	Lys	Glu	His	Pro
	785				790					795					800
Val	Glu	Asn	Thr	Gln	Leu	Gln	Asn	Glu	Lys	Leu	Tyr	Leu	Tyr	Tyr	Leu
			805					810					815		
Gln	Asn	Gly	Arg	Asp	Met	Tyr	Val	Asp	Gln	Glu	Leu	Asp	Ile	Asn	Arg
		820						825					830		
Leu	Ser	Asp	Tyr	Asp	Val	Asp	Ala	Ile	Val	Pro	Gln	Ser	Phe	Leu	Lys
		835					840					845			
Asp	Asp	Ser	Ile	Asp	Asn	Lys	Val	Leu	Thr	Arg	Ser	Asp	Lys	Asn	Arg
	850					855					860				
Gly	Lys	Ser	Asp	Asn	Val	Pro	Ser	Glu	Glu	Val	Val	Lys	Lys	Met	Lys
	865				870					875				880	
Asn	Tyr	Trp	Arg	Gln	Leu	Leu	Asn	Ala	Lys	Leu	Ile	Thr	Gln	Arg	Lys
			885					890					895		
Phe	Asp	Asn	Leu	Thr	Lys	Ala	Glu	Arg	Gly	Gly	Leu	Ser	Glu	Leu	Asp
		900						905					910		
Lys	Ala	Gly	Phe	Ile	Lys	Arg	Gln	Leu	Val	Glu	Thr	Arg	Gln	Ile	Thr
		915					920					925			
Lys	His	Val	Ala	Gln	Ile	Leu	Asp	Ser	Arg	Met	Asn	Thr	Lys	Tyr	Asp
	930					935					940				
Glu	Asn	Asp	Lys	Leu	Ile	Arg	Glu	Val	Lys	Val	Ile	Thr	Leu	Lys	Ser
	945				950					955					960
Lys	Leu	Val	Ser	Asp	Phe	Arg	Lys	Asp	Phe	Gln	Phe	Tyr	Lys	Val	Arg
			965					970						975	

-continued

---

Glu	Ile	Asn	Asn	Tyr	His	His	Ala	His	Asp	Ala	Tyr	Leu	Asn	Ala	Val	980	985	990
Val	Gly	Thr	Ala	Leu	Ile	Lys	Lys	Tyr	Pro	Lys	Leu	Glu	Ser	Glu	Phe	995	1000	1005
Val	Tyr	Gly	Asp	Tyr	Lys	Val	Tyr	Asp	Val	Arg	Lys	Met	Ile	Ala		1010	1015	1020
Lys	Ser	Glu	Gln	Glu	Ile	Gly	Lys	Ala	Thr	Ala	Lys	Tyr	Phe	Phe		1025	1030	1035
Tyr	Ser	Asn	Ile	Met	Asn	Phe	Phe	Lys	Thr	Glu	Ile	Thr	Leu	Ala		1040	1045	1050
Asn	Gly	Glu	Ile	Arg	Lys	Arg	Pro	Leu	Ile	Glu	Thr	Asn	Gly	Glu		1055	1060	1065
Thr	Gly	Glu	Ile	Val	Trp	Asp	Lys	Gly	Arg	Asp	Phe	Ala	Thr	Val		1070	1075	1080
Arg	Lys	Val	Leu	Ser	Met	Pro	Gln	Val	Asn	Ile	Val	Lys	Lys	Thr		1085	1090	1095
Glu	Val	Gln	Thr	Gly	Gly	Phe	Ser	Lys	Glu	Ser	Ile	Leu	Pro	Lys		1100	1105	1110
Arg	Asn	Ser	Asp	Lys	Leu	Ile	Ala	Arg	Lys	Lys	Asp	Trp	Asp	Pro		1115	1120	1125
Lys	Lys	Tyr	Gly	Gly	Phe	Asp	Ser	Pro	Thr	Val	Ala	Tyr	Ser	Val		1130	1135	1140
Leu	Val	Val	Ala	Lys	Val	Glu	Lys	Gly	Lys	Ser	Lys	Lys	Leu	Lys		1145	1150	1155
Ser	Val	Lys	Glu	Leu	Leu	Gly	Ile	Thr	Ile	Met	Glu	Arg	Ser	Ser		1160	1165	1170
Phe	Glu	Lys	Asn	Pro	Ile	Asp	Phe	Leu	Glu	Ala	Lys	Gly	Tyr	Lys		1175	1180	1185
Glu	Val	Lys	Lys	Asp	Leu	Ile	Ile	Lys	Leu	Pro	Lys	Tyr	Ser	Leu		1190	1195	1200
Phe	Glu	Leu	Glu	Asn	Gly	Arg	Lys	Arg	Met	Leu	Ala	Ser	Ala	Gly		1205	1210	1215
Glu	Leu	Gln	Lys	Gly	Asn	Glu	Leu	Ala	Leu	Pro	Ser	Lys	Tyr	Val		1220	1225	1230
Asn	Phe	Leu	Tyr	Leu	Ala	Ser	His	Tyr	Glu	Lys	Leu	Lys	Gly	Ser		1235	1240	1245
Pro	Glu	Asp	Asn	Glu	Gln	Lys	Gln	Leu	Phe	Val	Glu	Gln	His	Lys		1250	1255	1260
His	Tyr	Leu	Asp	Glu	Ile	Ile	Glu	Gln	Ile	Ser	Glu	Phe	Ser	Lys		1265	1270	1275
Arg	Val	Ile	Leu	Ala	Asp	Ala	Asn	Leu	Asp	Lys	Val	Leu	Ser	Ala		1280	1285	1290
Tyr	Asn	Lys	His	Arg	Asp	Lys	Pro	Ile	Arg	Glu	Gln	Ala	Glu	Asn		1295	1300	1305
Ile	Ile	His	Leu	Phe	Thr	Leu	Thr	Asn	Leu	Gly	Ala	Pro	Ala	Ala		1310	1315	1320
Phe	Lys	Tyr	Phe	Asp	Thr	Thr	Ile	Asp	Arg	Lys	Arg	Tyr	Thr	Ser		1325	1330	1335
Thr	Lys	Glu	Val	Leu	Asp	Ala	Thr	Leu	Ile	His	Gln	Ser	Ile	Thr		1340	1345	1350
Gly	Leu	Tyr	Glu	Thr	Arg	Ile	Asp	Leu	Ser	Gln	Leu	Gly	Gly	Asp				

-continued

1355	1360	1365	
<210> SEQ ID NO 7			
<211> LENGTH: 4107			
<212> TYPE: DNA			
<213> ORGANISM: Streptococcus pyogenes			
<400> SEQUENCE: 7			
atggataaga aataactcaat aggccttagat atcggcacaa atagcgtcgg atgggcggtg			60
atcactgatg aatataaggt tccgtctaaa aagttcaagg ttctgggaaa tacagaccgc			120
cacagtatca aaaaaaatct tataggggct cttttatttg acagtggaga gacagcggaa			180
gcgactcgtc tcaaacggac agctcgtaga aggtatacac gtcggaagaa tcgtatttgt			240
tatctacagg agattttttc aaatgagatg gcgaaagtag atgatagttt ctttcatcga			300
cttgaagagt cttttttggt ggaagaagac aagaagcatg aacgtcatcc tatttttgga			360
aatatagtag atgaagtgtc ttatcatgag aaatatccaa ctatctatca tctgcgaaaa			420
aaattggtag attctactga taaagcggat ttgcgcttaa tctatttggc cttagcgcgt			480
atgattaagt ttcgtgggtc ttttttgatt gagggagatt taaatcctga taatagtgat			540
gtggacaaac tatttatcca gttggtacaa acctacaatc aattatttga agaaaaccct			600
attaacgcaa gtggagtaga tgctaaagcg attctttctg cagattgag taaatcaaga			660
cgattagaaa atctcattgc tcagctcccc ggtgagaaga aaaatggctt atttgggaat			720
ctcattgctt tgtcattggg ttgacccct aattttaaat caaattttga tttggcagaa			780
gatgctaaat tacagctttc aaaagatact tacgatgatg atttagataa tttattggcg			840
caaatggag atcaatatgc tgatttggtt ttggcagcta agaatttacc agatgctatt			900
ttactttcag atatcctaag agtaaatact gaaataacta aggtccctc atcagettca			960
atgattaaac gctacgatga acatcatcaa gacttgactc ttttaaaagc tttagttcga			1020
caacaacttc cagaaaagta taaagaaatc ttttttgatc aatcaaaaa cggaatgca			1080
ggttatatatg atgggggagc tagccaagaa gaattttata aatttatcaa accaatttta			1140
gaaaaaatgg atggtactga ggaattattg gtgaaactaa atcgtgaaga ttgctgcgc			1200
aagcaacgga cctttgacaa cggctctatt ccccatcaaa ttcacttggg tgagctgcat			1260
gctattttga gaagacaaga agacttttat ccatttttaa aagacaatcg tgagaagatt			1320
gaaaaaatct tgacttttcg aattccttat tatgttggtc cattggcgcg tggcaatagt			1380
cgttttgcgt ggatgactcg gaagtctgaa gaaacaatta ccccatggaa ttttgaagaa			1440
gttgctgata aaggtgcttc agctcaatca tttattgaac gcatgacaaa ctttgataaa			1500
aatcttccaa atgaaaaagt actaccaaaa catagtgtgc tttatgagta tttacgggt			1560
tataacgaat tgacaaaagg caaatatggt actgaaggaa tgcgaaaacc agcatttctt			1620
tcagggtgaac agaagaaagc cattgttgat ttactcttca aaacaaatcg aaaagtaacc			1680
gttaagcaat taaaagaaga ttatttcaaa aaaatagaat gttttgatag tgttgaaatt			1740
tcaggagttg aagatagatt taatgcttca ttaggtacct accatgattt gctaaaaatt			1800
attaagata aagatttttt ggataatgaa gaaaatgaag atatcttaga ggatattgtt			1860
ttaacattga ccttatttga agatagggag atgattgagg aaagacttaa aacatatgct			1920
cacctcttgg atgataaggt gatgaaacag cttaaacgtc gccgtttatac tggttgggga			1980

-continued

---

cgtttgctc	gaaaattgat	taatggtatt	agggataagc	aatctggcaa	aacaatatta	2040
gattttttga	aatcagatgg	ttttgccaat	cgcaatttta	tgcagctgat	ccatgatgat	2100
agtttgacat	ttaaagaaga	cattcaaaaa	gcacaagtgt	ctggacaagg	cgatagttta	2160
catgaacata	ttgcaaattt	agctggtagc	cctgctatta	aaaaaggtat	tttacagact	2220
gtaaaagtgt	ttgatgaatt	ggcoaaagta	atggggcgcc	ataagccaga	aaatatcggt	2280
attgaaatgg	cacgtgaaaa	tcagacaact	caaaagggcc	agaaaaattc	gcgagagcgt	2340
atgaaacgaa	tcgaagaagg	tatcaaagaa	ttaggaagtc	agattcttaa	agagcatcct	2400
gttgaaaata	ctcaattgca	aaatgaaaag	ctctatctct	attatctcca	aaatggaaga	2460
gacatgtatg	tggaccaaga	attagatatt	aatcgtttaa	gtgattatga	tgtcgatcac	2520
attgttccac	aaagtttctt	taaagacgat	tcaatagaca	ataaggtctt	aacgcgttct	2580
gataaaaatc	gtggtaaatc	ggataacgtt	ccaagtgaag	aagtagtcaa	aaagatgaaa	2640
aactattgga	gacaacttct	aaacgccaa	ttaatcactc	aacgtaagtt	tgataattta	2700
acgaaagctg	aacgtggagg	tttgagttaa	cttgataaag	ctggttttat	caaacgccaa	2760
ttggttgaaa	ctcgccaat	cactaagcat	gtggcacaaa	ttttggatag	tcgcatgaat	2820
actaaatacg	atgaaaatga	taaacttatt	cgagaggtta	aagtgttac	cttaaatct	2880
aaattagttt	ctgacttccg	aaaagatttc	caattctata	aagtacgtga	gattaacaat	2940
taccatcatg	cccatgatgc	gtatctaaat	gccgtcgttg	gaactgcttt	gattaagaaa	3000
tatccaaaac	ttgaatcgga	gtttgtctat	ggtgattata	aagtttatga	tgttcgtaaa	3060
atgattgcta	agtctgagca	agaaataggc	aaagcaaccg	caaaatattt	cttttactct	3120
aatatcatga	acttcttcaa	aacagaaatt	acacttgcaa	atggagagat	tcgcaaacgc	3180
cctctaactg	aaactaatgg	ggaaactgga	gaaattgtct	gggataaagg	gcgagatttt	3240
gccacagtgc	gcaaagtatt	gtccatgccc	caagtcaata	ttgtcaagaa	aacagaagta	3300
cagacaggcg	gattctccaa	ggagtcaatt	ttaccaaaaa	gaaattcgga	caagcttatt	3360
gctcgtaaaa	aagactggga	tccaaaaaaa	tatggtgggt	ttgatagtcc	aacggtagct	3420
tattcagtc	tagtgggtgc	taagggtgaa	aaagggaaat	cgaagaagtt	aaaatccgtt	3480
aaagagttac	tagggatcac	aattatggaa	agaagttcct	ttgaaaaaaa	tccgattgac	3540
tttttagaag	ctaaaggata	taagggaagt	aaaaaagact	taatcattaa	actacctaaa	3600
tatagtcttt	ttgagttaga	aaacggtcgt	aaacggatgc	tggctagtgc	cgagaatta	3660
caaaaaggaa	atgagctggc	tctgccaa	aaatatgtga	attttttata	tttagctagt	3720
cattatgaaa	agttgaaggg	tagtccagaa	gataacgaac	aaaaacaatt	gtttgtggag	3780
cagcataagc	attatttaga	tgagattatt	gagcaaata	gtgaattttc	taagcgtgtt	3840
atttttagcag	atgccaat	agataaagt	cttagtgcat	ataacaaaca	tagagacaaa	3900
ccaatacgtg	aacaagcaga	aaatattatt	catttattta	cgttgacgaa	tcttggagct	3960
cccgtgctt	ttaaatattt	tgatacaaca	attgatcgta	aacgatatac	gtctacaaaa	4020
gaagtttttag	atgccactct	tatccatcaa	tccatcactg	gtctttatga	aacacgcatt	4080
gatttgagtc	agctaggagg	tgactga				4107

&lt;210&gt; SEQ ID NO 8

&lt;211&gt; LENGTH: 4107

&lt;212&gt; TYPE: DNA



-continued

<213> ORGANISM: *Streptococcus pyogenes*

&lt;400&gt; SEQUENCE: 8

```

atggacaaga agtactccat tgggctcgct atcggcacaa acagcgtcgg ctgggcccgtc   60
attacggacg agtacaaggt gccgagcaaa aaattcaaag ttctgggcaa taccgatcgc   120
cacagcataa agaagaacct cattggcgcc ctctgttcg actccgggga gacggccgaa   180
gccacgcggc tcaaaagaac agcacggcgc agatataccc gcagaaagaa tcggatctgc   240
tacctgcagg agatctttag taatgagatg gctaagggtg atgactcttt cttecatagg   300
ctggaggagt cctttttggt ggaggaggat aaaaagcacg agcgcacccc aatctttggc   360
aatatcgtgg acgagggtgc gtaccatgaa aagtacccaa ccatatatca tctgagggaag   420
aagcttgtag acagtactga taaggctgac ttgcggttga tctatctcgc gctggcgcat   480
atgatcaaat ttcggggaca ctccctcacc gagggggacc tgaaccagaa caacagcgat   540
gtcgacaaac tctttatcca actggttcag acttacaate agcttttcga agagaacccg   600
atcaacgcac ccggagttag cgccaaagca atcctgagcg ctaggctgtc caaatcccgg   660
cggctcgaac acctcatcgc acagctccct ggggagaaga agaacggcct gtttggtaat   720
cttatcgccc tgtcactcgg gctgaccccc aactttaaat ctaacttcga cctggccgaa   780
gatgccaaag ttcaactgag caaagacacc tacgatgatg atctcgacaa tctgctggcc   840
cagatcggcg accagtacgc agaccttttt ttggcggcaa agaacctgtc agacgccatt   900
ctgctgagtg atattctcgc agtgaacacg gagatcacca aagctccgct gagcgctagt   960
atgatcaagc gctatgatga gcaccaccaa gacttgactt tgctgaaggc ccttgtcaga  1020
cagcaactgc ctgagaagta caaggaaatt ttcttcgacc agtctaaaaa tggctacgcc  1080
ggatacattg acggcggagc aagccaggag gaattttaca aatttattaa gcccatcttg  1140
gaaaaaatgg acggcaccca ggagctgctg gtaaaagcta acagagaaga tctgttgccg  1200
aaacagcgca ctttcgacaa tggaaagcacc cccaccagaa ttcacctggg cgaactgcac  1260
gctatcctca ggcggcaaga ggattttctac ccttttttga aagataacag ggaaaagatt  1320
gagaaaaatc tcacatttcg gataccctac tatgtaggcc ccctgccccg gggaaattcc  1380
agattcgcgt ggatgactcg caaatcagaa gagaccatca ctccctggaa cttcgaggaa  1440
gtcgtggata aggggggcctc tgcccagtc ttcatcgaaa ggatgactaa ctttgataaa  1500
aatctgccta acgaaaaggt gcttcctaaa cactctctgc tgtacagta ctteacagtt  1560
tataacgagc tcaccaaggt caaatcgcgc acagaaggga tgagaaagcc agcatcctg  1620
tctggagagc agaagaaagc tatcgtggac ctctcttcca agacgaaccg gaaagttacc  1680
gtgaaacagc tcaagaaga ctatttcaaa aagattgaat gtttcgactc tgttgaaatc  1740
agcggagtgg aggatcgctt caacgcatcc ctgggaacgt atcacgatct cctgaaaatc  1800
attaagaca aggacttctt ggacaatgag gagaacgagg acattcttga ggacattgtc  1860
ctcaccctta cgttggttga agatagggag atgattgaag aacgcttgaa aacttacgct  1920
catctcttcg acgacaaagt catgaaacag ctcaaggagg gccgatatac aggatggggg  1980
cggctgtcaa gaaaactgat caatgggacg cgagacaagc agagtggaaa gacaatcctg  2040
gattttctta agtccgatgg atttgccaac cggaacttca tgcagttgat ccatgatgac  2100
tctctcacct ttaaggagga catccagaaa gcacaagttt ctggccaggg ggacagtctt  2160

```

-continued

---

cacgagcaca	tcgctaattct	tgcaggtagc	ccagctatca	aaaagggaat	actgcagacc	2220
gttaaggctc	tggatgaact	cgtaaaagta	atgggaaggc	ataagcccga	gaatatcggt	2280
atcgagatgg	cccagagaaa	ccaaactacc	cagaaggagc	agaagaacag	tagggaaagg	2340
atgaagagga	ttgaagaggg	tataaaagaa	ctgggggtccc	aaatccttaa	ggaacaccca	2400
gttgaaaaca	cccagcttca	gaatgagaag	ctctacctgt	actacctgca	gaacggcagg	2460
gacatgtacg	tggatcagga	actggacatc	aatcggtctc	ccgactacga	cgtggctgct	2520
atcgtgcccc	agtcttttct	caaagatgat	tctattgata	ataaagtgtt	gacaagatcc	2580
gataaagcta	gagggaagag	tgataacgtc	ccctcagaag	aagttgtcaa	gaaaatgaaa	2640
aattattggc	ggcagctgct	gaacgcaaaa	ctgatcacac	aacggaagtt	cgataatctg	2700
actaaggctg	aacgaggtgg	cctgtctgag	ttggataaag	ccggtctcat	caaaaggcag	2760
cttggtgaga	cacgccagat	caccaagcac	gtggcccaaa	ttctcgattc	acgcataaac	2820
accaagtacg	atgaaaatga	caaactgatt	cgagaggtga	aagttattac	tctgaagtct	2880
aagctggtct	cagatttcag	aaaggacttt	cagttttata	aggtgagaga	gatcaacaat	2940
taccaccatg	cgcattgatc	ctacctgaat	gcagtggtag	gcactgcact	tatcaaaaaa	3000
tatcccaagc	ttgaatctga	atttgtttac	ggagactata	aagtgtacga	tgtaggaaaa	3060
atgatcgcaa	agtctgagca	ggaaataggc	aaggccaccg	ctaagtactt	cttttacagc	3120
aatattatga	attttttcaa	gaccgagatt	acactggcca	atggagagat	tcggaagcga	3180
ccacttatcg	aaacaaacgg	agaacagga	gaaatcgtgt	gggacaaggg	tagggatttc	3240
gcgacagtcc	ggaaggctct	gtccatgccg	cagggtgaaca	tcgttaaaaa	gaccgaagta	3300
cagaccggag	gcttctccaa	ggaagtatac	ctcccgaaaa	ggaacagcga	caagctgatc	3360
gcacgcacaa	aagattggga	ccccaaagaa	tacggcggat	tcgattcttc	tacagtcgct	3420
tacagtgtac	tggttggtgg	caaagtggag	aaagggaagt	ctaaaaaact	caaaagcgtc	3480
aaggaaactg	tgggcatcac	aatcatggag	cgatcaagct	tcgaaaaaaa	ccccatcgac	3540
tttctcgagg	cgaaaggata	taaagaggtc	aaaaaagacc	tcattcattaa	gcttcccaag	3600
tactctctct	ttgagcttga	aaacggccgg	aaacgaatgc	tcgctagtgc	ggcgagagctg	3660
cagaaaggta	acgagctggc	actgcctctc	aaatacgtta	atttcttgta	tctggccagc	3720
cactatgaaa	agctcaaaag	gtctcccgaa	gataatgagc	agaagcagct	gttcgtggaa	3780
caacacaaac	actaccttga	tgagatcacc	gagcaataaa	gcgaattctc	caaaagagtg	3840
atcctcgccg	acgctaacct	cgataagggtg	ctttctgctt	acaataagca	cagggataag	3900
cccatcaggg	agcaggcaga	aaacattatc	cacttggtta	ctctgaccaa	cttgggcgcg	3960
cctgcagcct	tcaagtactt	cgacaccacc	atagacagaa	agcggtagac	ctctacaaag	4020
gaggtcctgg	acgccacact	gattcatcag	tcaattacgg	ggctctatga	aacaagaatc	4080
gacctctctc	agctcggtgg	agactaaa				4107

&lt;210&gt; SEQ ID NO 9

&lt;211&gt; LENGTH: 3366

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Streptococcus thermophilus

&lt;400&gt; SEQUENCE: 9

atgagcgacc tgggtgctggg cctggacatc ggcacggcca gcgtgggcgt gggcatcctg 60

-continued

---

aacaaggtga	ccggcgagat	catccacaag	aacagtcgca	tettccctgc	tgtcagggt	120
gagaacaacc	tgggtgcgcg	caccaaccgc	cagggtcgcc	ggcttgctcg	ccgaagaag	180
caccggcgcg	tgcgctgaa	cgccctgttc	gaggagagcg	gcctgatcac	cgacttcacc	240
aagatcagca	tcaacctgaa	cccctaccag	ctgcgcgtga	agggcctgac	cgacgagctg	300
agcaacgagg	agctgttcat	cgccctgaag	aacatgggtga	agcaccgcgg	catcagctac	360
ctggacgacg	ccagcgacga	cggcaacagc	agcgtggcg	actacgcccc	gatcgtgaag	420
gagaacagca	agcagctgga	gaccaagacc	cccgccaga	tccagctgga	gcgtaccag	480
acctacggcc	agctgcgcgg	cgacttcacc	gtggagaagg	acggcaagaa	gcaccgcctg	540
atcaacgtgt	tccccaccag	cgctaccgc	agcgaggccc	tgcgcacctc	gcagaccag	600
caggagttea	acccccagat	caccgacgag	ttcatcaacc	gctacctgga	gatcctgacc	660
ggcaagcgca	agtactacca	cggccccggc	aacgagaaga	gccgcaccga	ctacggccgc	720
taccgcacca	gcggcgagac	cctggacaac	atcttcggca	tcctgatcgg	caagtgcacc	780
ttctaccccg	acgagttccg	cgccgccaag	gccagctaca	ccgccagga	gttcaacctg	840
ctgaacgacc	tgaacaacct	gacctgccc	accgagacca	agaagctgag	caaggagcag	900
aagaaccaga	tcataaacta	cgtgaagaac	gagaaggcca	tgggccccgc	caagtgttc	960
aagtacatcg	ccaagctgct	gagctgcgac	gtggccgaca	tcaagggcta	ccgcacgac	1020
aagagcggca	aggccgagat	ccacaccttc	gaggcctacc	gcaagatgaa	gaccctggag	1080
accctggaca	tcgagcagat	ggaccgcgag	accctggaca	agctggccta	cgtgctgacc	1140
ctgaacaccg	agcgcgaggg	catccaggag	gccctggagc	acgagttcgc	cgacggcagc	1200
ttcagccaga	agcaggtgga	cgagctggtg	cagttccgca	aggccaacag	cagcatcttc	1260
ggcaagggtc	ggcacaactt	cagcgtgaag	ctgatgatgg	agctgatccc	cgagctgtac	1320
gagaccagcg	aggagcagat	gaccatctcg	acccgcctgg	gcaagcagaa	gaccaccagc	1380
agcagcaaca	agaccaagta	catcgacgag	aagctgctga	ccgaggagat	ctacaacccc	1440
gtggtggcca	agagcgtgcg	ccaggccatc	aagatcgtga	acgcccctat	caaggagtac	1500
ggcgacttcg	acaacatcgt	gatcgagatg	gcccgcgaga	ccaacgagga	cgacgagaag	1560
aaggccatcc	agaagatcca	gaaggccaac	aaggacgaga	aggacgccgc	catgctgaag	1620
gccgccaacc	agtacaacgg	caaggccgag	ctgccccaca	gcgtgttcca	cgccacaag	1680
cagctggcca	ccaagatccg	cctgtggcac	cagcaggggcg	agcgtgcctc	gtacaccggc	1740
aagaccatca	gcattccacga	cctgatcaac	aacagcaacc	agttcgagggt	ggaccacatc	1800
ctgccccctga	gcattcacctt	cgacgacagc	ctggccaaca	aggtgctggt	gtacgccacc	1860
gccaaccagg	agaagggcca	gcgcaccccc	taccaggccc	tggacagcat	ggacgacgcc	1920
tggagcttcc	gcgagctgaa	ggccttcgtg	cgcgagagca	agaccctgag	caacaagaag	1980
aaggagtacc	tgctgaccga	ggaggacatc	agcaagtctg	acgtgcgcaa	gaagttcatc	2040
gagcgcaacc	tgggtggacac	ccgctacgcc	agccgcgtgg	tgctgaacgc	cctgcaggag	2100
cacttcgcg	cccacaagat	cgacaccaag	gtgagcgtgg	tgcgcgcca	gttcaccagc	2160
cagctgcgcc	gccactgggg	catcgagaag	acccgcgaca	cctaccacca	ccacgccgtg	2220
gacgccctga	tcattgctggc	ttctagccag	ctgaacctgt	ggaagaagca	gaagaacacc	2280
ctggtgagct	acagcgagga	ccagctgctg	gacatcgaga	ccggcgagct	gatcagcgac	2340

-continued

---

gacgagtaca aggagagcgt gttcaaggcc ccctaccagc acttcgtgga caccctgaag	2400
agcaaggagt tcgaggacag catcctgttc agctaccagg tggacagcaa gttcaaccgc	2460
aagatcagcg acgccaccat ctacgccacc cgccaggcca aggtgggcaa ggacaaggcc	2520
gacgagacct acgtgctggg caagatcaag gacatctaca cccaggacgg ctacgacgcc	2580
ttcatgaaga tctacaagaa ggacaagagc aagttcctga tgtaccgcca cgacccccag	2640
accttcgaga aggtgatcga gcccatcctg gagaactacc ccaacaagca gatcaacgat	2700
aaaggcaagg aggtgccctg caacccttc ctgaagtaca aggaggagca cggtacatc	2760
cgcaagtaca gcaagaaggg caacggcccc gagatcaaga gcctgaagta ctacgacagc	2820
aagctgggca accacatcga catcaccccc aaggacagca acaacaagg ggtgctgcag	2880
agcgtgagcc cctggcgcg cgacgtgtac ttcaacaaga ccaccggcaa gtacgagatc	2940
ctgggcctga agtacgcga cctgcagttt gataagggca ccggcaccta caagatcagc	3000
caggagaagt acaacgacat caagaagaag gagggcgtgg acagcgacag cgagtcaag	3060
ttcacctgt acaagaacga ccttctgtg gtgaaggaca ccgagaccaa ggagcaacag	3120
ctgttcgcgt tcctgagccg caccatgccc aagcagaagc actacgtgga gctgaagccc	3180
tacgacaagc agaagttcga gggcgcgag gccctgatca aggtgctggg caacgtggcc	3240
aacagcggcc agtgaagaa gggcctgggc aagagcaaca tcagcatcta caaggtgcgc	3300
accgacgtgc tgggcaacca gcacatcacc aagaacgagg gcgacaagcc caagctggac	3360
ttctaa	3366

&lt;210&gt; SEQ ID NO 10

&lt;211&gt; LENGTH: 3366

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Streptococcus thermophilus

&lt;400&gt; SEQUENCE: 10

atgagcgacc tgggtgctggg cctggccatc ggcacggca gcgtgggctg gggcatcctg	60
aacaagggtga ccggcgagat catccacaag aacagtgcga tcttcctgc tgetcaggct	120
gagaacaacc tgggtgcgcg caccaaccgc cagggtcgcc ggcttgctcg ccgcaagaag	180
caccggcgcg tgcgcctgaa ccgcctgttc gaggagagcg gcctgatcac cgacttcacc	240
aagatcagca tcaacctgaa ccctaccag ctgcgcgtga agggcctgac cgacgagctg	300
agcaacgagg agctgttcat cgccctgaag aacatggtga agcaccgagg catcagctac	360
ctggacgacg ccagcgacga cggcaacagc agcgtgggcg actacgcca gatcgtgaag	420
gagaacagca agcagctgga gaccaagacc ccggccaga tccagctgga gcgctaccag	480
acctacggcc agctgcgcg cgacttcacc gtggagaagg acgcaagaa gcaccgctg	540
atcaacgtgt tccccaccag cgctaccgc agcgaggccc tgcgcatect gcagaccag	600
caggagttca acccccagat caccgacgag ttcacaaacc gctacctgga gatcctgacc	660
ggcaagcgca agtactacca cggccccggc aacgagaaga gccgcaccga ctacggccgc	720
taccgcacca gcggcgagac cctggacaac atcttcggca tctgatcgg caagtgcacc	780
ttctaccccg acgagttccg cgccgccaag gccagctaca ccgcccagga gttcaacctg	840
ctgaacgacc tgaacaacct gaccgtgccc accgagacca agaagctgag caaggagcag	900
aagaaccaga tcatcaacta cgtgaagaac gagaaggcca tgggccccgc caagctgttc	960

-continued

---

aagtacatcg	ccaagctgct	gagctgcgac	gtggccgaca	tcaagggcta	ccgcacgcac	1020
aagagcggca	aggccgagat	ccacaccttc	gaggcctacc	gcaagatgaa	gaccctggag	1080
accctggaca	tcgagcagat	ggaccgcgag	accctggaca	agctggccta	cgtgctgacc	1140
ctgaacaccg	agcgcgaggg	catccaggag	gccctggagc	acgagttcgc	cgacggcagc	1200
ttcagccaga	agcaggtgga	cgagctggtg	cagttccgca	aggccaacag	cagcatcttc	1260
ggcaagggtc	ggcacaactt	cagcgtgaag	ctgatgatgg	agctgatccc	cgagctgtac	1320
gagaccagcg	aggagcagat	gaccatcctg	acccgcctgg	gcaagcagaa	gaccaccagc	1380
agcagcaaca	agaccaagta	catcgacgag	aagctgctga	ccgaggagat	ctacaacccc	1440
gtggtggcca	agagcgtgcg	ccaggccatc	aagatcgtga	acgccgccat	caaggagtac	1500
ggcgacttcg	acaacatcgt	gatcgagatg	gcccgcgaga	ccaacgagga	cgacgagaag	1560
aaggccatcc	agaagatcca	gaaggccaac	aaggacgaga	aggacgccgc	catgctgaag	1620
gccgcccaacc	agtacaacgg	caaggccgag	ctgccccaca	gcgtgttcca	cggccacaag	1680
cagctggcca	ccaagatccg	cctgtggcac	cagcagggcg	agcgtgcctc	gtacaccggc	1740
aagaccatca	gcacccacga	cctgatcaac	aacagcaacc	agttcgaggt	ggctgccatc	1800
ctgccccctga	gcacacacct	cgacgacagc	ctggccaaca	aggtgctggt	gtacgccacc	1860
gccgctcagg	agaagggccca	gcgcaccccc	taccaggccc	tggacagcat	ggacgacgcc	1920
tggagcttcc	gcgagctgaa	ggccttcgtg	cgcgagagca	agaccctgag	caacaagaag	1980
aaggagtacc	tgctgaccga	ggaggacatc	agcaagttcg	acgtgcgcaa	gaagttcatc	2040
gagcgcaacc	tggtggacac	ccgctacgcc	agccgcgtgg	tgctgaacgc	cctgcaggag	2100
cacttcgcgc	cccacaagat	cgacaccaag	gtgagcgtgg	tgcgcgcca	gttcaccagc	2160
cagctgcgcc	gccactgggg	catcgagaag	acccgcgaca	cctaccacca	ccacgccgtg	2220
gacgccctga	tcattgcggc	ttctagccag	ctgaacctgt	ggaagaagca	gaagaacacc	2280
ctggtgagct	acagcgagga	ccagctgctg	gacatcgaga	ccggcgagct	gatcagcgac	2340
gacgagtaca	aggagagcgt	gttcaaggcc	ccctaccagc	acttcgtgga	cacctgaag	2400
agcaaggagt	tcgaggacag	catcctgttc	agctaccagg	tggacagcaa	gttcaaccgc	2460
aagatcagcg	acgccaccat	ctacgccacc	cgcaggcca	aggtgggcaa	ggacaaggcc	2520
gacgagacct	acgtgctggg	caagatcaag	gacatctaca	cccaggacgg	ctacgacgcc	2580
ttcatgaaga	tctacaagaa	ggacaagagc	aagttcctga	tgtaccgcca	cgacccccag	2640
accttcgaga	aggtgatcga	gcccatactg	gagaactacc	ccaacaagca	gatcaacgat	2700
aaaggcaagg	aggtgccttg	caaccccttc	ctgaagtaca	aggaggagca	cggctacatc	2760
cgcaagtaca	gcaagaaggg	caacggcccc	gagatcaaga	gcctgaagta	ctacgacagc	2820
aagctgggca	accacatcga	catcaccccc	aaggacagca	acaacaaggt	ggtgctgcag	2880
agcgtgagcc	cctggcgcg	cgacgtgtac	ttcaacaaga	ccaccggcaa	gtacgagatc	2940
ctgggcctga	agtacgcoga	cctgcagttt	gataagggca	ccggcaccta	caagatcagc	3000
caggagaagt	acaacgacat	caagaagaag	gagggcgtgg	acagcgacag	cgagtccaag	3060
ttcacctctg	acaagaacga	ccttctgctg	gtgaaggaca	ccgagaccaa	ggagcaacag	3120
ctgttcgcgt	tcctgagccg	caccatgccc	aagcagaagc	actacgtgga	gctgaagccc	3180
tacgacaagc	agaagttcga	ggcgcgcgag	gccctgatca	aggtgctggg	caacgtggcc	3240

-continued

---

aacagcggcc agtgcaagaa gggcctgggc aagagcaaca tcagcatcta caaggtgcgc	3300
accgacgtgc tgggcaacca gcacatcatc aagaacgagg gcgacaagcc caagctggac	3360
ttctaa	3366

<210> SEQ ID NO 11  
 <211> LENGTH: 3249  
 <212> TYPE: DNA  
 <213> ORGANISM: *Neisseria meningitidis*

<400> SEQUENCE: 11

atggccgcct tcaagcccaa ccccatcaac tacatcctgg gcctggacat cggcacgcgc	60
agcgtgggct gggccatggt ggagatcgac gaggacgaga accccatctg cctgatcgac	120
ctgggtgtgc gcgtgttcga gcgcgctgag gtgcccaga ctggtgacag tctggctatg	180
gtcgcgcggc ttgctcgtc tgttcgggc cttactcgcc ggcgcgctca ccgccttctg	240
cgcgctcgcc gcctgctgaa gcgcgagggt gtgctgcagg ctgcccactt cgacgagaac	300
ggcctgatca agagcctgcc caacactcct tggcagctgc gcgctgccgc tctggaccgc	360
aagctgactc ctctggagtg gagcgccgtg ctgctgcacc tgatcaagca ccgcggctac	420
ctgagccagc gcaagaacga gggcgagacc gccgacaagg agctgggtgc tctgctgaag	480
ggcgtggcgc acaacgcccc cgccctgcag actggtgact tccgcactcc tgctgagctg	540
gccctgaaca agttcgagaa ggagagcggc cacatccgca accagcgcg cgactacagc	600
cacaccttca gccgcaagga cctgcaggcc gagctgatcc tgctgttcga gaagcagaag	660
gagttcgga acccccacgt gagcgcgggc ctgaaggagg gcacgagac cctgctgatg	720
accagcgccc ccgcccctgag cggcgacgcc gtgcagaaga tgctgggcca ctgcaccttc	780
gagccagcgc agcccaaggc cgccaagaac acctacaccg ccgagcgctt catctggctg	840
accaagctga acaacctgcg catcctggag cagggcagcg agcgccccct gaccgacacc	900
gagcgcgcca cctgatgga cgagccctac cgcaagagca agctgacctc cgcccaggcc	960
cgcaagctgc tgggtctgga ggacaccgcc ttcttcaagg gcctgcgcta cggcaaggac	1020
aacgcccagg ccagcacccct gatggagatg aaggcctacc acgccaacag ccgcccctg	1080
gagaaggagg gcctgaagga caagaagat cctctgaacc tgagccccga gctgcaggac	1140
gagatcgga ccgccttcag cctgttcaag accgacgagg acatcaccgg ccgcctgaag	1200
gaccgcatcc agcccagat cctggaggcc ctgctgaagc acatcagctt cgacaagtcc	1260
gtgcagatca gcctgaaggc cctgcgccgc atcgtgcccc tgatggagca gggcaagcgc	1320
tacgacgagg cctgcgcga gatctacggc gaccactacg gcaagaagaa caccgaggag	1380
aagatctacc tgctctctat ccccgccgac gagatccgca acccgtgggt gctgcgcgcc	1440
ctgagccagg cccgcaaggt gatcaacggc gtggtgcgcc gctacggcag ccccgcccgc	1500
atccacatcg agaccgccc cgagggtggc aagagcttca aggaccgcaa ggagatcgag	1560
aagcgccagg aggagaaccg caaggaccgc gagaaggccg ccgccaagtt ccgcgagtac	1620
ttccccaaact tcgtgggcga gcccaagagc aaggacatcc tgaagctgcg cctgtacgag	1680
cagcagcacg gcaagtgcct gtacagcgcc aaggagatca acctgggccc cctgaacgag	1740
aagggtctac tggagatcga ccacgcctg ccttcagcc gcacctggga cgacagcttc	1800
aacaacaagg tgctggtgct gggcagcgag aaccagaaca agggcaacca gaccacctac	1860

-continued

---

gagtacttca acggcaagga caacagccgc gagtggcagg agttcaaggc ccgcgtggag	1920
accagccgct tcccccgag caagaagcag cgcacccctgc tgcagaagtt cgacgaggac	1980
ggcttcaagg agcgcaacct gaacgacacc cgctacgtga accgcttctc gtgccagttc	2040
gtggccgacc gcctgcgct gaccggcaag ggcaagaagc gcgtgttcgc cagcaacggc	2100
cagatcacca acctgctgcg cggtctcttg ggccctgcga aggtgcgcgc cgagaacgac	2160
cgccaccacg ccctggacgc cgtggtggtg gcctgcagca ccgtggccat gcagcagaag	2220
atcacccgct tcgtgcgcta caaggagatg aacgccttcg accgtaaaac catcgacaag	2280
gagaccggcg aggtgctgca ccagaagacc cacttcccc agccctggga gttcttcgcc	2340
caggaggtag tgatccgctg gtctcgcaag ccgacgcga agcccgagtt cgaggaggcc	2400
gacacccccg agaagctgcg caccctgctg gccgagaagc tgagcagccg ccctgaggcc	2460
gtgcacgagt acgtgactcc tctgttcgtg agccgcgccc ccaaccgcaa gatgagcggt	2520
cagggtcaca tggagaccgt gaagagcgcc aagcgcttg acgaggcggt gagcgtgctg	2580
cgcggtcccc tgaccagct gaagctgaag gacctggaga agatggtgaa ccgcgagcgc	2640
gagcccaagc tgtacgaggc cctgaaggcc cgcctggagg ccacacaagga cgaccccgcc	2700
aaggccttcg ccgagccctt ctacaagtac gacaaggccg gcaaccgcac ccagcaggtg	2760
aaggccgtgc gcgtggagca ggtgcagaag accggcggtg ggggtgcgcaa ccacaacggc	2820
atcgccgaca acgcccacat ggtgcgcgtg gacgtgttcg agaagggcga caagtactac	2880
ctggtgcccc tctacagctg gcaggtggcc aagggcaccc tgcccagacc cgccgtggtg	2940
cagggaagg acgaggagga ctggcagctg atcgacgaca gcttcaactt caagttcagc	3000
ctgcacccca acgacctggt ggaggtgata accaagaagg ccgcacatgt cggtacttc	3060
gccagctgcc acccgggcac cggcaacatc aacatccgca tccacgacct ggaccacaag	3120
atcggaaga acggcatcct ggagggcac gcgctgaaga ccgcctgag ctccagaag	3180
taccagatcg acgagctggg caaggagatc cgccctgcc gcctgaagaa gcgcctcct	3240
gtgcgctaa	3249

&lt;210&gt; SEQ ID NO 12

&lt;211&gt; LENGTH: 3249

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Neisseria meningitidis

&lt;400&gt; SEQUENCE: 12

atggccgct tcaagcccaa ccccatcaac tacatcctgg gcctggccat cggcatcgcc	60
agcgtgggct gggccatggt ggagatcgac gaggacgaga accccatctg cctgatcgac	120
ctgggtgtgc gcgtgttcga gcgcgctgag gtgccaaga ctggtgacag tctggctatg	180
gtcgcgggc ttgctcgtc tgttcggcgc ctactcgc ggcgcgctca ccgccttctg	240
cgcgctcgcc gcctgctgaa gcgcgagggt gtgctgcagg ctgccgactt cgacgagaac	300
ggcctgatca agagcctgcc caacactcct tggcagctgc gcgtgccgc tctggaccgc	360
aagctgactc ctctggagtg gacgcgctg ctgctgcacc tgatcaagca ccgcggctac	420
ctgagccagc gcaagaacga gggcgagacc gccgacaagg agctgggtgc tctgctgaag	480
ggcgtggcgc acaacgcaca cgccctgcag actggtgact tccgactcc tgctgagctg	540
gccctgaaca agttcgagaa ggagagcggc cacatccgca accagcgcg cgactacagc	600

-continued

---

cacacettca	gcccgaagga	cctgcaggcc	gagctgatcc	tgtgtttcga	gaagcagaag	660
gagttcggca	acccccacgt	gagcggcgcc	ctgaaggagg	gcacgcagac	cctgctgatg	720
accagcgcc	ccgccctgag	cggcgacgcc	gtgcagaaga	tgtgtggcca	ctgcaccttc	780
gagccagccg	agcccaaggc	cgccaagaac	acctacaccg	ccgagcgctt	catctggctg	840
accaagctga	acaacctgcg	catcctggag	cagggcagcg	agcgcacct	gaccgacacc	900
gagcgcgcca	ccctgatgga	cgagccctac	cgcaagagca	agctgacct	cgccaggcc	960
cgcaagctgc	tgggtctgga	ggacaccgcc	ttcttcaagg	gcctgcgcta	cgcaaggac	1020
aacgccgagg	ccagcacct	gatggagatg	aaggcctacc	acgccatcag	ccgcgcctg	1080
gagaaggagg	gcctgaagga	caagaagagt	cctctgaacc	tgagcccgga	gctgcaggac	1140
gagatcggca	ccgccttcag	cctgttcaag	accgacgagg	acatcaccgg	ccgcctgaag	1200
gaccgcatcc	agcccgagat	cctggaggcc	ctgctgaagc	acatcagctt	cgacaagttc	1260
gtgcagatca	gcctgaaggc	cctgcgccgc	atcgtgcccc	tgatggagca	gggcaagcgc	1320
tacgacgagg	cctgcgcgga	gatctacggc	gaccactacg	gcaagaagaa	caccgaggag	1380
aagatctacc	tgctctctat	ccccgcgcac	gagatccgca	accccgtagt	gctgcgcgcc	1440
ctgagccagg	cccgaaggt	gatcaacggc	gtgggtgcgc	gctacggcag	ccccgcgcgc	1500
atccacatcg	agaccgcccc	cgagggtggc	aagagcttca	aggaccgcaa	ggagatcgag	1560
aagcgccagg	aggagaaccg	caaggaccgc	gagaaggccg	ccgccaagtt	ccgcgagtac	1620
ttccccaact	tcgtggcgga	gcccgaagac	aaggacatcc	tgaagctgcg	cctgtacgag	1680
cagcagcacg	gcaagtgcct	gtacagcgcc	aaggagatca	acctgggccg	cctgaacgag	1740
aagggtctacg	tggagatcgc	cgtgcacctg	cccttcagcc	gcacctggga	cgacagcttc	1800
aacaacaagg	tgtgtgtgct	gggcagcgag	gctcagaaca	agggcaacca	gacccctac	1860
gagtacttca	acggcaagga	caacagccgc	gagtggcagg	agttcaaggc	ccgcgtggag	1920
accagccgct	tcccccgag	caagaagcag	cgcacctcgc	tgcagaagtt	cgacgaggac	1980
ggcttcaagg	agcgcaacct	gaacgacacc	cgctacgtga	accgcttctt	gtgccagttc	2040
gtggccgacc	gcctgcgcct	gaccggcaag	ggcaagaagc	gcgtgttcgc	cagcaacggc	2100
cagatcacca	acctgctgcg	cggtctctgg	ggcctgcgca	aggtgcgcgc	cgagaacgac	2160
cgccaccacg	ccctggacgc	cgtgggtgtg	gcctgcagca	ccgtggccat	gcagcagaag	2220
atcacccgct	tcgtgcgcta	caaggagatg	aacgccttcg	acggtaaaac	catcgacaag	2280
gagaccggcg	aggtgctgca	ccagaagacc	cacttcccc	agccctggga	gttcttcgcc	2340
caggagggtga	tgatccgcgt	gttcggcaag	cccgcaggca	agcccgagtt	cgaggaggcc	2400
gacacccccg	agaagctgcg	cacctgctg	gccgagaagc	tgagcagccg	ccctgaggcc	2460
gtgcacgagt	acgtgactcc	tctgttcgtg	agccgcgccc	ccaaccgcaa	gatgagcggt	2520
cagggtcaca	tggagaccgt	gaagagcgcc	aagcgctcgg	acgaggcggt	gagcgtgctg	2580
cgcggtcccc	tgacccagct	gaagctgaag	gacctggaga	agatggtgaa	ccgcgagcgc	2640
gagcccaagc	tgtacgaggc	cctgaaggcc	cgcttgaggg	cccacaagga	cgaccccgcc	2700
aaggccttcg	ccgagccctt	ctacaagtac	gacaaggccg	gcaaccgcac	ccagcagggtg	2760
aaggccgtgc	gcgtggagca	ggtgcagaag	accggcgtgt	gggtgcgcaa	ccacaacggc	2820
atcgccgaca	acgccaccat	ggtgcgcgtg	gacgtgttcg	agaaggcgca	caagtactac	2880



-continued

---

ctggtgcccc tctacagctg gcaggtggcc aagggcatcc tgcccagacc cgccgtggtg	2940
cagggcaagg acgaggagga ctggcagctg atcgacgaca gcttcaactt caagttcagc	3000
ctgcacccca acgacctggt ggaggtgata accaagaagg cccgcatggt cggtacttc	3060
gccagctgcc accgcggcac cggaacatc aacatccgca tccacgacct ggaccacaag	3120
atcggaaga acggcatcct ggagggcatc ggctgaaga ccgccctgag cttccagaag	3180
taccagatcg acgagctggg caaggagatc cgccctgcc gcctgaagaa gcgccctcct	3240
gtgcgctaa	3249

&lt;210&gt; SEQ ID NO 13

&lt;211&gt; LENGTH: 4188

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Treponema denticola

&lt;400&gt; SEQUENCE: 13

atgaagaagg agatcaagga ctacttctcg ggctggacg tgggcacccg cagcgtgggc	60
tgggcccgtga ccgacaccga ctacaagctg ctgaaggcca accgcaagga cctgtggggc	120
atgcgctgct tcgagactgc tgagaccgcc gaggtgcgcc ggctgcaccg cgggtgctcg	180
cggcgcatcg agcgccgcaa gaagcgcata aagctgctgc aggagctgtt cagccaggag	240
atcgccaaga ccgacgaggg cttcttccag cgcataagg agagccctt ctacgccgag	300
gacaagacca tcctgcagga gaacaccctg ttcaacgaca aggacttcgc cgacaagacc	360
taccacaagg cctacccacc catcaaccac ctgatcaagg cctggatcga gaacaaggtg	420
aagcccgaac ctgcctgct gtacctggcc tgccacaaca tcatcaagaa gcgcggccac	480
ttcctgttcg agggcgactt cgacagcgag aaccagttcg acaccagcat ccaggccctg	540
ttcgagtacc tgcgcgagga catggaggtg gacatcgacg ccgacagcca gaaggtgaag	600
gagatcctga aggacagcag cctgaagaac agcgagaagc agagccgctt gaacaagatc	660
ctgggcctga agcccagcga caagcagaag aaggccatca ccaacctgat cagcggcaac	720
aagatcaact tcgccgaact gtacgacaac cccgaactga aggacgccga gaagaacagc	780
atcagcttca gcaaggacga cttcgacgcc ctgagcgacg acctggccag catcctgggc	840
gacagcttcg agctgctgct gaaggccaag gccgtgtaca actgcagcgt gctgagcaag	900
gtgatcggcg acgagcagta cctgagcttc gccaaaggtg agatctacga gaagcacaag	960
accgacctta ccaagctgaa gaacgtgatc aagaagcact tcccaagga ctacaagaag	1020
gtgttcggct acaacaagaa cgagaagaac aacaacaact acagcggcta cgtgggcgtg	1080
tgcaagacca agagcaagaa gctgatcacc aacaacagcg tgaaccagga ggacttctac	1140
aagttcctga agaccatcct gagcgccaag agcgagatca aggaggtgaa cgacatcctg	1200
accgagatcg agaccggcac cttcctgccc aagcagatca gcaagagcaa cgccgagatc	1260
ccctaccagc tgcgaagat ggagctggag aagatcctga gcaacgccga gaagcacttc	1320
agcttcctga agcagaagga cgagaagggc ctgagccaca gcgagaagat catcatgctg	1380
ctgaccttca agatccctca ctacatcgcc cccatcaacg acaaccacaa gaagttcttc	1440
cccgaaccgt gctgggtggt gaagaaggag aagagcccca gcgcaagac caccctctgg	1500
aacttcttcg accacatcga caaggagaag accgcccagg ctttcacac cagccgcacc	1560
aacttctgca catacctggt gggcgagagc gtgctgcccc agagcagcct gctgtacagc	1620

-continued

---

gagtacaccg	tgctgaacga	gatcaacaac	ctgcagatca	tcatecgacgg	caagaacatc	1680
tgcgacatca	agctgaagca	gaagatctac	gaggacctgt	tcaagaagta	caagaagatc	1740
accagaagc	agatcagcac	cttcatcaag	cacgagggca	tctgcaacaa	gaccgacgag	1800
gtgatcatcc	tgggcatcga	caaggagtgc	accagcagcc	tgaagagcta	catcgagctg	1860
aagaacatct	tcggcaagca	ggtggacgag	atcagcacca	agaacatgct	ggaggagatc	1920
atccgctggg	ccaccatcta	cgacgagggc	gagggcaaga	ccatcctgaa	gaccaagatc	1980
aaggccgagt	acggcaagta	ctgcagcgac	gagcagatca	agaagatcct	gaacctgaag	2040
ttcagcggct	ggggccgcct	gagccgcaag	ttcctggaga	ccgtgaccag	cgagatgccc	2100
ggcttcagcg	agcccgtaaa	catcatcacc	gccatgcgcg	agaccagaaa	caacctgatg	2160
gagctgctga	gcagcgagtt	caccttcacc	gagaacatca	agaagatcaa	cagcggttcc	2220
gaggacgccc	agaagcagtt	cagctacgac	ggcctgggtg	agccctggtt	cctgagcccc	2280
agcgtgaaga	agatgctgtg	gcagaccctg	aagctgggtg	aggagatcag	ccacatcacc	2340
caggctcttc	ctaagaagat	cttcatcgag	atggccaagg	gcgcccagct	ggagcctgct	2400
cgcaccaaga	cccgcctgaa	gatcctgcag	gacctgtaca	acaactgcaa	gaacgacgcc	2460
gacgcattca	gcagcgagat	caaggacctg	agcggcaaga	tcgagaacga	ggacaacctg	2520
cgcttcgcga	gcgacaagct	gtacctgtac	tacaccacgc	tgggcaagtg	catgtactgc	2580
ggcaagccca	tcgagatcgg	ccacgtgttc	gacaccagca	actacgacat	cgaccacatc	2640
tacccccaga	gcaagatcaa	ggacgacagc	atcagcaacc	gcgtgctggt	gtgcagcagc	2700
tgcaacaaga	acaaggagga	caagtaccct	ctgaagagcg	agatccagag	caagcagcgc	2760
ggctttctgga	acttctcgca	gcgcaacaac	ttcatcagcc	tgagagaagct	gaaccgcctg	2820
acccgcgcga	cccccatcag	cgacgacgag	accgccaagt	tcatcgcccc	ccagctggtg	2880
gagactcgcc	aagctaccaa	ggtggccgcc	aaggtgctgg	agaagatggt	ccccgagacc	2940
aagatcgtgt	acagcaaggc	cgagaccgtg	agcatgttcc	gcaacaagtt	cgacatcgtg	3000
aagtgcgcgc	agatcaacga	cttccaccac	gcccacgacg	cctacctgaa	catcgtggtg	3060
ggcaacgtgt	acaacaccaa	gttcaccaac	aaccctcgga	atttcattaa	ggagaagcgc	3120
gacaacccca	agatcgccga	cacctacaac	tactacaagg	tggtcgacta	cgacgtgaag	3180
cgcaacaaca	tcaccgcctg	ggagaagggc	aagaccatca	tcaccgtgaa	ggacatgctg	3240
aagcgcaaca	cccccatcta	caccgcgcag	gccgcctgca	agaaggcgca	gctgttcaac	3300
cagaccatca	tgaagaaggg	cctgggccag	cacccctgga	agaaggaggg	ccccttcagc	3360
aacatcagca	agtagcgccg	ctacaacaag	gtgagcgccg	cctactacac	cctgatcgag	3420
tacgaggaga	agggcaacaa	gatccgcagc	ctggagacca	tccccctgta	cctgggtgaag	3480
gacatccaga	aggaccagga	cgtgctgaag	agctacctga	ccgacctgct	gggcaagaag	3540
gagttcaaga	tcctggtgcc	caagatcaag	atcaacagcc	tgctgaagat	caacggcttc	3600
ccctgccaca	tcaccggcaa	gaccaacgac	agcttctctg	tgccccccgc	cgtgcagttc	3660
tgctgcagca	acaacgaggt	gctgtacttc	aagaagatca	tccgcttcag	cgagatccgc	3720
agccagcgcg	agaagatcgg	caagaccatc	agccctacg	aggacctgag	cttccgcagc	3780
tacatcaagg	agaacctgtg	gaagaagacc	aagaacgacg	agatcggcga	gaaggagttc	3840
tacgacctgc	tgcaagaaga	gaacctggag	atctacgaca	tgctgctgac	caagcacaag	3900

-continued

---

gacacccatct acaagaagcg ccccaacagc gccaccatcg acatcctggg gaagggcaag	3960
gagaagttca agagcctgat catcgagaac cagttcgagg tgatcctgga gatcctgaag	4020
ctgttcagcg ccaccgcga cgtgagcgac ctgcagcaca tcggcgcgag caagtacagc	4080
ggcgtggcca agatcggcaa caagatcagc agcctggaca actgcatcct gatctaccag	4140
agcatcaccg gcatcttcga gaagcgcatc gacctgctga aggtgtaa	4188

&lt;210&gt; SEQ ID NO 14

&lt;211&gt; LENGTH: 4188

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Treponema denticola

&lt;400&gt; SEQUENCE: 14

atgaagaagg agatcaagga ctacttctcg ggcctggccg tgggcaccgg cagcgtgggc	60
tggggccgtga ccgacaccga ctacaagctg ctgaaggcca accgcaagga cctgtggggc	120
atgcgctgct tcgagactgc tgagaccgcc gaggtgcgcc ggctgcaccg cgggtgctcg	180
cggcgcatcg agcgccgcaa gaagcgcatc aagctgctgc aggagctgtt cagccaggag	240
atcgccaaga ccgacgaggg ctctctccag cgcataagga agagcccctt ctacgccgag	300
gacaagacca tctgcagga gaacacctg ttcaacgaca aggacttcgc cgacaagacc	360
taccacaagg cctacccac catcaaccac ctgatcaagg cctggatcga gaacaaggtg	420
aagcccgaac ctgcctgct gtacctggcc tgccacaaca tcatcaagaa gcgcggccac	480
ttcctgttcg agggcgactt cgacagcgag aaccagttcg acaccagcat ccaggccctg	540
ttcgagtacc tgcgcgagga catggagggt gacatcgacg ccgacagcca gaagggtgaag	600
gagatcctga aggacagcag cctgaagaac agcgagaagc agagccgcct gaacaagatc	660
ctgggcctga agcccagcga caagcagaag aaggccatca ccaacctgat cagcggcaac	720
aagatcaact tcgccgaact gtacgacaac cccgacctga aggacgcca gaagaacagc	780
atcagcttca gcaaggacga ctctgacgcc ctgagcgacg acctggccag catcctgggc	840
gacagcttcg agctgctgct gaaggccaag gccgtgtaca actgcagcgt gctgagcaag	900
gtgatcggcg acgagcagta cctgagcttc gccaaaggta agatctacga gaagcacaag	960
accgacctta ccaagctgaa gaacgtgatc aagaagcact tccccaagga ctacaagaag	1020
gtgttcggct acaacaagaa cgagaagaac aacaacaact acagcggcta cgtgggcgtg	1080
tgcaagacca agagcaagaa gctgatcatt aacaacagcg tgaaccagga ggactttctac	1140
aagttcctga agaccatcct gagcgccaag agcgagatca aggaggtgaa cgacatcctg	1200
accgagatcg agaccggcac ctctctgccc aagcagatca gcaagagcaa cgccgagatc	1260
ccctaccagc tgcgcaagat ggagctggag aagatcctga gcaacgcca gaagcacttc	1320
agcttcctga agcagaagga cgagaaggc ctgagccaca gcgagaagat catcatgctg	1380
ctgaccttca agatccccta ctacatcgcc cccatcaacg acaaccacaa gaagttcttc	1440
cccgaaccgt gctgggtggg gaagaaggag aagagcccca gcggcaagac cccccctgg	1500
aactttctcg accacatcga caaggagaag accgcccagg ccttctatcac cagccgcacc	1560
aactttctgca catacctggg gggcgagagc gtgctgcccc agagcagcct gctgtacagc	1620
gagtacaccg tgctgaacga gatcaacaac ctgcagatca tcatcgacgg caagaacatc	1680
tgcgacatca agctgaagca gaagatctac gaggacctgt tcaagaagta caagaagatc	1740

-continued

---

acccagaagc	agatcagcac	cttcatacaag	cacgagggca	tctgcaacaa	gaccgacgag	1800
gtgatcatcc	tgggcatcga	caaggagtgc	accagcagcc	tgaagagcta	catcgagctg	1860
aagaacatct	tcggaagca	ggtggacgag	atcagcacca	agaacatgct	ggaggagatc	1920
atccgctggg	ccaccatcta	cgacgagggc	gagggcaaga	ccatcctgaa	gaccaagatc	1980
aaggccgagt	acggaagta	ctgcagcgac	gagcagatca	agaagatcct	gaacctgaag	2040
ttcagcggt	ggggccgct	gagccgcaag	ttcctggaga	ccgtgaccag	cgagatgccc	2100
ggcttcagcg	agcccgtgaa	catcatcacc	gccatgcgcg	agaccagaa	caacctgatg	2160
gagctgtcga	gcagcgagtt	caccttcacc	gagaacatca	agaagatcaa	cagcggttct	2220
gaggacgccc	agaagcagtt	cagctacgac	ggcctggta	agccctggt	cctgagcccc	2280
agcgtgaaga	agatgctgtg	gcagaccctg	aagctggta	aggagatcag	ccacatcacc	2340
caggctcttc	ctaagaagat	cttcatacag	atggccaagg	gcgccgagct	ggagcctgct	2400
cgcaccaaga	ccgcctgaa	gatcctgcag	gacctgtaca	acaactgcaa	gaacgacgcc	2460
gacgcattca	gcagcgagat	caaggacctg	agcggcaaga	tcgagaacga	ggacaacctg	2520
cgcctgcgca	gcgacaagct	gtacctgtac	tacaccacgc	tggaagtg	catgtactgc	2580
ggcaagccca	tcgagatcgg	ccagctgttc	gacaccagca	actacgacat	cgctgctatc	2640
tacccccaga	gcaagatcaa	ggacgacagc	atcagcaacc	gcgtgctggt	gtgcagcagc	2700
tgcgccaaga	acaaggagga	caagtaccct	ctgaagagcg	agatccagag	caagcagcgc	2760
ggcttctgga	acttctgca	gcgcaacaac	ttcatcagcc	tggaagagct	gaaccgctg	2820
acccgcgcca	cccccatcag	cgacgacgag	accgccaagt	tcacgcccc	ccagctggtg	2880
gagactcgcc	aagctaccaa	ggtggccgccc	aaggtgctgg	agaagatggt	ccccgagacc	2940
aagatcgtgt	acagcaaggc	cgagaccgtg	agcatgttcc	gcaacaagtt	cgacatcgtg	3000
aagtgcgcg	agatcaacga	cttcaccacc	gcccacgacg	cctacctgaa	catcgtggtg	3060
ggcaacgtgt	acaacaccaa	gttcaccaac	aacctctgga	atttcattaa	ggagaagcgc	3120
gacaacccca	agatcgccga	cacctacaac	tactacaagg	tggtcgacta	cgacgtgaag	3180
cgcaacaaca	tcaccgcctg	ggagaagggc	aagaccatca	tcaccgtgaa	ggacatgctg	3240
aagcgcaaca	cccccatcta	caccgcgccag	gccgcctgca	agaagggcga	gctgttcaac	3300
cagaccatca	tgaagaaggg	cctgggcccag	cacccctga	agaaggaggg	ccccctcagc	3360
aacatcagca	agtacggcgg	ctacaacaag	gtgagcgccg	cctactacac	cctgatcagag	3420
tacgaggaga	agggaacaa	gatccgcagc	ctggagacca	ccccctgta	cctgggtaag	3480
gacatccaga	aggaccagga	cgtgctgaag	agctacctga	ccgacctgct	gggcaagaag	3540
gagttcaaga	tcctggtgcc	caagatcaag	atcaacagcc	tgctgaagat	caacggcttc	3600
ccctgccaca	tcaccggcaa	gaccaacgac	agcttctcgc	tgccccccgc	cgtgcagttc	3660
tgctgcagca	acaacgaggt	gctgtacttc	aagaagatca	tcgccttcag	cgagatccgc	3720
agccagcgcg	agaagatcgg	caagaccatc	agccctacg	aggacctgag	cttcgcgacg	3780
tacatcaagg	agaacctgtg	gaagaagacc	aagaacgacg	agatcgccga	gaaggagttc	3840
tacgacctgc	tgcaagaaga	gaacctggag	atctacgaca	tgctgctgac	caagcacaag	3900
gacaccatct	acaagaagcg	ccccaacagc	gccaccatcg	acatcctggt	gaagggaag	3960
gagaagttca	agagcctgat	catcgagaac	cagttcgagg	tgatcctgga	gatcctgaag	4020

---

-continued

---

ctgttcagcg ccacccgcaa cgtgagcgac ctgcagcaca tcggcggcag caagtacagc 4080  
ggcgtggcca agatcggcaa caagatcagc agcctggaca actgcatect gatctaccag 4140  
agcatcacgg gcatcttcga gaagcgcacg gacctgctga aggtgtaa 4188

<210> SEQ ID NO 15  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 15

aacaaatgtg tcacaaagta 20

<210> SEQ ID NO 16  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 16

acaaaactgt gctagacatg 20

<210> SEQ ID NO 17  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 17

tgtgctagac atgaggtcta 20

<210> SEQ ID NO 18  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 18

gcccacgaca ccaaccacca 20

<210> SEQ ID NO 19  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 19

tcttccttag gaatgatgac 20

<210> SEQ ID NO 20  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 20

-continued

---

gcggtccctg aggtgcaccg 20

<210> SEQ ID NO 21  
 <211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 21

agaagtggaa tacagagcgg 20

<210> SEQ ID NO 22  
 <211> LENGTH: 1491  
 <212> TYPE: DNA  
 <213> ORGANISM: adeno-associated virus

<400> SEQUENCE: 22

 atggagagaa ggaatcctag tgagagggga gtgcccgccg gggtttcttg tcacgcctcc 60  
 gtggaatccg gatgtgagac tcaggagtcc cccgccaccg tgggtgttccg cccaccagga 120  
 gacaacactg acggtggcgc ggcggctgct gcaggtggaa gccaaagccg cgctgctggg 180  
 gccgagccga tggaaaccga atccagaccc ggtccctctg gcataaacgt tgtgcaggtc 240  
 gcagaactct accccgaact ccgcaggatc ttgacaatca cggaggacgg ccagggcctc 300  
 aaggagtgta agagagagag aggggcttgt gaggccactg aggaagctcg caatctggcg 360  
 ttttcattga tgacaaggca caggccggaa tgcattacat tccaacagat taaggacaac 420  
 tgcgcaaacg agctcgatct cctggcccag aagtatagca tcgagcagct gacaacctat 480  
 tggctgcagc ccggcgacga ttttgaagag gccatcccg tgtacgcaa ggtggccctg 540  
 cgacctgact gcaaatataa gatttccaaa ctggttaaca tccggaattg ttgttatatt 600  
 agtggaaatg gcgcagaagt ggagattgac acagaggatc gactcgcttt ccggtgctct 660  
 atgatcaaca tgtggcccg tgtgctcggc atggatggcg tagtcattat gaatgtggct 720  
 ttcaccggac ctaattttag cggaaaccgt ttcctggcaa aactaatct gatcctgcat 780  
 ggagtttctt tctatggatt taataacacc tgtgttgaag cttggaccga cgtgcgggtt 840  
 agagggtgtg ctttttattg ctgctggaaa ggcgtcgtgt gtagaccaa aagtagagct 900  
 tctatcaaga aatgcctgtt cgagaggtgt actctgggca ttctcagtga aggtaatagc 960  
 agggtcaggc ataacgtggc ctcagattgc ggatgtttta tgttggttaa atccgtggct 1020  
 gtgatcaagc acaacatggt gtgtggcaat tgtgaggacc gggcatctca aatgctgaca 1080  
 tgttccgatg gcaactgtca cctgctcaaa acaattcacg ttgcgagcca ttctcggaag 1140  
 gcctggccag ttttcgagca taacatcctg acgcgctgta gtctccacct gggtaacaga 1200  
 cggggcgctt tcctgccata tcagtgtaac ctgtcacata ccaagatact cctggaacca 1260  
 gaatctatga gtaaagtga cctgaatggt gtattcgata tgaccatgaa gatatggaaa 1320  
 gtctccgct atgacgaaac taggactagg ttagggcct gcgagtgtgg cggcaagcat 1380  
 atccgcaacc aaccctgat gctggacgtg accgaggagc tgcgccccga tcacctggtg 1440  
 ctggcctgca ccagagcaga attcgggagc tcagacgaag aactgatta a 1491

<210> SEQ ID NO 23  
 <211> LENGTH: 888  
 <212> TYPE: DNA

-continued

&lt;213&gt; ORGANISM: adeno-associated virus

&lt;400&gt; SEQUENCE: 23

```

atgggcacta ctagtggggt accctttggc atgacccctc gcccactcg gtcaaggctc    60
tcccggagaa ctcccttactc tcgcgatagg ctctctccgt tcgaaaccga aacacgggca    120
accattctgg aagatcatcc actgctgcc aagtgttaata ccctgacgat gcataacgtt    180
tcttacgtcc gcggtctgcc ctgttccgtg ggttttactc tgatccagga gtgggtcgtg    240
ccttgggata tggctcctc acgcgaggag ctggtgatcc tgagaaagtg tatgcatgtc    300
tgcttgtgtt gcgcaaacat cgacattatg accagtatga tgattcatgg atacgagagc    360
tgggcgcttc actgccactg ctcatccctc ggcagcctgc agtgtattgc agggggccag    420
gtgctcgctt cctggtttag aatggtagt gatggcgcca tgtttaatca gagattcatt    480
tggtatcggg aggttgtgaa ctataacatg ccaaaggaag tcatgtttat gagcagcgtg    540
ttcatgcggg ggcggcatct gatatactg agactgtggt acgacggtea cgtgggctct    600
gtcgtgcctg caatgtcctt cggatacagc gccctgcact gtgggacctc caataatata    660
gtcgtcttgt gttgctctta ttgcgcagat ctcatgtaga taagagtcag gtgctgtgca    720
agacggaccg caagggcgat gctccgcgcc gtgcgcacca ttgccgagga gacaactgcc    780
atgctttaca gctgtagaac agagcgcaga cgccagcagt ttatcagagc cctgctgcag    840
caccaccgcc ccatactcat gcatgactac gacagtacgc caatgtaa    888

```

1. A system for editing at least one target gene in a cell, the system comprising:

- a first nucleic acid sequence, or a set of nucleic acid sequences, encoding one or more CRISPR guide RNAs, wherein the one or more CRISPR guide RNA is complimentary to the at least one target gene in a cell and, wherein the first nucleic acid sequence, or the set of nucleic acid sequences, may be comprised in one or more vectors, but not required to be comprised in one or more vectors;

a Cas9 protein or a second nucleic acid sequence encoding a Cas9 protein;

a third nucleic acid sequence encoding a first adenoviral protein; and

a fourth nucleic acid sequence encoding a second adenoviral protein.

2.-96. (canceled)

\* \* \* \* \*